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ABSTRACT 
 Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease 
with multiple distinct molecular subtypes. Increased NF-κB activity and expression of the 
microRNA miR-155 (product of the BIC gene) are associated with one subtype, called 
the activated B-cell (ABC) subtype. It is shown here that induction of NF-κB activity 
leads to increased miR-155 expression, the levels of miR-155 in a panel of B-lymphoma 
cell lines correlate with increased NF-κB activity, and the NF-κB p50/p65 heterodimer 
binds to a specific DNA site in the BIC promoter. Also described is a regulatory network 
wherein NF-κB-dependent up-regulation of miR-155 leads to reduced PU.1 transcription 
factor expression and consequently reduced PU.1-driven expression of B-lymphoma 
marker CD10 in the human B-lymphoma cell line BJAB. 
 Genetic variation in DLBCL can be used to explain the response of individual 
patients to chemotherapy. One cancer therapeutic approach currently in clinical trials uses 
histone deacetylase inhibitors (HDACi’s) as a monotherapy or in combination with other 
  vi 
agents. It is shown here that two pan-HDACi’s, trichostatin A and vorinostat, induce 
apoptosis in seven of eight human DLBCL cell lines. Ectopic over-expression of anti-
apoptotic proteins BCL-2 and BCL-XL or the pro-apoptotic protein BIM in select 
DLBCL cell lines can confer further resistance or sensitivity, respectively, to HDACi 
treatment. Additionally, the BCL-2 family antagonist ABT-737 can increase the 
sensitivity of several DLBCL cell lines to vorinostat-induced apoptosis, including the 
HDACi-resistant SUDHL6 cell line. Moreover, one vorinostat-resistant variant of the 
HDACi-sensitive cell line SUDHL4 has increased expression of anti-apoptotic proteins 
BCL-XL and MCL-1 and decreased sensitivity to ABT-737, and a second such variant 
cell line has increased expression of anti-apoptotic protein MCL-1. These results suggest 
that the balance of anti- to pro-apoptotic BCL-2 family protein expression is important in 
determining the sensitivity of DLBCL cell lines to HDACi-induced apoptosis. Thus, the 
sensitivity of DLBCL cell lines to treatment with HDACi’s appears to depend on the 
complex regulation of BCL-2 family members, suggesting that the response of a subset of 
DLBCL patients to HDACi treatment may benefit from co-treatment with BCL-2 
antagonists. 
 
 
 
 
 
 
  vii 
Table of Contents 
Acknowledgments             iii 
Abstract               v 
Table of Contents            vii 
List of Tables           xvii 
List of Figures          xviii 
List of Abbreviations            xx 
        
Chapter 1 Introduction              1 
 1.1  Patient Data, Treatment, and Subtyping Mutations          3 
  in DLBCL 
1.1.1  Clinical Features and Current Treatment         3 
1.1.2  Gene Expression Studies Have Led to Distinct                    6 
 DLBCL Subtype Classifications 
1.1.3 Genetic Abnormalities, Mutations, and Molecular                    12 
 Markers Associated with DLBCL 
1.2  Molecular Function of the NF-κB Signal Transduction                  17
 Pathways Affecting B Cells and DLBCL 
1.3  Regulation of the ↑NF-κB → ↑miR-155 → ↓PU.1 → ↓CD10              21 
Pathway 
1.4  HDACs and Regulation of HDACi-mediated Apoptosis                 25 
 in DLBCL by the BCL-2 Family of Proteins 
  viii 
  1.4.1  The Complex Relationship Between HDACs       27 
and HATs  
1.4.2 The Classical HDAC Family         29 
 1.4.3  The Sirtuins: Class III HDACs        32 
  1.4.4 HDACS in Hematopoietic Function           32 
  1.4.5 Involvement of HDACs in Hematopoietic        38 
Malignancies 
  1.4.6  HDACi and Hematopoietic Malignancies       39 
  1.4.7  Clinical Success of HDACi’s         44 
 1.5 Thesis Rationale           48 
 
Chapter 2 Materials and Methods          61 
2.1 Recombinant DNA Techniques         61 
  2.1.1 Preparation of Competent Cells        61 
  2.1.2 Plasmid Constructions         62 
  2.1.3 DNA Ligation and Transformation        62 
  2.1.4 Small-scale Plasmid Preparation        63 
  2.1.5 Large-scale, Cesium Chloride Gradient        64 
Plasmid Preparation 
2.2 Polymerase Chain Reaction (PCR) Based Site-directed       66 
Mutagenesis 
2.3 Cell Culture            67 
  ix 
2.3.1 General Cell Culture Protocols and Reagents      67 
  2.3.2 Freezing and Thawing Cells         68 
 2.4 Transfection of Adherent Cells         68 
2.4.1 Polyethylenimine Method of Transfection       69 
  2.4.2 Effectene Method of Transfection        69 
 2.5 Dual Luciferase Assay          70 
 2.6 Retroviral Stock Preparation and Cell Infection       71 
2.7 Soft Agar Colony Formation Assay         72 
2.8 Preparation of Whole Cell Extracts Using Triton-X-100       73 
(AT) Buffer Method 
 2.9 Preparation of Cytosolic and Nuclear cell Extracts       73 
 2.10 Protein Concentration Determination         74 
 2.11 SDS-polyacrylamide Gel Electrophoresis and        75 
Western Blotting 
2.11.1 SDS-polyacrylamide Gels         75 
  2.11.2 Western Blotting          76 
2.12  Electrophoretic Mobility Shift Assays (EMSAs)       77 
2.12.1 Annealing of Double-Stranded Probes for EMSAs      77 
2.12.2 Double-Stranded Probe End-labeling with        77 
Polynucleotide Kinase  
2.12.3 EMSA Assay           78 
2.13 RNA Isolation            78 
  x 
2.14 Reverse Transcriptase-PCR (RT-PCR) of Whole        79 
Cell RNA 
2.15 Quantitative-PCR (qPCR)           80 
2.16 Reverse Transcription and qPCR of microRNAs        80 
and Small RNAs 
2.17 5-aza-2′ Deoxycytidine, Tricostatin A, Vorinostat,        81 
ABT-737, and Lipopolysaccharide Treatment of  
DLBCL Cell Lines 
2.18 Caspase-3 Activity Assay          82 
2.19 Percent Growth Inhibition of HDACi Treated Cells       82 
2.20 Acridine Orange and Ethidium Bromide Stain for        83 
Apoptosis and Necrosis 
2.21 Selection of HDACi-resistant Variant of the SUDHL4       83 
Cell Line 
2.22 Prediction of Transcription Factor Binding Sites in the       84 
BIC Promoter 
2.23 Statistical Analysis           84 
 
Chapter 3 NF-κB Down-regulates Expression of the B-lymphoma     102 
Marker CD10 through a miR-155/PU.1 Pathway 
 3.1 Introduction          102 
3.2 PU.1 and CD10 Protein Levels Are Inversely Correlated     105 
  xi 
with miR-155 Levels in Several B-Lymphoma Cell Lines 
3.3 Lipopolysaccharide Treatment Causes NF-κB-mediated     106 
Expression of miR-155 and Loss of PU.1-induced  
Expression of CD10 in BJAB Cells  
3.3.1 LPS Treatment Decreases PU.1 Binding to the     107 
PU-1 Site in the CD10 Promoter 
3.3.2 p65 Nuclear Translocation, Increased miR-155     108 
Expression, and Increased DNA Binding to the BIC  
Promoter are Early Responses to LPS Treatment 
3.4 Expression of a Constitutively Active Form of CARD11 in     109 
BJAB Cells Causes Down-regulation of CD10 and PU.1 Protein 
Expression and Up-regulation of miR-155 Expression 
3.4.1 Stable Expression of CARD11-mutant10 Down-    109 
regulates PU.1 and CD10 and Up-regulates BCL-2  
and miR-155 
3.4.2 Dox Inducible CARD11-mutant10 Down-regulates     110 
CD10 and Up-regulates miR-155 
3.4.3 Stable Expression of CARD11-mutant10 Down-    110 
regulates PU.1 DNA Binding and Up-regulates NF-κB  
DNA Binding 
3.5 NF-κB Family Member p65 binds to the BIC Promoter     111 
and Directs Gene Transcription 
  xii 
3.5.1 There are at Least Three Predicted NF-κB Binding     111 
Sites in the BIC Promoter 
3.5.2 p65 Up-regulates Luciferase Activity Driven by a     112 
1494 bp Portion of the BIC Promoter 
3.5.3 Deletion Mutants of the BIC Promoter Reveals an     113 
NF-κB-responsive Region  
3.5.4 Mutation of the Predicted NF-κB Binding Sites     113 
Revealed the p65-responsive Site in the BIC Promoter 
3.5.5 The p50/p65 Heterodimer Binds to the -178 Site     114 
in the BIC Promoter 
3.5.6 p65-mediated Transcription From the BIC Promoter    115 
Requires Other NF-κB Family Members 
3.5.7 Increased NF-κB Activity Correlates with Mature     116 
miR-155 Expression in a Panel of B-lymphoma  
Cell Lines 
3.6 CD10 Protein Levels Are Affected by Alterations in the     117 
Expression of miR-155 or PU.1 
3.6.1 Over-expression of miR-155 in BJAB Cells Down-    118 
regulates CD10 and PU.1 
3.6.2 Knockdown of PU.1 Results in Down-regulation     118 
of CD10 
3.6.3 Stable Expression of v-Rel in Chicken DT40     118 
  xiii 
Fibroblasts Resulted in Down-regulation of PU.1 mRNA 
3.7 Alternative Ways to Regulate CD10 Expression     119 
3.7.1 Identification of Non-consensus PU.1 Binding Sites    119 
in the CD10 Promoter 
3.7.2 Changes in Epigenetic Function can Control     120 
CD10 Expression 
3.8 Over-expression of CD10 in BJAB Cells Results in ~2.2     121 
Fold Increase in Soft Agar Colony Formation 
3.9  Chapter 3 Summary         122 
 
Chapter 4 The Sensitivity of Diffuse Large B-cell Lymphoma     146
 Cell Lines to Histone Deacetylase Inhibitor-induced  
Apoptosis is Modulated by BCL-2 Family Protein Activity 
4.1 Introduction          146 
4.2 Inhibition of HDAC Activity Induces Apoptosis in      149 
the Majority of Cell Lines from a Select Panel of Diffuse  
Large B-cell Lymphoma Cell Lines 
4.3 Tricostatin A and Vorinostat Induce Apoptosis in SUDHL4,    150 
but not in SUDHL6 Cells 
4.3.1 Tricostatin A and Vorinostat Induce Apoptosis in a     150 
Time- and Dose-Dependent Manner in SUDHL4 Cells 
4.3.2 Vorinostat Inhibits Cell Proliferation in SUDHL4     151 
  xiv 
at a Lower IC50 Than SUDHL6 Cells 
4.3.3 Vorinostat Induces BIM Expression in HDACi-    151 
resistant SUDHL6 cells 
4.3.4 SUDHL6 Cells Are Not Resistant to all      152 
Chemotherapeutic Agents  
4.4 Over-expression of BCL-2, BCL-XL, and BIM Can Affect     152 
the Sensitivity of DLBCL Cell Lines to HDACi-induced  
Apoptosis  
4.4.1 Over-expression of BCL-2 in SUDHL2 Cells     153 
Confers Decreased Sensitivity to HDACi- 
Induced Apoptosis 
4.4.2 Over-expression of BCL-XL in SUDHL4 and     153 
Farage Cells Confers Decreased Sensitivity to  
HDACi-Induced Apoptosis 
4.4.3 Over-expression of BIM in Farage Cells Confers     154 
Increased Sensitivity to HDACi-Induced Apoptosis 
4.5 Pharmacological Modulation of BCL-2 Family Member     155 
Interactions Can Also Sensitize DLBCL Cell Lines to  
Vorinostat-induced Apoptosis  
4.6 Creation of SUDHL4 Cell Line with Reduced Sensitivity     156 
to Vorinostat 
4.6.1 SUDHL4-VR Cells Display Resistance to      157 
  xv 
HDACi Treatment 
4.6.2 SUDHL4-VR Cells are Sensitive to Staurosporine     157 
Treatment 
4.6.3 Induced Vorinostat Resistance May Be Due to     158 
Increased BCL-XL and MCL-1 Expression 
4.7 Chapter 4 Summary         158 
 
Chapter 5 Discussion          180 
5.1  NF-κB Down-regulates Expression of the B-lymphoma     180 
Marker CD10 Through a miR-155/PU.1 Pathway 
5.1.1  The Importance of CD10 Regulations and      180 
Expression in DLBCL 
  5.1.2 BIC/miR-155 Regulations and Activity in     183 
   B-lymphoma Cell Lines 
  5.1.3 The Clinical Implications of the       187 
   ↑NF-κB → ↑miR-155 → ↓PU.1 → ↓CD10  
   Pathway 
5.2  The Sensitivity of Diffuse Large B-cell Lymphoma Cell     191 
Lines to Histone Deacetylase Inhibitor-induced Apoptosis  
is Modulated by BCL-2 Family Protein Activity 
5.2.1 HDACi-resistance in DLBCL Cell Lines Can be     192 
Overcome by Co-treatment with BH3  
  xvi 
Antagonist ABT-737 
  5.2.2 Clinical Implications of HDACi/ABT-737      195 
Treatment of DLBCL 
5.3  Conclusions and Perspectives        196 
 5.3.1 Linking HDAC Activity to the Opposing Actions     196 
of BCL6 and NF-κB Transcription Factor  
Activity in DLBCL 
  5.3.2 Combination Therapies Involving HDACi’s Represent    199 
a New Treatment Strategy for DLBCL Patients 
 
List of Journal Abbreviations          202  
References            210 
Curriculum Vitae           285 
 
 
 
 
 
 
 
  xvii 
List of Tables 
 
1.1  DLBCL gene expression profile subtype classifications     50 
1.2 Summary of HDACs and their function in hematopoietic cells    51 
1.3  HDACi compounds shown to induce apoptosis in lymphoma,     55 
leukemia, and myeloma. 
1.4  Summary of published clinical trials of FDA approved HDACi in     59 
 lymphoma, leukemia, and myeloma. 
2.1 Plasmids used in this study         85 
2.2  Oligonucleotides Used in This Study        93 
2.3  B-lymphoma Cell Lines Used in This Study       97 
2.4  Concentration of Puromycin Used For Selections      99 
2.5  Antibodies Used in This Study      100 
4.1  Quantification of the extent of PARP cleavage in Fig. 4.3    160  
 
 
 
 
 
  xviii 
List of Figures 
 
1.1  B-cell receptor mediated NF-κB signaling       60 
3.1  Elevated miR-155 expression correlates with reduced PU.1   124 
and CD10 expression levels in several B-lymphoma cell lines 
3.2 LPS treatment of BJAB cells causes a loss in PU.1 binding    126 
 to the CD10 promoter  
3.3  LPS treatment of BJAB cells leads to p65 nuclear localization and   127
 increased DNA binding to the BIC promoter  
3.4 Expression of the B-lymphoma CARD11mut10 protein can decrease  130
 the expression of PU.1 and CD10 in BJAB cells  
3.5 NF-κB family member p65 directs reporter gene transcription   132
 from the BIC promoter  
3.6  p65-activated transcription from the BIC promoter requires   135
 other NF-κB family members  
3.7 Activation of the NF-κB signaling pathway correlates with    139
 expression of miR-155  
3.8  Alterations in the cellular levels of miR-155 or PU.1 affect   140
 the expression of CD10 
3.9 Alternate ways to control CD10 expression     142 
3.10  Over-expression of CD10 in BJAB cells causes ~2.2 fold    145 
increase in soft agar colony formation  
  xix 
4.1 Tricostatin A and vorinostat induce PARP cleavage in a subset   161
 of DLBCL cell lines  
4.2 Tricostatin A and vorinostat induce apoptosis and inhibit growth  162 
 in a time- and dose-dependent manner  
4.3 HDACi sensitivity is decreased by over-expression of BCL-2  168 
 or BCL-XL and increased by over-expression of BIM  
4.4 Vorinostat cooperates with the BH3 mimetic ABT-737 to increase   170
 apoptosis in DLBCL cell lines 
4.5  Expression of individual BCL-2 family members and common   171
 DLBCL markers does not correlate with HDACi sensitivity   
 in DLBCL cell lines 
4.6 SUDHL4 cells induced to be vorinostat-resistant show decreased   174 
 sensitivity to vorinostat-induced apoptosis 
5.1 Model of proposed NF-κB/HDACi regulatory network   201 
 
 
 
 
 
 
 
 
  xx 
List of Abbreviations 
-/-   knockout 
°C   degrees Celsius 
aa   amino acid(s) 
ABC   activated B-cell 
AID   activated-induced cytidine deaminase 
ALL   acute lymphoblastic leukemia 
AML   acute myeloid leukemia 
Amp   ampicillin 
AP-1   activated protein-1 
APAF1  apoptotic protease activating factor 1 
APL   acute promyelocytic leukemia 
APS    ammonium persulfate 
ATP   adenosine triphosphate 
ATRA   all-trans retinoic acid 
AZA   5-aza-2-deoxycytidine  
BAD   BCL-2-associated death promoter 
BAK   BCL-2 homologous antagonist killer 
BAX   BCL-2-associated X protein 
BCL   B-cell lymphoma 
BCR   B-cell receptor 
BH3   BCL-2 homolgy 3 
  xxi 
BID   BH3 interacting-domain death agonist 
BIM   Bcl2-interacting mediator of cell death 
BL    Burkitt’s lymphoma 
bp   base pair(s) 
BPI   BCL6 peptide inhibitor 
BSA   bovine serum albumin 
BSAP   B-cell lineage specific activator protein 
BTG-1   B-cell translocation gene 1 
CALLA  common acute lymphocytic leukemia antigen 
CARD11  Caspase recruitment domain-containing protein 11 
CBP   CREB-binding protein 
CD   cluster of differentiation 
CDK   cyclin-dependent kinase 
cDNA   complementary DNA 
C/EBP   ccaat-enhancer-binding protein 
ChIP   chromatin immunoprecipitation 
CHOP   Cyclophosphamid, Hydroxydaunorubicin, Oncovin, Prednisone 
CIP   calf intestinal phosphatase 
CLL   chronic lymphocytic leukemia 
CLP   common lymphoid progenitors 
CML   chronic myelogenous leukemia 
CMP   common myeloid progenitors 
  xxii 
CMV   cytomegalovirus 
CoA   coenzyme A 
cpm   counts per minute 
CR   complete response 
CTCL   cutaneous T-cell lymphoma 
CTP   cytidine triphosphate 
Δ   deletion 
DAG   diacylglycerol 
dH2O   deionized water 
DLBCL  diffuse large B-cell lymphoma 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO   dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
dNTPs   deoxyribonucleotide triphosphate 
DR5   death receptor 5 
DTT   dithiothreitol 
E. coli   Escherichia coli 
EBF   early B-cell factor 
EBV   Epstien-Barr virus 
EDTA   ethylenediamine tetraacetic acid disodium salt 
EGTA   ethylene glycol tetraacetic acid 
EGFR   epidermal growth factor receptor 
  xxiii 
EP300 (p300)  E1A binding protein 300 
FADD   fas-associated protein and death domain 
FBS   fetal bovine serum 
FL   follicular lymphoma 
FLIP   FLICE-like inhibitor protein 
FOXP1  forkhead box protein P1 
FW   forward primer 
g    gram(s) 
GADD   growth arrest and DNA damage 
GATA3  GATA-binding factor 3 
GC   germinal center 
GCB   germinal center B-cell 
GEP   gene expression profile 
GOI   gene of interest 
h   hour(s) 
H   histone 
HAT   histone acetyl transferase 
HDAC   histone deacetylase 
HDACi  histone deacetylase inhibitor 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HL   Hodgkin lymphoma 
HR   host response 
  xxiv 
HRK   harakiri 
HRP   horseradish peroxidase 
HSC   hematopoietic stem cells 
ICAM   intercellular adhesion molecule 
IFN   interferon 
Ig   immunoglobulin 
IκB   inhibitor of NF-kB 
IKK   IκB kinase 
IL   interleukin 
IP3   inositol triphosphate 
IPTG   isophropyl-1-thio-b-D-galactoside 
JAK   janus kinase 
JNK   c-Jun N-terminal kinase 
K   lysine 
kbp   kilobase pair 
kDa   kilodalton(s) 
LB   Luria broth 
LMP   latent membrane protein 
LPS   lipopolysaccharide 
LTR   long terminal repeat 
luc   luciferase 
M   molar 
  xxv 
mA   milliamp(s) 
MALT1 Mucosa-associated lymphoid tissue lymphoma translocation 
protein 1 
MAPK mitogen activated protein kinase 
MCL mantel cell lymphoma 
MCL-1 myeloid leukemia cell differentiation protein 
MCS   multiple cloning site 
MEF   mouse embryonic fibroblast 
MHC   major histocompatibility complex 
min   minute(s) 
MITF   microphthalmia-associated transcription factor  
miR-155  microRNA-155 
ml   milliliter(s) 
mM   millimolar 
MM   multiple myeloma 
M-MLV  Moloney murine leukemia virus 
MOPS   3-(N-morpholino)propanesulfonic acid 
mRNA   messenger RNA 
MSCV   murine stem cell virus 
MUM1  multiple myeloma oncogene 1 
mut   mutant  
MYC   myelocytomatosis 
  xxvi 
MYD88  myeloid differentiation primary response gene (88) 
µCi   microCurie(s) 
µg   micrograms(s) 
µl   microliter(s) 
µM   micromolar 
N   amino 
NaB   sodium butyrate 
NCI   National Cancer Institute 
N-CoR   nuclear receptor co-repressor 
NEB   New England Biolabs 
NEMO  NF-κB essential modulator 
NEP   neutral endopeptidase 
ng   nanogram(s) 
NES   nuclear export signal 
NFATC1  nuclear factor of activated T-cells, cytoplasmic 1 
NF-κB   nuclear factor-κB 
NHL   non-Hodgkin lymphoma 
NLS   nuclear localization sequence 
nM   nanomolar 
NRG   non-REL gene 
n.s.   non-specific band 
nt   nucleotide 
  xxvii 
OD   optical density 
ONPG   O-nitrophenyl-b-D-galactopyranoside 
OS   overall survival 
OxPhos  oxidative phosphorylation 
PARP   poly ADP ribose polymerase 
Pax   paired box 
PBS   phosphate-buffered saline 
PCAF   p300/CBP-associated factor 
PCR   polymerase chain reaction 
PEG   polyethylene glycol 
PEI   polyethylenimine 
PEN   penicillin 
PKC   calcium-dependent protein kinase  
PMBCL  primary mediastinal B-cell lymphoma 
pmol   picomole(s) 
PMSF   phenylmethylsulfonyl fluoride 
Pol   polymerase 
PR   partial response 
PTCL   peripheral T-cell lymphoma 
PTEN phosphate and tensin homolog 
PUMA p53 up-regulated modulator of apoptosis 
qPCR quantitative PCR 
  xxviii 
R-CHOP Rituximab, Cyclophosphamid, Hydroxydaunorubicin, Oncovin, 
Prednisone 
REL   reticuloendotheliosis 
RHD   Rel homology domain 
RIP1   receptor-interacting serine/threonine-protein kinase 
RISC   RNA-induced silencing complex 
RNA   ribonucleic acid 
RNase   ribonuclease 
ROS   Reactive oxygen species 
rpm   revolutions per minute 
RSV   Rous sarcoma virus 
RT   room temperature 
RT-PCR  reverse transcription PCR 
RV   reverse primer 
S   Serine 
SD   stable disease 
SDS   sodium dodecyl sulfate 
SDS-PAGE  SDS-polyacrylamide gel electrophoresis 
SE   standard error 
sec   second(s) 
shRNA  short-hairpin RNA 
sIg   secreted Ig 
  xxix 
siRNA   small-interfering RNA 
SIRT   sirtuin 
SLL   small lymphocytic lymphoma 
SMAD3  mothers against decapentaplegic homolog 3 
SMRT   silencing mediator for retinoid or thyroid-hormone receptors 
SOCS1  Suppressor of cytokine signaling 1 
SS   supershift 
STAT   signal transducers and activators of transcription 
Strep   streptomycin 
SV40   simian virus 40 
Syk   Spleen tyrosine kinase 
t(14;18)  chromosomal translocation fusing chromosomes 14 and 18 
TAD   transactivation domain 
TAK1   TGFβ-activated kinase 1 
TB   terrific broth 
TBS   Tris-buffered saline 
TBS-Tween  TBS with Tween 20 
TCR   T-cell receptor 
TD   Tris buffer with divalent cations 
TE   Tris buffer with EDTA 
TENS   Tris, EDTA, NaOH, SDS buffer 
TEMED  N,N,N’,N’-tetramethylethylenediamine 
  xxx 
TGF   transforming growth factor 
TLR   Toll-like receptor 
TNF   tumor necrosis factor 
TP21 (p21)  tumor protein 2 
TP53 (p53)  tumor protein 53 
TRAF   TNFR-associated factor 
TRAIL  TNF-related apoptosis-inducing ligand 
Treg   regulatory T cell 
Tris   1-[bis(2,3-dibromopropoxy)phosphinoyloxy]-2,3-dibromo-propane 
TSA   Trichostatin A 
TSS   transcription start site 
Tween-20  polyxyethelene sorbitan monolaurate 
TYM   tryptone/yeast extract media 
UTR   untranslated region 
UV   ultraviolet 
v   volume 
V   volts 
VEGF   vascular endothelial growth factor 
VPA   valproic acid 
w   weight 
WB   Western blotting 
WT   wild-type 
  xxxi 
XBP-1   X-box binding protein 1 
XIAP   X-linked inhibitor of apoptosis protein 
ZAP-70  Zeta-chain-associated protein kinase 70 
  
1 
 
CHAPTER 1 
INTRODUCTION AND BACKGROUND 
 
Diffuse large B-cell lymphoma (DLBCL) is the most common form of 
lymphoma, accounting for 40% of non-Hodgkin and 30% of all lymphomas (Hunt and 
Reichard, 2008). The high prevalence of DLBCL makes it important to understand the 
molecular pathways that define the disease with the goal of developing improved 
diagnostic markers and targeted therapies. In one approach, gene expression arrays have 
identified three distinct DLBCL subtypes: germinal center B-cell (GCB), activated B-cell 
(ABC), and primary mediastinal B-cell lymphoma (PMBCL) (Alizadeh et al., 2000; Bea 
et al., 2005; Lenz et al., 2008c; Rosenwald et al., 2002). The two most commonly studied 
subtypes are ABC and GCB, which have been defined based on their NF-κB activity 
levels and prognoses in response to conventional chemotherapy. ABC DLBCL have high 
NF-κB and a poorer prognosis (35% 5-year survival rate), whereas GCB DLBCL have 
low NF-κB and a more favorable prognosis (60% 5-year survival rate) (Rosenwald et al., 
2002; Wright et al., 2003). These two subtypes can also be classified by the expression of 
various markers. The ABC subtype is BCL-2+, CD10-, BCL6-, and miR-155high, whereas 
the GCB subtype is BCL-2-, CD10+, BCL6+, and miR-155low (Davis et al., 2001; Hans et 
al., 2003; Wright et al., 2003). These diagnostic markers for DLBCL, while informative, 
are limited in fully predicting patient prognosis. This chapter will describe the molecular 
pathogenesis of DLBCL, the involvement of NF-κB-dependent gene regulation in 
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DLBCL, key genetic abnormalities and mutations associated with DLBCL, and discuss 
new alternatives to conventional DLBCL therapy. 
 A number of studies have been published identifying chromosome copy number 
changes, genetic mutations, and epigenetic modifications associated with DLBCL (Bea et 
al., 2005; Davis et al., 2010; Hans et al., 2003; Lenz et al., 2008c; Wright et al., 2003). 
Most tumors have acquired two or more of these abnormalities, suggesting that mutations 
play synergistic roles in the progression of DLBCL. Chromosomal gains of the NF-κB 
member REL are found in 10-20% of non-Hodgkin’s B-cell lymphomas and are 
associated with the clinically favorable GCB DLBCL, while chromosomal amplification 
of BCL-2 and MALT1, both located on 18q, is associated with ABC DLBCL (Lenz et al., 
2008c). In addition to chromosomal abnormalities, a recent study highlighted the 
importance of accumulating mutations in genes encoding proteins involved in the NF-κB 
signal transduction pathway in the development of ABC DLBCL (Davis et al., 2010). In 
particular, 51% of ABC DLBCL samples (patient biopsies and cell lines) have mutations 
in one or more of several upstream NF-κB signaling genes, whereas 23% of the GCB 
DLBCL samples have only one. These NF-κB pathway genes include A20, CARD11, 
TRAF2, TRAF5, and TAK1 (Compagno et al., 2009). This is supported by studies 
showing that ABC DLBCL is associated with increased NF-κB activity, whereas 
chromosomal gains of REL do not correlate with increased NF-κB activity (Lenz et al., 
2008c).  
Studies describing mutations associated with DLBCL highlight the heterogeneity of 
the disease and the importance of research aimed at discovering new diagnostic tools and 
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targeted therapeutics. While the conventional antibody/chemotherapy regimen (R-CHOP 
therapy) successfully treats 60-70% of patients as defined by 5-year survival rates 
(Gisselbrecht et al., 2008; Hunt and Reichard, 2008), a large number of patients do not 
survive for unknown reasons. There are many promising drug trials currently underway, 
with one promising class of drugs known as histone deacetylase inhibitors (HDACi’s). 
When used as a single agent treatment or in combination with other drugs, lymphoma 
patients treated with the FDA approved HDACi’s vorinostat or romidepsin show 
increased survival, and in some cases achieve a cure, with little toxicity and adverse side 
effects (Campas-Moya, 2009; Mann et al., 2007). In laboratory experiments, various 
cancer cell lines and numerous mouse models treated with HDACi’s have shown 
increased tumor cell cycle arrest and cell death (Bolden et al., 2006; Cotto et al., 2010; 
Piekarz and Bates, 2009; Wiegmans et al., 2011; Zain and O’Connor, 2010). HDACi 
treatment is proving to be an effective and safe treatment and therefore understanding 
how these drugs promote apoptosis in tumor cells is important in identifying patients that 
would benefit from HDACi treatments. 
 
1.1  Patient Data, Treatment, and Subtyping Mutations in DLBCL 
1.1.1  Clinical Features and Current Treatment 
Review of the Surveillance, Epidemiology, and End Results registry, which 
collected data on approximately 30 million cancer patients nation-wide from 1973 to 
2004, found that nearly 60,000 of those patients were diagnosed with DLBCL, with a 
mean age of 63 years, 54.4% male, and 86.7% white (Komrokji, et al., 2011). The overall 
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survival (OS) of patients over 60 years of age was far worse (16 months) as compared to 
patients younger than 60 years old (78 months). Interestingly, the median survival time 
increased each decade of this study, with the most significant jump coming in the 2000’s: 
1973-1979, 15 months; 1980-1989, 18 months; 1990-1999, 20 months; 2000-2004, 47 
months. This large increase in survival appears to be due to increased patient care and 
newer therapies such as the use of the CD20 antibody rituximab with the standard 
chemotherapy regimen CHOP (discussed below). 
Some of the most readily observed clinical features of DLBCL include enlarged 
lymph nodes, spreading of the disease to non-lymphatic organs, elevated lactate 
dehydrogenase levels in half of patients with advanced cases, and involvement of the 
bone marrow in ~15% of patients. The OS is 60-70%, though rates range from 20% to 
70% depending on how many common risk factors a patient has, including age over 60 
years, late stage disease, elevated lactate dehydrogenase levels, physician assessed 
performance status, and number of extranodal disease sites (Gisselbrecht, 2008; Hunt and 
Reichard, 2008).  
Proteins such as BCL-2, BCL6, and CD10 are reliable markers to classify 
DLBCL subtypes, whereas other markers have reproducibility issues between studies 
(Leich et al., 2007). Lossos and Morgenstern (2006) performed a Pubmed search of 
current DLBCL markers that highlighted this point. Their search was performed using the 
following terms: “prognosis”, “outcome”, or “survival” and “diffuse large B-cell 
lymphoma” or “intermediate-grade lymphoma” (Lossos and Morgenstern, 2006). This 
search resulted in the classification of sets of markers termed cell cycle regulators, B-cell 
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differentiation molecules, apoptotic proteins, and miscellaneous markers. They noted 
mutations in some well-known oncogenes, such as TP53, but found that the compilation 
of these studies produced conflicting results in relation to patient survival and prognostic 
value. Some markers were found to be consistent across studies such as over-expression 
of cyclin D3, anti-apoptotic gene BCL-2, and PKC-β, all of which are associated with 
poor patient prognosis and tumor resistance to CHOP therapy. Regardless, much effort 
has gone into identifying gene signatures that will give researchers and physicians insight 
into patient diagnosis, prognosis, and targeted therapeutics.  
The current standard treatment for DLBCL consists of an antibody-chemotherapy 
approach that includes the anti-CD20 IgG monoclonal antibody rituximab (Coiffier, 
2005) and the chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and 
prednisone (R-CHOP) (Cillessen et al., 2010). R-CHOP therapy has significantly 
impacted patient survival as compared to its predecessor, CHOP treatment alone, leading 
to an increase in the 5-year survival rates from 45% to 58% (Gisselbrecht, 2008; Hunt 
and Reichard, 2008). Gisselbrecht (2008) also reported that no long-term toxicity is seen 
in patients treated with R-CHOP. Although the addition of rituximab has improved 
patient survival, the molecularly defined high NF-κB ABC DLBCL subtype has a 
reduced rate of survival as compared to the low NF-κB GCB DLBCL subtype (Nyman et 
al., 2009). This could be due to increased expression of anti-apoptotic genes like BCL-2 
in ABC DLBCL (Alizedah et al., 2000; Lenz et al., 2008c; Obermann et al., 2009). 
Moreover, elevated expression of BCL-2 in GCB DLBCL patients is also correlated with 
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a poor prognosis (Iqbal et al., 2011). Nevertheless, overall, GCB DLBCL has a more 
favorable prognosis than ABC DLBCL. 
 
1.1.2  Gene Expression Studies Have Led to Distinct DLBCL Subtype 
Classifications  
DLBCL has long been a difficult disease to treat, and attempts to subtype tumors 
based on slight morphological differences have proven irreproducible between physicians 
and unsuccessful in determining prognosis (Hunt and Reichard, 2008). With 60-70% of 
patients surviving more than five years after the use of standard R-CHOP treatment, 
researchers have asked the question “What about the rest?”  The use of gene expression 
microarrays has given researchers like Dr. Louis Staudt at the NCI the ability to address 
this question. Microarrays measure the relative expression of mRNAs in a group of 
sample types and compare them to a control group, giving a gene expression profile 
(GEP). Staudt and his team compared a set of DLBCL tumors to their matched peripheral 
blood samples using a specially designed microarray, termed a “Lymphochip”. This array 
contains approximately 18,000 probes for mRNAs that are preferentially expressed in 
lymphoid cells as well as genes thought to be important in immune responses and cancer 
(Alizadeh et al., 2000). Two-thirds of the genes probed were chosen from the germinal 
center (GC) B-cell library due to the suspected importance of the GC in DLBCL. Other 
mRNAs were picked from libraries of follicular lymphoma, DLBCL, chronic 
lymphocytic leukemia, B- and T-cell activation, and cancer biology.  
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 The most significant finding from this work was the designation of three DLBCL 
subtypes: germinal center B cell-like (GCB), activated B cell-like (ABC), and primary 
mediastinal DLBCL (PMBCL) (Table 1.1) (Alizadeh et al., 2000; Bea et al., 2005; 
Rosenwald et al., 2002; Wright et al., 2003). The GCB and ABC subtypes have distinct 
GEPs whereas PMBCL is not as well defined and has been the focus of less work. 
Results from Alizadeh et al. (2000) showed that the GCB and ABC DLBCL subtypes 
most likely arise from their suspected cell of origin due to the similarities found in the 
GEP of the DLBCL and the normal cell of origin. That is, the GEP of the GCB subtype 
resembles that of normal germinal center B cells, which arise in response to antigen 
stimulation of lymphoid follicles and is associated with the generation of memory B cells 
undergoing rapid proliferation and apoptosis in an attempt to select and expand high 
affinity B cells for an inducing antigen (Thorbecke et al., 1994). The ABC subtype 
resembles activated B cells, which arise from resting blood B cells that are quickly 
induced to produce antibodies and interleukins in response to receptor stimulation (Tolar 
et al., 2008).  
 The cell of origin sub-classification method proved to have clinical importance. 
The small set of patients that participated in the original study had biopsies taken pre-
chemotherapy and the patients were then enrolled in standard therapy similar to or 
including CHOP. Patients were then followed for at least five years to assess survival 
rates. Microarrays were then performed and it was found that GCB patients had a better 
probability of survival as compared to ABC patients (Alizadeh et al., 2000). Given these 
results, Staudt’s group looked at a further 240 patients who had not been treated with 
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standard CHOP therapy, obtained biopsies of normal and tumor tissue for the microarray, 
and followed patient survival after CHOP therapy (Rosenwald et al., 2002). Again, GCB 
patients had a more favorable clinical outcome with a 5-year survival rate of 60% 
whereas the ABC patients had a 5-year survival rate of 39%. This study highlighted the 
need for molecular definition of DLBCL patients, since their diseases are molecularly 
distinct and have different clinical outcomes in response to standard therapy. 
 Narrowing down the distinct GEPs between GCB and ABC subtypes to a minimal 
set of genetic alterations and expression markers that can accurately describe these two 
subtypes has been the focus of much research. The Staudt lab was successful at this when 
they showed that the GCB and ABC subtypes can be delineated by a set of 43 genes 
found on both thy Lymphochip and the Affymetrix array (Wright et al., 2003), which 
included the ABC marker BCL-2. Although this method was successful in describing a 
small set of genes that can classify patients as GCB vs ABC DLCBL, the cell of origin 
method still has limitations in its ability to accurately predict which patients will respond 
to standard treatment. 
 Examining the chromosomes for common genetic alterations showed that the 
ABC subtype had a high frequency of trisomy 3 and gain of chromosome arm 3p, which 
contains the FOXP1 gene, loss of chromosome arm 6q, and gain of chromosome arm 
18q, which contains the BCL-2 and NFATC1 genes (Lenz et al., 2008c). The GCB 
subtype had a high frequency of chromosome 2q amplification containing the NF-κB 
family REL gene, loss of the 10q chromosome arm, which contains the PTEN tumor 
suppressor, and the genetic translocation t(14;18), which puts the anti-apoptotic BCL-2 
  
9 
 
gene under constitutive expression (Lenz et al., 2008c; Rosenwald et al., 2002). 
Interestingly, microarry and functional data suggest that chromosomal aberrations are not 
reliable markers for subtype designation. Activated B cells and the ABC subtype 
consistently display increased expression of BCL-2 and a higher frequency of the 
t(14;18) translocation, as compared to the GCB subtype (Alizadeh et al., 2000; Lenz et 
al., 2008c), and the ABC subtype is dependent on constitutive NF-κB activity whereas 
the GCB subtype has low NF-κB activity, regardless of REL expression (Davis et al., 
2001 and 2010). This is surprising since typically when a chromosomal region containing 
a particular gene is amplified, it results in increased expression and tumor dependence on 
that gene, as seen with MYC, cyclin D1, EGFR, and RAS amplification (Croce, 2008). 
Nevertheless, DLBCL tumors seem to have a more complex relationship with their 
oncogenes than many other cancer types.   
 There are a few fundamental problems with the cell of origin approach. First, 
even though there are distinct differences between the GCB and ABC subtypes, PMBCL 
still remains in the population at a rate of ~20-25% (Bea et al., 2005; Rosenwald et al., 
2002 and 2003), although PMBCL has been suggested to be more closely related to 
classical Hodgkin’s lymphoma than DLBCL (Savage et al., 2003). The PMBCL subtype 
cannot be further classified using the Lymphochip or by using other known 
lymphmogenic markers and shows no correlation with survival rates. Second, the 
Lymphochip can be considered biased since the probed cDNAs were specifically picked 
instead of using a whole genome approach. This lack of an unbiased approach allowed 
the researches to place these lymphomas into subtypes based on their predictions. This is 
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exemplified by the fact that two-thirds of the chip contains probes for cDNAs thought to 
be specifically involved in the GC (Alizadeh et al., 2000). Additionally, one of the 
proposed cells of origin, the activated B cell, is derived from general peripheral blood 
cells activated to down-regulate the GC-specific transcription factor BCL6, increase NF-
κB activity, and up-regulate antibody production in memory B cells. In other words, this 
presumed cell of origin to which the tumor samples were compared is an in vitro model 
of a primary cell type and not a biopsy from a patient. It therefore imparts an inherent 
bias toward the researchers’ methods and predictions. Even with this bias, GCB DLBCL 
cells are sensitive to down-regulation of BCL6 and exhibit a better clinical prognosis 
while ABC DLBCL cell are sensitive to down-regulation of NF-κB and exhibit a worse 
clinical prognosis (Alizadeh et al., 2000; Bea et al., 2005; Lenz et al., 2008c; Rosenwald 
et al., 2002; Wright et al., 2003). This disparity in OS indicates that these two 
molecularly defined subtypes represent distinct diseases and that this approach to 
molecularly defining DLBCL is useful.  
 With all of the gene expression data available for DLBCL tumors, there is still 
controversy on which markers provide the best prognostic value (Perry et al., 2012). 
What can be said is that GCB DLBCL patients have a better clinical outcome than ABC 
DLBCL patients when treated with standard therapy, but accurately assessing these 
patients still relies on costly gene expression profiling techniques. In all, due to the ~40-
50% failure rate with conventional therapeutic approaches and the development of new 
therapies, new ways to subtype DLBCL patients with more reliable markers need to be 
developed. 
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Margaret Shipp and her team at Dana Farber Cancer Institute tried to address this 
issue by performing their own microarrays on DLBCL patients. She states that “DLBCLs 
are not a homogeneous group of tumors that differ only with respect to outcome or 
possible cell of origin…there are likely to be subsets of tumors with different 
pathogenetic mechanisms and possible treatment targets” (Monti et al., 2005). Their 
initial study analyzed 176 patients using a microarray that contained a probe set for 
33,000 genes across the whole genome. They processed the data using an analysis 
method they termed consensus clustering, which combined the top 5% of genes with the 
highest reproducibility from each of three independent unsupervised clustering 
algorithms (Monti et al., 2005). This method revealed three distinct subtypes (Table 1.1): 
OxPhos, showing increased expression of genes involved in oxidative phosphorylation 
and other mitochondrial enzymes; BCR/proliferation, having increased expression of 
cell-cycle regulators and DNA repair genes; and host response (HR), which showed 
increased expression of markers of T cell-mediated immune response, inflammatory 
mediators, and connective tissue components. There was extensive agreement between 
any two clustering algorithms for a given patient and 141/176 patients were classified in 
the same cluster by all three algorithms. Interestingly, all three subtypes had similar 5-
year survival rates of ~55%, suggesting this clustering method will be more useful in 
determining pathogenic abnormalities and targeted therapies instead of describing 
survival rates based on the current R-CHOP therapy.  
The cell of origin classification system does not overlap much with the consensus 
clustering method. There is some enrichment of the GCB DLBCL subtype GEP in the 
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OxPhos and BCR/proliferation subtypes, but these subtypes contain a reasonable number 
of ABC and unspecified (probably PMBCL) tumors as well. Additionally, there are more 
unspecified tumors than GCB and ABC DLBCL in the HR subtype, but no correlation 
could be made. Taken together, these results indicate that the Staudt and Shipp 
classification methods are relatively unrelated and further emphasize the heterogeneity of 
DLBCL. Of interest, there was not as strong of a correlation between the consensus 
clustering method and NF-κB activity as was found with the cell of origin classification, 
although the HR subgroup was found to have increased expression of a number of TNF-
induced NF-κB target genes, which overlap with the PMBCL signature and not the ABC 
signature (Feuerhake et al,, 2005). 
 
1.1.3 Genetic Abnormalities, Mutations, and Molecular Markers Associated with 
DLBCL 
DLBCL can be molecularly diagnosed by the presence of pan-B-cell markers 
CD19, CD20, CD22, CD79a, and surface immunoglobulin (Abramson and Shipp, 2005), 
but these markers do not necessarily correlate with subtype or survival. To identify useful 
markers, a number of studies have identified chromosome copy number changes, genetic 
mutations, and epigenetic changes associated with DLBCL prognosis. Many tumors have 
acquired two or more of these abnormalities, suggesting a synergistic role in the 
progression of DLBCL (Bea et al., 2005; Davis et al., 2010; Lenz et al., 2008a; Oudejans 
et al., 2009). Amplification of short chromosomal arm 2p12-16 containing NF-κB 
member REL is found in 10-20% of non-Hodgkin’s B-cell lymphomas (Courtois and 
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Gilmore, 2006; Houldsworth et al., 2004) and is associated with the GCB and PMBCL 
subtypes (Lenz et al., 2008c). Interestingly, chromosomal gains of REL are often not 
associated with increased nuclear REL expression and increased NF-κB activity 
(Houldsworth et al., 2004). In contrast, increased REL mRNA expression has been 
associated with the ABC subtype (Rosenwald et al., 2002) and siRNA-mediated knock-
down of REL mRNA blocks mouse B-cell lymphoma growth (Rhodes et al., 2005; Tian 
and Liou, 2009). This suggests that aberrant activation of the NF-κB signaling pathway 
plays a more important role in DLBCL pathophysiology than chromosomal amplification 
of REL. Accordingly, ABC DLBCLs accumulate mutations in genes encoding proteins 
involved in NF-κB signal transduction, including A20, CD79, TRAF2, TRAF5, TAK1, 
and CARD11, resulting in tumor dependence on constitutive NF-κB activity (Compagno 
et al., 2009; Davis et al., 2001 and 2010; Lenz et al., 2008a; Lim et al., 2012).  
Many genes that are not members of the NF-κB signal transduction pathway are 
deregulated in DLBCL as well. Two of the most commonly deregulated genes in DLBCL 
are BCL-2 and BCL6, both of which can be found as part of chromosomal translocations 
that put the gene downstream of a constitutively active immunoglobulin regulatory 
element (Abramson and Shipp, 2005). BCL-2, located on chromosomal arm 18q, is an 
anti-apoptotic protein that regulates caspase-dependent apoptosis (Strasser et al., 2011; 
Youle and Strasser, 2008), and its expression is associated with ABC DLBCL and a 
worse clinical outcome as compared to GCB DLBCL (Alizadeh et al., 2000; Iqbal et al., 
2006; Lenz et al., 2008c; Obermann et al., 2009). Although BCL-2 is commonly found as 
part of the t(14;18) translocation in a number of cancer types, this translocation does not 
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correlate with DLBCL patient outcome (Lossos and Morgenstern, 2006). Furthermore, 
translocations involving the oncogenic transcription factor c-Myc can be found in 
DLBCL tumors that also contain BCL-2 translocations, termed double-hit DLBCL, and 
represent a distinct population of patients with a rare pathogenic form of DLBCL, though 
the prognostic value of this event is controversial (Johnson et al., 2009; Kobayashi et al., 
2012; Tomita, 2011; Visco et al., 2013).  
BCL6, located on chromosome 3q27, is the master regulator of the GC, where it 
acts as a transcriptional repressor to maintain the GC B-cell state and to ensure that GC 
cells do not preemptively mature into antibody-secreting cells (Basso and Dalla-Favera, 
2012; Jardin et al., 2010). High expression of BCL6 is associated with the GCB DLBCL 
(Alizadeh et al., 2000) and BCL/proliferation (Monti et al., 2005) subtypes, as well as a 
favorable clinical outcome (Jardin et al., 2010). There are BCL6-dependent DLBCL cell 
lines that fall into the BCR/proliferation subtype, representing a discrete subgroup of 
tumors that are reliant on BCL6 signaling and transcriptional control (Cerchietti et al., 
2009; Polo et al., 2007). These BCR/proliferation cell lines are more sensitive to BCL6 
peptide inhibitor (BPI) than OxPhos cell lines (Cerchietti et al., 2009; Polo et al., 2007). 
Moreover, BCL6 expression in GCB and BCR/proliferation DLBCL cells can repress 
PRDM1-driven plasma cell differentiation, keeping these cells in a GC-like state (Parekh 
et al., 2007). A number of ABC DLBCL tumors also exhibit high BCL6 expression 
concurrent with high NF-κB activity and are sensitive to BPI treatment (Ci et al., 2008), 
suggesting that ABC DLBCL can also be sub-classified in terms of BCL6 expression. 
Interestingly, BCL6 can down-regulate BCL-2 expression by suppressing Miz-1-induced 
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expression of BCL-2 in normal GC B cells and this regulatory mechanism is frequently 
lost in DLBCL cells (Saito et al., 2009).    
CD10 is commonly used as a diagnostic marker for a number of malignancies 
including DLBCL, renal cancer, prostate cancer, liver cancer, and lung cancer (Ahuja et 
al., 2008; Alizadeh et al., 2000; Fleischmann et al., 2008 and 2011; Gürel et al., 2012; 
Iqbal et al., 2007; Langner et al., 2004; Shen et al., 2012; Voutsadakis et al., 2012). 
Interestingly, the diagnostic power of CD10 does not always translate into prognostic 
value. Independent studies of renal and prostate cancers have produced weak or 
contradicting evidence for prognostic predictions using CD10 expression (Fleischmann et 
al., 2008 and 2011; Langner et al., 2004; Shen et al., 2012; Voutsadakis et al., 2012). 
One study of non-small cell lung cancer showed that CD10 expression in stromal cells 
correlated with poor clinical outcome whereas CD10 expression in the tumor showed no 
such correlation (Gürel et al., 2012). In DLBCL, CD10 expression has been correlated 
with the clinically favorable GCB subtype (Alizadeh et al., 2000), but the prognostic 
value of CD10 as an independent marker remains controversial (Fabiani et al., 2004; 
Iqbal et al., 2007) and is absent from major reports describing DLBCL prognostic 
markers (Lenz et al., 2008c; Staudt and Dave, 2005). As such, the role that CD10 plays in 
tumor biology beyond its diagnostic importance remains poorly understood. 
Recently, new evidence has emerged that non-traditional markers of DLBCL 
might hold prognostic value (Bodoor et al., 2012; Peroja et al., 2012; Zhong et al., 2012). 
One study assessed levels of oxidative stress markers by immunohistochemical staining 
in patient tumors that were treated with R-CHOP or a similar regimen (Peroja et al., 
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2012). Results showed that tumors with strong staining for thioredoxin or nitrotyrosine 
had significantly worse survival compared to other patients. Another study showed that 
expression of CD138, a cell surface adhesion molecule, served as a marker for poor 
prognosis while CD10 and MUM-1 were not correlated with survival. Additionally, low 
expression of the microRNAs miR-155 and miR146a were associated with a better 
clinical outcome and OS (Zhong et al., 2012).  
In addition to chromosomal abnormalities and gene expression levels, a number 
of proteins are frequently mutated in DLBCL, including TP53, TP21, MYD88, BLIMP1, 
TNFAIP3, CD79B, and CARD11 (Bagg, 2011; Davis et al., 2010; Lenz et al., 2008a; 
Lossos and Morgenstern, 2006; Perry et al., 2012). Mutations in TP53 can be found in 
18-30% of DLBCL patients (Lossos and Morgenstern, 2006) and specific mutations 
found in the DNA-binding domain are associated with a poorer outcome compared to 
other mutations (Perry et al., 2012). Mutations in the coiled-coil domain of the 
scaffolding molecule CARD11 and in a component of the B-cell receptor (BCR), CD79β, 
are mainly found in ABC DLBCL tumors and lead to tumor addiction to increased NF-
κB activity (Davis et al., 2010; Lenz et al., 2008a). These mutated genes, and many 
others, are all found in small percentages of DLBCL patients but represent plausible 
markers for targeted therapy, strengthening the argument that gene expression profiling 
of DLBCL is informative but not as useful in identifying therapeutic targets as molecular 
biology and genetic screening assays. 
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1.2  Molecular Function of the NF-κB Signal Transduction Pathways Affecting B 
Cells and DLBCL 
The NF-κB signaling pathway is misregulated in a variety of human diseases 
including many chronic inflammatory diseases and cancers (see www.nf-kb.org). As 
such, an understanding the molecular details of NF-κB-dependent gene networks has 
implications for improved disease diagnoses and therapies. 
The NF-κB superfamily of proteins can be categorized into two subfamilies - NF-
κB and Rel - both of which contain a Rel Homology Domain (RHD) that is responsible 
for DNA binding and dimerization (Gilmore, 2006). The Rel subfamily (RelA [p65], 
RelB, and c-Rel [REL]) is characterized by having a C-terminal transactivation domain 
(TAD) that can activate the transcription of target genes (Gilmore, 2006). The NF-κB 
subfamily includes p105 and p100, which contain multiple C-terminal ankryin repeats 
that act as a self-inhibitor. Activation of p100 and p105 occurs when the proteins undergo 
partial proteolysis or early arrest in translation, truncating the proteins into their p50 and 
p52 subunits, respectively (Gilmore, 2006). Typically, the NF-κB subfamily is not 
transcriptional activators, as the proteins do not contain a TAD. The transcriptionally 
active p50/p65 heterodimer is the most abundant NF-κB dimer in immune cells and is 
responsible for a majority of NF-κB target expression (Gilmore, 2006; Hayden and 
Ghosh, 2008), as NF-κB plays an important role in both the innate and adaptive immune 
responses (Hayden et al., 2006).   
There are two general pathways of the receptor-mediated NF-κB signaling: the 
canonical (classical) and the non-canonical (alternative) pathways, though other lesser-
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used mechanisms certainly exist (Gilmore, 2006; Hayden and Ghosh, 2008). Many 
hematopoietic cell types exhibit increased canonical NF-κB signaling when their Toll-
like receptors sense inflammatory inducers like lipopolysaccharide (LPS) (Chekulaeva 
and Filipowicz, 2009; Guha and Machman, 2001; Hayden and Ghosh, 2008; Sakuma et 
al., 2012; Schneider et al., 2012; Wu et al., 2012) and tumor necrosis factor α (TNFα) 
(Boehrer et al., 2006; Hayden and Ghosh, 2008; Sakuma et al., 2012; Vallabhapurapu 
and Karin, 2009), are infected with LMP1-expressing Epstein Barr Virus (EBV) (Gatto et 
al., 2008; Luftig et al., 2003; Song et al., 2006 and 2008), or when the BCR is engaged 
by an antigen (Castro et al., 2009; Hayden and Ghosh, 2008; Hayden et al., 2006; Pone et 
al., 2012; Vendel et al., 2009).  
When an antigen is bound to the BCR, multiple BCR molecules congregate in 
lipid rafts at one site on the cell membrane to allow for efficient association with 
intracellular adaptor molecules such as Syk and Lyn, which help to direct the B cell to 
proliferate and differentiate into an antibody-secreting cell (Hayden et al., 2006; Pierce 
and Liu, 2010; Tolar et al., 2008). Adaptor molecules like Syk and Lyn activate the 
following signal transduction cascade: activation of protein kinase C β (PKCβ), 
formation of the CARD11-BCL10-MALT1 (CBM) complex, recruitment of other 
proteins to form the signalosome, activation of the TAK1 kinase, activation of the IKK 
(inhibitor of NF-κB kinase) complex, phosphorylation of IκB as a tag for ubiquitin-
mediated degradation, the subsequent proteasomal degradation of IκB, and the release of 
a transcriptionally active NF-κB dimer to direct expression of target genes (Fig. 1.1) 
(Gilmore, 2006; Hayden et al., 2006). Additionally, B cells engulf the antigen, process it 
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into many pieces, and present those parts on the cell surface in association with MHC 
class II molecules (Batista and Harwood, 2009; Tolar et al. 2008). This new MHCII 
complex recruit CD4+ T cells to the surface of the B cell to make cell-cell interactions 
that trigger a host of immune responses to help fight an infection. Part of the process of 
antigen engulfment and presentation described above is the activation of many 
intracellular signaling pathways, including NF-κB. 
 IKK-initiated degradation of IκB is a highly regulated process that involves a 
complex of four IKK subunits (Hayden et al., 2006; Perkins, 2007). In the canonical 
pathway, the IKK complex is made up of two catalytic subunits, IKKα and IKKβ, and 
two IKKγ (also known as NEMO) scaffolding/regulatory subunits, and activation of this 
complex requires phosphorylation of two serines on either IKKα or IKKβ (Hayden and 
Ghosh, 2008; Perkins, 2007; Solt and May, 2008). Once active, IKK phosphorylates IκB, 
tagging it for proteasomal degradation, resulting in increased NF-κB activity and cell 
proliferation (Hayden et al., 2006; Perkins, 2007). All signaling events that activate NF-
κB proceed through the IKK complex, making IKK a central regulator of NF-κB 
signaling (Hayden et al., 2006; Perkins, 2007; Vallabhapurapu and Karin, 2009). 
 There are five IκB proteins: three “typical” IκB proteins, IκBα, IκBβ, and IκBε, 
which are largely interchangeable but have some differences in rates of degradation and 
resynthesis, and two “atypical” IκB proteins, IκBζ and Bcl3, which have specialized 
functions (Hayden and Ghosh, 2008). IκB binds to and prevents the DNA-binding 
activity of NF-κB dimers and effectively halts transcription of NF-κB target genes 
(Hayden and Ghosh, 2008; Tergaonkar et al., 2005). After being activated, NF-κB also 
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needs to be shut off quickly, so regulating IκB expression is a key component of NF-κB 
activity. Therefore, it is not surprising that the IκB proteins are transcriptional targets of 
NF-κB. As NF-κB activity increases, the level of IκB also increases and binds to the 
transcriptionally active p50/p65 dimers. Once bound by IκB, the p50/p65 dimer becomes 
inactive, releases DNA, and is exported from the nucleus, shutting off transcription 
(Arenzana-Seisdedos et al., 1997; Vallabhapurapu and Karin, 2009). When IκB binds to 
the p50/p65 heterodimer, it covers up the nuclear localization signal (NLS) of p50 but not 
p65, allowing the complex to still signal for nuclear translocation. Both p65 and IκB have 
exposed nuclear export signals (NES) though, which override the p65 NLS and signals 
for quick nuclear export. This causes a constant shuttling of the NF-κB/IκB complexes in 
and out of the nucleus without binding to DNA or enhancing the transcription of target 
genes (Hayden and Ghosh, 2008).  
 Aberrant NF-κB signaling in DLBCL, as well as many other cancer types, results 
in target gene transcription that aids in the prevention of apoptosis, progression from 
local to metastatic tumors, and increased angiogenesis (Naugler and Karin, 2008). In 
most cases, constitutive NF-κB activity can result from deregulation or mutation of any 
number of the upstream signaling molecules including CARD11, MALT1, CD79α and β, 
A20, IκB, TRAF2, TRAF5, or TAK1 (Compagno et al., 2009; Courtois and Gilmore, 
2006; Davis et al., 2010; Dierlamm et al. 2008; Gilmore et al., 2004; Kato et al, 2009; 
Lenz et al., 2008a). Additionally, over-expression of a mutant form of REL that is 
missing the first of two transactivation domains (termed RELΔTAD1) has been shown to 
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have enhanced transforming activity in chicken spleen cells and the GCB DLBCL cell 
line BJAB (Chin et al., 2009; Starczynowski et al., 2003). 
 
1.3  Regulation of the ↑NF-κB → ↑miR-155 → ↓PU.1 → ↓CD10 Pathway 
 CD10, also known as the common acute lymphocytic leukemia antigen (CALLA) 
or neutral endopeptidase (NEP), is a cell-surface zinc metallo-endopeptidase (Salles et 
al., 1992; Shipp et al., 1989). The activity of CD10 is to cleave signaling peptides such as 
enkephalins, chemotactic peptide, substance P, atrial natriuretic factor, endothelin, 
oxytocin, neurotensin, bradykinin, and angiotensin I and II (Boranic et al., 1997), which 
affects cell proliferation, differentiation, and migration (Salles et al., 1992 and 1993; 
Sumitomo et al., 2005; Sunday et al., 1992). Expression of CD10 can also be used as a 
diagnostic marker for a variety of cancers, including DLBCL (Ahuja et al., 2008; 
Alizadeh et al., 2000; Deschamps et al., 2006; Fleischmann et al., 2008 and 2011; Gürel 
et al., 2012; Iqbal et al., 2007; Ishimaru et al., 1996; Langner et al., 2004; Shen et al., 
2012; Voutsadakis et al., 2012). Little is known about the control of CD10 transcription, 
although sequence analysis of the CD10 promoter/enhancer region revealed the presence 
of at least three consensus binding sites for the transcription factor PU.1 (Ishimaru et al., 
1995). CD10 expression is also inversely correlated with promoter methylation, 
suggesting a mechanism of epigenetic control (Taylor et al., 2006).  
 PU.1 is a member of the Ets family of transcription factors that is required for 
proper hematopoietic stem cell development and differentiation into mature lymphoid 
and myeloid cells (Medina et al., 2004; Ramírez et al., 2010; Turkistany and DeKoter, 
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2011). In particular, high expression of PU.1 favors granulocyte and macrophage 
development and low expression favors B-cell development. Moreover, forced 
expression of PU.1 in early B cells leads to blocked development (Turkistany and 
DeKoter, 2011). PU.1 expression and activity is therefore tightly regulated through a 
number of mechanisms that control transcription, translation, and protein-protein 
interactions (Turkistany and DeKoter, 2011). Relevant to this study, translational control 
of PU.1 can be achieved by the microRNA miR-155 (Faraoni et al., 2009; Martinez-
Nunez et al., 2009; Vigorito et al., 2007). Reduced PU.1 expression caused by miR-155 
is important for the proper production of IgG1 antibodies (Vigorito et al., 2007), and 
PU.1 knockout mice have defects in the development of certain B-cell lineages (Medina 
et al., 2004). In general, there is little known about the downstream transcriptional 
network of PU.1 or how the expression of PU.1 target genes is important in immune cell 
function and regulation. 
Patients with ABC DLBCL have a high NF-κB GEP, high expression of miR-155 
reduced expression of CD10 and PU.1, and a poor clinical prognosis as compared to 
GCB DLBCL patients (Alizadeh et al., 2000; Hans et al., 2004; Iqbal et al., 2007; Staudt 
and Dave, 2005; Wright et al., 2003). The correlation between high NF-κB activity and 
reduced CD10 expression has been observed in several other settings as well. One study 
reported an inverse correlation between NF-κB activity and CD10 expression in prostate 
cancer (Voutsadakis et al., 2012) while our lab showed that over-expression of 
RELΔTAD1 in BJAB cells leads to increased NF-κB target gene expression but reduced 
CD10 expression (Chin et al., 2009). Moreover, infection of cells with EBV or human 
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cytomegalovirus, both inducers of NF-κB, causes reduced expression of CD10 (Carter et 
al., 2002; Phillips et al., 1998). Taken together, such results suggested that NF-κB or a 
target of NF-κB is involved in repressing CD10 expression in certain B-cell lymphomas, 
potentially through the regulation of PU.1. 
Interestingly, ABC DLBCL primary tumors and cell lines also have increased 
levels of the proposed NF-κB target gene product miR-155 (Davis et al., 2001; Eis et al., 
2005; Kluiver et al., 2005; Lawrie et al., 2007; Rahadiani et al., 2008; Rai et al., 2008), 
while GCB DLBCL have lower NF-κB activity and lower levels of miR-155 (Chin et al., 
2009; Rahadiani et al., 2008; Rai et al., 2008). The mature miR-155 RNA is excised from 
an exon of its primary microRNA (pri-miRNA) precursor transcript BIC by Dicer and is 
subsequently loaded into the RISC complex (Eis et al., 2005; Faraoni et al., 2009; Lagos-
Quintana et al., 2002; O’Connell et al., 2010; Tam, 2001). This miR-155/RISC complex 
can then bind to and inhibit the translation of mRNAs with a miR-155 target sequence in 
their 3`-UTR, such as PU.1, AID, IKKε, C/EBPβ, SOCS1, MITF and FADD 
(Chekulaeva et al., 2009; Dorsett et al., 2008; Faraoni et al., 2009; Teng et al., 2008; 
Thompson et al., 2010; Zhang et al., 2012a). Transgenic mice over-expressing miR-155 
in their B cells develop lymphoblastic leukemias and lymphomas and have an expanded 
population of B cells with low CD10 expression (Costinean et al., 2006; Compagno et 
al., 2009). Moreover, elevated levels of miR-155 are present in various types of B-cell 
lymphoma (Eis et al., 2005). Inhibition of NF-κB, which would be expected to reduce 
miR-155 expression, has been shown to specifically inhibit the proliferation of ABC 
DLBCL cell lines, including RC-K8 (Davis et al., 2001; Kalaitzidis et al., 2002). 
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BIC/miR-155 is one of the most extensively studied and reviewed microRNAs, 
and it is involved in immune responses and various diseases (Baltimore et al., 2008, 
Calame, 2007; Faraoni et al., 2009; Leng et al., 2011; O’Connell et al., 2010 and 2012; 
O’Connell and Baltimore, 2012; Okada et al., 2010; Pedersen and David, 2008; Quinn 
and O’Neill, 2011; Rodriguez et al., 2007; Roy and Sen, 2011; Thai et al., 2007; Tsitsiou 
and Lindsay, 2009). Like many other genes, microRNAs can be selectively expressed at 
different stages during immune cell maturation including hematopoietic stem cells, B- 
and T-lymphocytes, and myeloid cells (Baltimore et al., 2008; Haasch et al., 2002; 
O’Connell et al., 2010; Pedersen and David, 2008; van den Berg et al., 2003), and miR-
155 expression is generally increased in activated cells in response to proinflammatory 
signaling molecules like LPS, interleukins, interferons, and tumor necrosis factors 
(O’Connell et al., 2010 and 2012; Pedersen and David, 2008; Rodriguez et al., 2007; 
Thompson et al., 2010; Zhang et al., 2012a). Increased miR-155 expression is also 
observed in many inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, 
and myeloproliferative disorders (O’Connell et al., 2012) and in aggressive 
hematopoietic malignancies such as B- and T-lymphomas and leukemias (Eis et al., 
2005; Kluiver et al., 2005; Lawrie et al., 2007; O’Connell et al., 2010; Rai et al., 2008; 
Thompson et al., 2010).  
To date, the majority of the evidence indicating that NF-κB directly activates 
miR-155 expression has been extrapolated from the positive correlation between high 
NF-κB activity and increased miR-155 expression in both primary cells and 
hematopoietic malignancies (Chin et al., 2008; Eis et al., 2005; Faraoni et al., 2009; 
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Gatto et al., 2008; Kluiver et al., 2005; Lawrie et al., 2007, Rai et al., 2008; Thompson et 
al., 2010). Although this correlation is strong, a direct interaction of any NF-κB family 
member with a specific site in the BIC promoter has not been convincingly shown. A 
number of studies have set out to identify NF-κB regulatory cis elements in the BIC 
promoter, producing mixed and controversial results. One study suggests that BIC 
expression is regulated by the AP-1 site found 40 nt upstream of the TSS (Yin et al., 
2008) while another states that it is an NF-κB site more than 1100 nt upstream of the TSS 
(Gatto et al., 2008). A third study suggests NF-κB up-regulates AP-1 components, which 
then bind to the proximal AP-1 site to up-regulate miR-155 expression (Cremer et al., 
2012). Moreover, these studies did not convincingly establish BIC as a direct target of 
NF-κB or AP-1 due to experimental issues or biases in their experimental systems. 
 Because BIC is a proposed NF-κB target gene and its expression is associated 
with ABC DLBCL, which also has low CD10 and PU.1 levels (Alizadeh et al., 2000; 
Chin et al., 2008; Davis et al., 2001; Eis et al., 2005; Faraoni et al., 2009; Gatto et al., 
2008; Hans et al., 2004; Iqbal et al., 2007; Kluiver et al., 2005; Lawrie et al., 2007; 
Rahadiani et al., 2008; Rai et al., 2008; Salles et al., 1992; Thompson et al., 2010; 
Wright et al., 2003) we were interested in investigating how increased NF-κB activity 
could lead to increased expression of miR-155 and down-regulation of PU.1 and CD10 
expression in B-cell lymphoma. 
 
1.4  HDACs and Regulation of HDACi-mediated Apoptosis in DLBCL by the 
BCL-2 Family of Proteins 
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 Double-stranded DNA is packaged into chromatin by wrapping around a protein 
complex called the nucleasome. The nucleasome is composed of two of each histone (H) 
subunit: H2A, H2B, H3, and H4 (Kruszewski and Szumiel, 2005; Thiagalingam et al., 
2003). These histones have flexible tails that are subject to modifications, which 
determine chromatin structure, degree of DNA condensation, and gene regulation. These 
modifications include acetylation, methylation, ADP-ribosylation, ubiquitination, and 
phosphorylation. In particular, acetylation of lysines (K) in the histone tails coupled with 
demethylated DNA decondenses the DNA so it can be remodeled for transcription and 
DNA repair. Conversely, histone deacetylation in a specific region allows the DNA to be 
methylated, condensing the DNA into heterochromatin and subsequent gene silencing. In 
fact, K9-acetylation on H3 is correlated with active chromatin while K9-methylation is 
correlated with condensed heterochromatin (Thiagalingam et al., 2003). 
 Histone tail acetylation is dependent of the opposing actions of two classes of 
enzymes: histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs 
transfer acetyl groups from acetyl-CoA to the ε-amino group of lysines on histone tails 
and many non-histone substrates (Stimson and Thangue, 2009), while HDACs remove 
the acetyl group (de Ruijter et al., 2003; Shakespear et al., 2011). Histone acetylation was 
first discovered in the mid-1960s and was hypothesized to regulate gene transcription 
(Allfrey, 1966). The first human histone acetylation-modifying protein was cloned from 
the Jurkat T-cell library in 1996, encoding a small histone deacetylase protein that was 
predicted to be similar to the yeast transcriptional regulator Rpd3p (Taunton et al., 1996). 
To date, 18 HDACs (Table 1.2) have been discovered in humans and they are involved in 
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a variety of biological processes including transcriptional regulation, cell cycle 
progression, gene silencing, differentiation, proliferation, DNA replication, stem cell 
development and maintenance, DNA damage response, chromatin remodeling, 
cytoskeleton reorganization, transcription factor function, and induction of apoptosis 
(Choudhary et al., 2009; de Ruijter et al., 2003; Marmorstein, 2001; Seidel et al., 2012; 
Shakespear et al., 2011; Stünkel and Campbell, 2011; Thiagalingam et al., 2003).  
 The HDAC superfamily contains two subfamilies: the Zn2+-dependent classical 
HDACs and the NAD+-dependent sirtuins. Classical HDACs consist of class I (HDAC1-
3, 8), IIa (HDAC4, 5, 7, 9), IIb (HDAC6, 10) and IV (HDAC11) HDACs while sirtuins 
make up class III (SIRT1-7) (de Ruijter et al., 2003; Seidel et al., 2012; Shakespear et al., 
2011; Stünkel and Campbell, 2011; Zschoering and Mahlknecht, 2008).  
 This section will focus on the effects of protein deacetylation carried out by 
HDACs in hematopoietic cell function, differentiation, and malignancies while 
illustrating the roles of HDACs in other cellular systems for comparison. Additionally, 
current treatment strategies that aim to disrupt HDAC activity will be discussed. Most 
notably, modulation of the cellular acetylation status by HDAC inhibitors has been 
correlated with improved outcome in a number of hematopoietic malignancies, resulting 
in FDA approval of vorinostat and romidepsin in the treatment of cutaneous T-cell 
lymphoma (Campas-Moya, 2009; Mann et al., 2007). 
 
1.4.1  The Complex Relationship Between HDACs and HATs 
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 Although it is widely accepted that HDACs turn off and HATs turn on gene 
expression, new research has shed light on a more dynamic and complex relationship. 
Wang et al. (2009) used genomic mapping to assess the binding sites of HDACs 
(HDAC1-3, 6) and HATs (CBP, p300, PCAF, Tip60, and MOF) in human CD4+ T cells. 
As expected, all HATs were associated with gene expression, Pol II binding, and 
increased acetylation and showed a similar global distribution. Surprisingly, HDAC 
binding positivity correlated with increased mRNA levels, RNA Pol II levels, and histone 
acetylation whereas silenced genes had little HDAC binding. These findings challenge 
the traditional view that HDAC binding is only associated with silenced genetic regions, 
suggesting that a delicate balance of histone acetylation and deacetylation controls gene 
transcription. Interestingly, there was little HDAC binding associated with inactive genes, 
while a subset of silenced genes were up-regulated within 10 min of HDACi treatment, 
suggesting that some genes are under a constant and transient cycle of acetylation and 
deacetylation, leaving them “poised” for expression. This set of “poised” genes is 
associated with H3K4-methylation as well as the presence of the important gene 
regulating histone variant H2A.Z in the gene promoter, further illustrating the importance 
of epigenetic balance in gene regulation (Wang et al., 2009). 
 Although HDACs and HATs were originally shown to regulate histone 
acetylation status, it is now well accepted that both families of proteins have a number of 
non-histone targets as well. One example is the regulation of Foxp3 expression and 
function in CD4+ suppressor T cells, known as Tregs. Foxp3 is the master regulator of 
Treg function: high Foxp3 expression leads to immunosuppressive Treg activity, 
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preventing self-reactivity of the immune system (Littman and Rudensky, 2010; 
Sakaguchi et al, 2008). The FOXP3 gene contains two enhancer regions downstream of 
the transcription start site (TSS) which contains an NF-AT/Smad3 binding site (Tone et 
al., 2008; Xu et al., 2010). Stimulation of CD4+ Tregs with TGF-β and retinoic acid leads 
to increased histone acetylation, Smad3 binding, and Foxp3 expression (Xu et al., 2010). 
Interestingly, the function of both murine and human Foxp3 proteins can be directly 
regulated by the opposing actions of HATs and HDACs on three specific lysines (Beier et 
al., 2011; Li et al., 2007; Nie et al., 2009; van Loosdregt et al., 2010, 2011). Acetylation 
and increased Foxp3 DNA binding leads to a reduction in NF-κB activity (Kwon et al., 
2006), loss of IL-2 production (Samanta et al., 2008; Tao et al., 2007), and suppression 
of CD4+ T-cell activation and proliferation in mice by loss of AP-1 actvity (Zhang et al., 
2009). Additionally, HDAC9-/- mice have increased Foxp3 acetylation and function, 
leading to expanded numbers of Tregs and protection from inflammatory-associated 
pathology in an irritable bowel disease model (de Zoeten et al., 2010).  
 It has become clear that HDACs and HATs are dynamic regulators of cell 
function. Histone and non-histone acetylation leads to a multitude of cellular changes, 
which vary depending on the cell type. Given the number of HDACs and HATs, it is not 
surprising that each would have specialized functions, which are summarized below. 
 
1.4.2 The Classical HDAC Family 
 The classical HDAC family has been reviewed in great detail and members of this 
family have been shown to vary in terms of subcellular localization and substrates, to be 
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ubiquitously expressed but varied in certain cell types, and are found in complexes with 
many different co-factors (Table 1.2) (de Ruijer et al., 2003; Shakespear et al., 2011; 
Thiagalingam et al., 2003; Villagra et al., 2010). Classical HDACs range in size from 
347-1122 amino acids (aa), contain at least one deacetylase domain, and vary in 
subcellular localization and the ability to shuttle between the cytoplasm and the nucleus 
as determined by the presense of nuclear localization signals (NLS) and/or nuclear export 
signals (NES). As a whole, HDACs are part of large regulatory complexes that effect 
transcription, hormone signaling, cell cycle, differentiation, development, DNA repair, 
proliferation, and cell death (de Ruijer et al., 2003; Hagelkruys et al., 2011; Seidel et al., 
2012; Shakespear et al., 2011; Thiagalingam et al., 2003; Villagra et al., 2010).  
 A hallmark of the classical HDAC family is their involvement in the regulation of 
proliferation, cell cycle progression, and cell survival. Loss of HDAC activity can result 
in terminal differentiation into a more mature cell type, cell cycle arrest at the G1/S or 
G2/M phase transitions, and apoptosis in transformed cells (de Ruijter et al., 2003; 
Hagelkruys et al., 2011). For instance, loss of either HDAC1 or 2 in neuronal precursors, 
differentiated fibroblasts, B cells, hematopoietic cells, and cardiomyocytes shows no 
obvious phenotype while loss of both HDAC1 and 2 results in major defects in cell cycle 
progression, survival, and development in a number of cell types including early B cells 
(Montgomery et al., 2007 and 2009; Wilting et al., 2010; Yamaguchi et al., 2010). 
Additionally, conditional deletion of HDAC1 and 2 in cardiomyocytes results in a 
complete block of tumor growth when these cells are injected into nude mice (Haberland 
et al., 2009a). Silencing of HDAC3 leads to induction of the cell cycle regulator p21 in 
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colon cancer and results in G2/M arrest and apoptosis, while conditional deletion in 
mouse embryonic fibroblasts (MEFs) results in delayed S-phase progression and DNA 
damage, with no obvious mitotic defects (Bhaskara et al., 2008; Wilson et al., 2006). 
Loss of HDAC3, as well as HDAC6, leads to decreased phosphorylation of H3S10, 
G2/M arrest, and proteasomal degradation of the serine/threonine kinases Aurora A and 
B in renal cancer (Cha et al., 2009; Wilson et al., 2006). Additionally, knock-down of 
HDAC4 causes reduced tumor-cell proliferation that is associated with increased p21 
expression and cell cycle arrest in a number of cancer cells (Mottet et al., 2009; Wilson et 
al., 2008). Down-regulation of HDAC4 or SMRT resulted in increased acetylation of H3 
in the p21 promoter, suggesting that p21 repression involves a co-repressor complex of 
HDAC4 with the HDAC3-N-CoR/SMRT complex (Wilson et al., 2008). 
 Mouse studies have shown that knockout of HDAC1 or 3 is embryonic lethal due 
to cell cycle defects (Bhaskara et al., 2008; Lagger et al., 2002; Montgomery et al., 
2008). Specifically, knockout of HDAC1 in mice is lethal due to proliferation defects, 
increased levels of p21 and p27, and severe development abnormalities (Lagger et al., 
2002). Knockout of HDAC2 or 8 results in peri/postnatal lethality due to cardiac defects 
and skull instability (Haberland et al., 2009b; Montgomery et al., 2007; Trivedi et al., 
2007). Knockout of HDAC7 in mice is embryonic lethal due to endothelial dysfunction 
(Chang et al., 2006) and HDAC4 knockout is peri/postnatal lethal due to ectopic cartilage 
ossification (Vega et al., 2004). Conversely, HDAC5 and 9 knockout mice are viable, but 
have myocardial hypertrophy after stress (Chang et al., 2004; Zhang et al., 2002). 
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1.4.3  The Sirtuins: Class III HDACs 
 The sirtuins make up the NAD+-dependent class III HDAC family and are 
comprised of seven members, SIRT1-7, that range in size from 33.9-81.7 kDa (reviewed 
in Finkel et al., 2009; Haigis and Sinclair, 2010; Seidel et al., 2012). SIRTs 3-7 also 
possess ADP-ribosylase activity (Finkel et al., 2009; Haigis and Sinclair, 2010; Seidel et 
al., 2012). The sirtuin family was first found to be involved in DNA damage and aging, 
but have since been shown to also regulate the immune system, metabolism, and cell 
cycle regulation (Finkel et al., 2009; Haigis and Sinclair, 2010; Stünkel and Campbell, 
2011) (Table 1.2). Sirtuin knockout mouse phenotypes vary depending on which sirtuin is 
eliminated and can result in embryonic lethality, reduced DNA damage repair, sterility in 
adulthood, developmental defects and die by 4 weeks, cardiac failure and reduced 
lifespan, or develop normally with minor defects (Cheng et al., 2003; Finkel et al., 2009; 
Haigis and Sinclair, 2010; Kelly, 2010; McBurney et al., 2003; Wang et al., 2008) (Table 
1.2). Because the sirtuin family is not a target of pan-HDACi compounds like vorinostat 
and romidepsin, the sirtuins are not discussed further in this thesis. 
 
1.4.4 HDACS in Hematopoietic Function 
 B- and T-lymphocytes are two of the many cell types that differentiate from 
hematopoietic stem cells (HSCs) (Ikuta et al., 1992; Northrup and Allman, 2008). HSCs 
have the ability to generate multipotent precursor cells including common myeloid 
progenitors (CMPs) and common lymphoid progenitors (CLPs) (Akashi et al., 2000; 
Kondo et al., 1997). CMPs and CLPs eventually develop into a number of hematopoietic 
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cell types, provided they have the right microenvironment and transcriptional regulation. 
B cells depend on a highly regulated balance between the transcription factors PU.1, 
Ikaros, E12, E47, EBF, and Pax5 to drive B-cell development (Hagman et al., 1991 and 
1993; Laslo et al., 2006; Lin et al., 1995; Thevenin et al., 1998; Urbanek et al., 1994; 
Yoshida et al., 2006; Zhuang et al., 2004), while T cells depend on the cell-surface 
receptor Notch-1 and the transcription factor GATA3 (Allman et al., 2002; Ko et al., 
1991; Maillard et al., 2005; Pai et al., 2003; Ting et al., 1996). Blimp-1 has also been 
shown to be an important regulator of B- and T-cell differentiation and function in 
lineage committed cells (Martins and Calame, 2008; Turner et al., 1994).  
  
 HDAC control of B-cell development and differentiation 
 A number of HDACs have also been implicated in lymphoid development. In B 
cells, co-deletion of HDAC1 and 2, but not single gene deletions, almost completely 
blocks early B-cell development and the remaining B cells exhibit an accumulation in G1 
phase and apoptosis (Yamaguchi et al., 2010). Additionally, when HDAC1 and 2 are 
selectively deleted from mature resting B cells, the B-cell compartment appears normal 
but these cells fail to elicit an immune response when challenged with IL-4 and LPS, 
resulting in apoptosis instead. HDAC6-/- mice show normal B-cell development with 
increased levels of acetylated microtubules, but have moderately reduced IgM and IgG 
levels following antigen stimulation (Zhang et al., 2008), which may be due to HDAC6 
involvement in immune synapse formation and T-cell migration (Cabrero et al., 2006; 
Serrador et al., 2004). Additionally, HDAC5 and 7 are phosphorylated by protein kinase 
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D1 and D3 and exported from the nucleus as a result of BCR signaling, pointing towards 
a role for these HDACs in epigenetic regulation by the BCR (Matthews et al., 2006).  
 HDACs have also been shown to be regulators of terminal B-cell differentiation 
of GC B cells into antibody-secreting plasma cells during the immune response. Overall, 
at least 100 genes are altered during this process including increased production of 
secreted Ig (sIg) with loss of cell-surface Ig expression, down-regualtion of MHC class II 
antigens and CD20, and changes in cell morphology (Burrows et al., 1997; Henderson 
and Calame, 1998; Turner et al., 1994).  
 A useful tool for understanding terminal B-cell differentiation has been the L10A 
mouse lymphoma cell line, which expresses high levels of surface IgM and IgD (Lee et 
al., 2003). Treatment of L10A cells with 30 nM Trichostatin A (TSA, a pan-HDACi) for 
8 and 48 h resulted in a 5-fold increase of acetylated H4. Between 4-12 h, 30 nM TSA 
caused an up-regulation of Blimp-1 and J-chain expression. Blimp-1, also known as the 
master regulator of B-cell differentiation, is a transcriptional repressor of c-Myc, CIITA 
(MHC class II transactivator), and Pax-5/BSAP in B cells (Messika et al., 1998; Turner et 
al., 1994). Importantly, Pax-5/BSAP is expressed in all stages of B cells except 
terminally differentiated plasma cells (Horcher et al., 2001; Usui et al., 1997). 
 An important transcription factor in B-cell differentiation is BCL6, which controls 
a particular set of genes involved in GC development (reviewed by Okada et al., 2012), 
serving as an anti-apoptotic factor for cell survival during an immune response due to the 
high frequency of Ig mutation that occurs (Arguni et al., 2006). To achieve GC-specific 
gene expression, BCL6 is recruited to a large repressor complex containing HDAC4, 5, 
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and 7 and localizes to the nucleus to regulate a specific set of target genes (Lemercier et 
al., 2002). Treatment with an HDACi results in hyper-acetylated BCL6, which 
derepresses expression of BCL6 target genes involved in lymphocyte activation, 
differentiation, and apoptosis (Bereshchenko et al., 2002; Pasqualucci et al., 2003). 
 
 HDAC control of T-cell development and differentiation 
 In T cells, HDAC7 has been shown to control negative selection of CD4+CD8+ T 
cells. When the T-cell receptor (TCR) is engaged by antigen, TCR signaling results in 
HDAC7 export from the nucleus and expression of genes involved in negative selection 
of T cells like the pro-apoptotic gene Nur77, and TCR-mediated apoptosis (Calnan et al., 
1995; Dequiedt et al., 2003; Woronicz et al., 1994). Interestingly, HDAC7 can also 
control positive selection of CD4+CD8+ T cells. Mice with a T-cell compartment that 
expresses a mutant HDAC7 that acts as an transcriptional activator in the absence of TCR 
induction exhibit perturbed thymocyte development, reduced T-cell life span, reduced 
numbers of CD4+ and CD8+ T cells, and constitutively phosphorylated HDAC7 that is 
exported from the nucleus (Kasler and Verdin, 2007). Additionally, conditional loss of 
HDAC1 in T cells results in increased cellular proliferation (Grausenburger et al., 2010).  
 HDACs have also been shown to control Foxp3, which is a major transcription 
factor in Treg function and development and is normally found in a regulatory complex 
with Tip60, HDAC7, and HDAC9 (Li et al., 2007). Foxp3 acetylation leads to increased 
binding to the IL-2 promoter and loss of IL-2 production, while Foxp3 is inhibited by 
HDAC9 deacetylation and promotes Treg fucntion and development (Samanta et al., 
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2008; Tao et al., 2007). Additionally, HDAC9 knockout mice have expanded numbers of 
Tregs, which protect mice from inflammatory-associated pathology in an irritable bowel 
disease model (de Zoeten et al., 2010). Conversely, HDAC6 knockout mice have 
enhanced immunosuppressive activity and constrained Treg function (de Zoeten et al., 
2011), suggesting specialized roles for each HDAC in normal cellular function. 
 
 Regulation of immune responses by HDACs 
HDACs can also regulate immune responses through direct deacetylation of 
transcription factors like NF-κB, STAT1, and STAT3 (Chen et al., 2001 and 2002; 
Nusinzon et al., 2003; Yuan et al., 2005). For instance, the NF-κB signal transduction 
pathway is regulated by HDACs at multiple points. HDAC1 binds to p50 in unstimulated 
cells to repress transcription of NF-κB target genes (Zhong et al., 2002). After cellular 
stimulation, the p50/p65 heterodimer translocates to the nucleus and displaces the 
p50/HDAC1 complex from DNA, resulting in target gene expression (Zhong et al., 
2002). There are seven lysine residues on p65 that can be acetylated, impacting DNA 
binding, transcriptional activity, and association with its inhibitor, IκB (Buerki et al., 
2008; Choi et al., 2005; Huang et al., 2010; Yang et al., 2009 and 2010). For example, 
lysines K314 and K315 can be methylated (activates p65) or acetylated (inhibits p65). 
Acetylation of K320 prevents the methylation of K314/K315 and blocks ubiquitin-
mediated degradation, allowing for nuclear translocation of p65 and activation of target 
genes including the anti-apoptotic XIAP and BCL-XL (Chen et al., 2000; Stehlik et al., 
1998). HDAC3 and SIRT1 can also deacetylate p65, resulting in increased association 
  
37 
 
with IκB, export from the nucleus, and loss of NF-κB activity (Chen et al., 2001, 2002; 
Yeung et al., 2004). Interestingly, though treatment with HDACi is associated with 
increased nuclear p65 (Dai et al., 2005), HDACi also reduces toll-like receptor (TLR)-
activated recruitment of p65 to the promoters of inflammatory genes (Bode et al., 2007; 
Roger et al., 2011), making HDAC-mediated control of NF-κB activity a complicated 
regulatory network. Moreover, in non-small cell lung cancer, HDACi treatment down-
regulates TNF-α induced NF-κB activity by inducing degradation of the regulator of NF-
κB activity, IKK, resulting in decreased NF-κB nuclear localization and DNA binding, as 
well as expression of TNF-α receptor-1, resulting in tumor cell death (Imre et al., 2006).  
Nevertheless, the compilation of these findings suggests that there might be a role 
for HDAC-mediated regulation of p65 in NF-κB-dependent cancers, including aggressive 
leukemia and lymphoma. One can imagine that the acetylation level of p65 in a tumor 
would be kept in balance by HDACs and HATs, resulting in a level of NF-κB activity 
that would allow for transcription of genes that aid in tumor survival and proliferation. 
The use of HDACi would then result in increased p65 acetylation and increased NF-κB 
activity to a point that would overwhelm the cell, resulting in tumor cell death. 
The STAT family of transcription factors can also be regulated by HDAC 
activity. Dephosphorylation or CBP-mediated acetylation of STAT1 results in nuclear 
export and loss of STAT1 activity (Kramer et al., 2006), whereas deacetylation of 
STAT1 by HDAC1, 2, or 3 allows for phosphorylation and activation (Klampfer et al., 
2004; Kramer et al., 2009). Furthermore, treatment of human melanoma cell lines with 
HDACi leads to increased STAT1 acetylation, increased interaction between STAT1 and 
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p65, nuclear export of p65, decreased NF-κB activity, and apoptosis (Kramer et al., 
2006). Additionally, acetylation status STAT3 and STAT1 has an opposite effect. STAT3 
is actviated by cytokine-mediated acetylation (Paulson et al., 1999), while deacetylation 
reduces STAT3 activity (Nie et al., 2009; Yuan et al., 2005). These results demonstrate 
the opposing forces that acetylation has on multiple members of the STAT family. 
 
1.4.5 Involvement of HDACs in Hematopoietic Malignancies 
 Many hematopoietic tumor cells are different from normal cells in that they show 
altered or no differentiation in the presence of continued proliferation. Although HDACs 
are ubiquitously expressed and histone acetylation is essential for all cells, there are many 
cancers that exhibit deregulated HDAC function. For instance, HDAC1 is over-expressed 
in prostate, gastric, colon, and breast cancers as well as T-cell lymphoma (Choi et al., 
2001; Halkidou et al., 2004; Marquard et al., 2009; Wilson et al., 2006; Zhang et al., 
2005). HDAC2 is over-expressed in colorectal, cervical, and gastric cancers (Huang et 
al., 2005; Song et al., 2005; Wilson et al., 2006; Zhu et al., 2004), HDAC3 is over-
expressed in colon cancers (Wilson et al., 2006), and HDAC6 is over-expressed in breast 
cancer and DLBCL (Marquard et al., 2009; Zhang et al., 2004). Additionally, over-
expression of BCL6 in DLBCL leads to increased interaction with HDAC2, which aids in 
sustaining the malignant state of the tumor (Deltour et al., 1999).  
There is great variation in HDAC expression among hemoatopoetic cancers. For 
example, one study showed that HDAC1 is more highly expressed in peripheral T-cell 
lymphoma (PTCL) than in DLBCL, while elevatedHDAC6 expression correlates with a 
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more favorable outcome in DLBCL and a less favorable outcome in PTCL (Marquard et 
al., 2009). Although HDAC1, 2, and 6 and acetylated H4 are over-represented in both 
lymphomas compared to normal lymphoid tissue, HDAC1 and 2 and acetyl-H4 had no 
significant correlation with survival of either DLBCL or PTCL patients. Another study 
characterized HDAC expression via immunohistochemistry in lymphoma (Gloghini et 
al., 2009). HDACs 1-3 were expressed in all patients tested and HDAC8 was expressed 
in 142/147 DLBCLs and 3/3 classical Hodgkin lymphomas tested. HDAC5, 10, and 11 
were similar, as they were expressed in all non-Hodgkin lymphomas tested, while 
HDAC5 was expressed in 2/3 classical Hodgkin lymphomas tested, HDAC10 was 
expressed in all classical Hodgkin lymphomas tested, and HDAC11 was not expressed in 
the four classical Hodgkin lymphomas tested. HDAC6 was the most variable HDAC, 
which was expressed in 2/52 DLBCL and all 22 classical Hodgkin lymphomas tested, 
and was also the most variably expressed HDAC in 14 lymphoid cell lines also tested in 
this study. Moreover, DLBCL and T-cell lymphomas often have over-expression of 
HDAC1, 2, or 6, and classical Hodgkin’s have over-expression of HDAC 1, 2, and 3 with 
HDAC1 expression correlating with a worse outcome (Adams et al., 2010). Overall, 
differences in expression levels of individual HDACs can be associated with different 
cancer types, but the clinical implications of these differences is still unknown. 
 
1.4.6  HDACi and Hematopoietic Malignancies 
 Initially developed to modulate chromatin condensation to affect transcriptional 
activation and gene expression, HDACi compounds like soduim butyrate (NaB) were 
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found to have anti-tumor capabilities when shown to induce terminal differentiation in 
erythroleukemia (Leder et al., 1975; Richon et al., 1998; Tanaka et al., 1975). It was later 
discovered that NaB-induced histone hyperacetylation (Riggs et al., 1977), which caused 
inhibition of tumor cell growth and survival (Richon et al., 1998; Yoshida et al., 1990). 
Today, there are a number of structurally diverse synthetic and natural product HDACi 
compounds, 11 of which are in clinical trials (Table 1.3). HDACi’s restore the balance 
between differentiation and proliferation, forcing tumor cells to differentiate into more 
mature cell types and relieving their constant proliferative potential (Hagelkruys et al., 
2011). This is achieved by regulating the acetylation status of histones and non-histone 
proteins that ultimately affect the expression of genes or the activity of proteins 
associated with inhibition of angiogenesis, the endoplasmic stress response, cellular 
differentiation, cell cycle arrest at both G1/S and G2/M phase transitions, BCL-2 family-
mediated apoptosis, and tumor suppressor genes or oncongenes in a number of cancer 
types, including a variety of lymphomas and leukemias (Bolden et al., 2006; Cotto et al., 
2010; Piekarz and Bates, 2009; Wiegmans et al., 2011; Zain and O’Connor, 2010).  
Gene expression profiling using microarrays has shown that up to 22% of genes 
are altered by HDACi as early as 4 h post treatment several cell types (Halsall et al., 
2012; Peart et al., 2003; Van Lint et al., 1996). A major conclusion from these profiling 
studies is that HDACi treatment results in expression of pro-apoptotic genes and 
suppression of anti-apoptotic genes (Inoue et al., 2007a; Mitsiades et al., 2004; Zhang et 
al., 2006; Zhang et al., 2012b). Apoptosis can be achieved through two different 
mechanisms: the intrinsic and extrinsic pathways. The intrinsic pathway is controlled by 
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BCL-2-mediated mitochondrial permeablization and cytochrome C release (Shamas-Din 
et al., 2011; Strasser et al., 2011; Youle and Strasser, 2008). Specific to this thesis, 
inhibition of HDAC activity results in a change in BCL-2 family expression to favor a 
pro-apoptotic state. The extrinsic pathway involves binding of ligands to their appropriate 
death receptors (Fas, TNF, TRAIL), leading to the release and activation of caspase-8 and 
-10, and subsequent activation of effector caspases (reviewed by Hagelkruys et al., 2011; 
Zain and O’Connor, 2010).  
 GEP studies of various lymphoma and leukemia cell lines have shown similar 
results across studies. CTCL cell lines treated with vorinostat showed that HDACi 
treatment led to hyperacetylation of all core histones, which is associated with changes in 
the expression of genes involved in cell cycle regulation of the G1/S and G2/M 
transitions, apoptosis, antiproliferation, and MAPK signaling (Richon et al., 2000). 
Treatment of the promyelocytic leukemia cell line HL60 with TSA, vorinostat, or VPA 
showed that all three HDACi’s induced G2/M cell cycle arrest, while only vorinostat and 
TSA induced apoptosis (Halsall et al., 2012). Microarry results showed that an 8-h 
treatment with either 2.5 µM vorinostat, 5 mM VPA, or 165 nM TSA changes only 258 
genes (5%), 369 genes (7%), and 675 genes (13%), respectively. Surprisingly, only seven 
of the 1167 genes were dysregulated by all three HDACi treatments, although histone 
acetylation status was increased to a similar degree, suggesting a pathway specific effect 
for each HDACi. Another study treated the K562 human chronic myelogenic leukemia 
cell line with 2 mM VPA for 12 h (Zhang et al., 2012b). The microarray identified 706 
altered transcripts, 34 of which are involved in apoptosis, including up-regulation of pro-
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apoptotic protein BAX and down-regulation of the BH3-only apoptosis modulator protein 
BID. GO analysis showed that genes involved in cytochrome C release were enriched. In 
another study (Mitsiades et al., 2004), vorinostat was shown to induce irreversible 
apoptosis in multiple myeloma cell lines, and gene expression profiling revealed an up-
regulation of p53 and the pro-apoptotic proteins Apaf-1 and caspase-9 while there was a 
down-regulation of the anti-apoptotic genes FLIP, survivin, Apo2L/TRAIL, and XBP-1, 
priming the cells for apoptosis. There was also an up-regulation in growth arrest and anti-
proliferative genes like p19, p21, p57, and BTG-1 while proliferation genes like CDK4, 
cyclins, and others were down-regulated. A number of other HDACi-regulated genes fall 
into groups including cytokine-induced proliferative/survival signaling cascades, 
oncogenes/tumor suppressor genes, regulators of apoptosis, DNA synthesis/repair and 
cell cycle, and proteasome/ubiquitin function. 
 Molecular studies of HDACi treatment in a variety of different cancer types have 
confirmed the GEP results, showing that there is a set of common HDACi-regulated 
genes including the cyclins A, E, B1, D1, and D3, p21, p53, Bax, BCL-2, c-myc, PKCδ, 
ICAM-1, IL-6 receptor, IL-2, IL-8, IL-10, VEGF, Notch, GADD45α and GADD45β, 
TGFβ receptor, CTP synthase, and thymidylate synthase (reviewed by Bolden et al., 
2006; de Ruijter et al., 2003; Zain and O’Connor, 2010). These types of molecular 
studies have shown that HDACi’s can induce cell cycle arrest by a p53-dependent 
induction of p21 in order to repress cyclin D and A, which contributes to the loss of 
CDK2 and 4 activity and up-regulation of cell cycle regulators GADD45α and 
GADD45β (reviewed by Bolden et al., 2006; Zain and O’Connor, 2010). HDACi 
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treatment also leads to hyperaceylation of p53, which stabilizes the protein and increases 
expression of pro-apoptotic target genes like BCL-2 family members BAX, PUMA, and 
NOXA (Xu, 2003). Additionally, p21 is up-regulated by the HDACi compounds 
vorinostat and VPA in many cancer types, including Hodgkin lymphoma (Buglio et al., 
2008), multiple myeloma (Mitsiades et al., 2004), and other human lymphoid cancers 
(Sakajiri et al., 2005), and is thought to be the important molecular event that makes 
HDACi treatment toxic to lymphomas and leukemias. Furthermore, vorinostat and VPA 
can decrease STAT6 and BCL-XL levels in Hodgkin lymphoma (Buglio et al., 2008) and 
cyclin D1/D2 in mantle cell lymphoma (Sakajiri et al., 2005) promoting cell cycle arrest 
and apoptosis. Vorinostat has also been shown to repress expression of TCR signaling 
genes including ZAP70, CD3DIL4, IL5, IL10, FOXP3 and to increase expression of 
FYN, IFNG, IL12A (reviewed by Zain and O’Connor, 2010). 
 Important to this thesis, HDACi treatment of tumor cells has been strongly linked 
to the modulation of BCL-2 family expression to favor a pro-apoptotic expression pattern 
(reviewed by Bolden et al., 2006; Hagelkruys et al., 2011; Zain and O’Connor, 2010). 
There are three classes of BCL-2 family proteins: anti-apoptotic, BH3-only modulators of 
apoptosis, and pro-apoptotic activators (reviewed by Shamas-Din et al., 2011; Strasser et 
al., 2011). In many cases, HDACi-induced apoptosis has been shown to act through the 
up-regulation of the pro-apoptotic BH3-only protein BIM (reviewed by Bolden et al., 
2006; Chen et al., 2009). Tumor cells attempt to protect themselves from BCL-2-
mediated apoptosis with increased expression of anti-apoptotic proteins or decreased 
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expression of pro-apoptotic proteins, thus shifting the balance of BCL-2 proteins to an 
anti-apoptotic state.  
 Ultimately, HDACi treatment results in p21-mediated cell cycle arrest, increased 
apoptosis, mitochondrial permeablization, release of cytochrome C, and BIM-mediated 
caspase-9 and -3 activation (reviewed by Bolden et al., 2006; Zain and O’Connor, 2010). 
The HDACi compounds MS-275 and vorinostat are also associated with hyperacetylation 
and increased nuclear localization of p65 in B- and T-cell leukemia cell lines (Dai et al., 
2005). The use of an NF-κB inhibitor with HDACi treatment also potentiates apoptosis 
and increases ROS production (Dai et al., 2005; Dasmahapatra et al., 2010; Moreira et 
al., 2003). 
 A common translocation found in B-cell lymphomas is the t(14,18) translocation 
that places the BCL-2 gene downstream of the IgH promoter (Graninger et al., 1987). 
This translocation is found in 85% of follicular lymphomas and 20% of DLBCLs. When 
treated with NaB or trichostatin A (TSA), cell lines harboring this translocation show an 
increase in c-Myc and NF-κB activity, undergo G0/G1 cell cycle arrest, transcriptional 
down-regulation of BCL-2, and apoptosis (Duan et al., 2005). There is also increased 
acetylation of Sp1 and C/EBPα, resulting in decreased DNA binding at the BCL-2 
promoter with decreased interactions with CBP and HDAC2. 
 
1.4.7  Clinical Success of HDACi’s 
 Vorinostat, romidepsin, and other HDACi compounds have been quite successful 
in treating hematopoietic malignancies in the clinic. Importantly, HDACi treatment 
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spares normal and premalignant cells from apoptosis with minimal, dose-limiting toxicity 
to the host including thrombocytopaenia, nausea, and fatigue, all of which are clinically 
manageable (reviewed by Bolden et al., 2006; Zain and O’Connor, 2010). Thus, in 
response to HDACi treatment, only malignant cells undergo apoptosis and show induced 
expression of important pro-apoptotic genes like TRAIL, death receptor 5 (DR5), Fas, 
and BIM (Bolden et al., 2006; Chen et al., 2009; Insinga et al., 2005). Currently, 
vorinostat and romidepsin are approved in the US for the treatment of relapsed and 
refractory T-cell lymphomas (Campas-Moya, 2009; Mann et al., 2007). Table 1.4 
summarizes a Pubmed search for the success of vorinostat and romidepsin in clinical 
trails of hematopoietic cancers. Overall, vorinostat and romidepsin have been successful 
at treating most hematopoietic malignancies, with response rates ranging from 40-68%.  
 Other HDACi compounds have recently been the focus of clinical trials and cell 
culture studies in hematopoietic cancers (Table 1.3). Three of these HDACi’s have made 
it to phase III clinical trials and have been studied in a wide range of lymphomas, 
leukemias, and myelomas: valproic acid (VPA), belinostat, and panobinostat. In addition 
to HDACi’s that target classical HDACs, new research has developed a handful of sirtuin 
inhibitors. The SIRT1-specific inhibitor tenovin-6 was shown to reduce growth of 
chronic myelogenous leukemia cells, with higher efficacy when combined with the 
tyrosine kinase inhibitor imatinib (Li et al., 2012). Another SIRT1 inhibitor, amurensin 
G, can also induce cell death in the TRAIL-resistant leukemic cell line K562 (Kim et al., 
2012). Additionally, synergism between classical HDAC inhibitors and sirtuin inhibitors 
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has been observed by co-treatment of leukemic cell lines, specifically valproic acid with 
EX527, sirtinol, or cambinol, respectively (Cea et al., 2011).  
 HDACi’s have been combined with a number of other cancer theraputics 
including gemcitabine (nucleoside analog), paclitaxel (mitotic inhibitor), cisplatin 
(alkylating agent), etoposide (topoisomerase inhibitor), doxorubicin (anthracycline 
antiboiotic), 17-AAG (Hsp90 inhibitor), bortezomib (proteasome inhibitor), carfilzomib 
(proteasome inhibitor), 5’-azacytidine (DNA methyltransferase inhibitor), and ABT-737 
(BH3 mimetic) (Chen et al., 2009; Dasmahapatra et al., 2010; reviewed by Stimson and 
Thangue, 2009) (Table 1.3) and have shown combinatorial or synergistic effects for the 
treatment of a variety of cancers including hematopoietic malignancies. Synergistic 
activity has been observed in mantle cell lymphoma and chronic lymphocytic leukemia 
cell lines with belinostat, vorinostat, or romidepsin and the proteasome inhibitor 
bortezomib (Dai et al., 2008; Heider et al., 2008; Paoluzzi et al., 2010), resulting in 
induced mitochondrial depolarization and apoptosis along with decreased cyclin D and 
BCL-XL expression and decreased NF-κB activity (Heider et al., 2008). Another 
proteasome inhibitor, carfilzomib, was shown to synergize with vorinostat in DLBCL 
(Dasmahapatra et al., 2010). This combination treatment led to activation of JNK and p38 
MAPK signaling, decreased NF-κB and AKT activity, and Ku70 acetylation, which led 
to cell cycle arrest at G2/M phase and caspase-mediated apoptosis. Additionally, the use 
of a PKCβ-inhibitor coupled with vorinostat or VPA increased apoptosis and cell cycle 
arrest at G2/M in DLBCL and T-cell lymphoma cell lines (Bodo et al., 2011). The class I 
HDAC specific inhibitor MGCD0103, synergizes in Hodgkin lymphoma cell lines with 
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protease inhibitors in an HDAC6-independent mechanism and induced apoptosis (Buglio 
et al., 2010). This apoptosis was associated with increased H3 acetylation, p21 
expression, and cleaved capsase-3 while decreases in cell viability and XIAP expression 
were also observed. GEP studies showed an up-regulation in genes involved in interferon 
gamma, IL-6, IL-8, and IL-23 signaling. Moreover, these GEP studies showed an up-
regulation of SOCS3, STAT1, and STAT4 and down-regulation of JAK2, JAK3, STAT5, 
and STAT6, all of which change JAK/STAT signaling in favor of a pro-apoptotic profile. 
 The BH3 mimetic ABT-737 has been successful at inducing apoptosis in a 
number of hematopoietic cell lines, especially in combination with HDACi. ABT-737 is a 
molecule that resembles the BH3 domain of the BCL-2 family member BAD (Oltersdorf 
et al., 2005), which specifically targets the BH3 binding pocket of BCL-2 and BCL-XL, 
thereby inhibiting binding of the BH3-containing BCL-2 members that modulate and 
activate apoptosis (Chen et al., 2009; Morales et al., 2011; reviewed by Strasser et al., 
2011; Shamas-Din et al., 2011). In human leukemia and multiple myeloma cell lines, the 
HDACi compound SBHA synergistically combined with ABT-737 to increase apoptosis 
(Chen et al., 2009). SBHA induced BIM expression, which becomes bound to BCL-2 and 
BCL-XL. ABT-737 results in BIM displacement and BAK/BAX-induced apoptosis, 
which can be prevented by ectopic expression of BCL-2 or BCL-XL. As discussed in this 
thesis, a similar effect is seen in human DLBCL cell lines treated with vorinostat and 
ABT-737 (Thompson et al., 2013). In a panel of eight DLBCL cell lines, seven exhibited 
a range of sensitivity to vorinostat treatment, while one cell line showed HDACi 
resistance, which was overcome by co-treatment with ABT-737. Lastly, in mouse Eµ-
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myc-induced lymphomas, a synergistic apoptotic effect was observed in the treatment of 
lymphomas over-expressing BCL-2 or BCL-XL, but not MCL-1, with vorinostat or VPA 
and ABT-737 (Whitecross et al., 2009; Wiegmans et al., 2001). 
 
1.5 Thesis Rationale 
 The two main DLBCL subtypes, GCB and ABC, can be distinguished based on 
NF-κB activity and the expression of certain gene and protein markers. Important to this 
thesis, GCB DLBCL tumors have low NF-κB activity and high CD10 expression 
whereas ABC DLBCL tumors have high NF-κB activity and low CD10 expression. 
Over-expression of an activated mutant form of REL in the GCB DLBCL cell line, 
BJAB, led to increased NF-κB activity, increased miR-155, and decreased CD10 
expression (Chin et al., 2009). It has also been shown that the promoter of CD10 has 
multiple binding sites for the transcription factor PU.1 (Ishimaru et al., 1995), and that 
miR-155 can down-regulate PU.1 expression (Vigorito et al., 2007). It is generally 
accepted that BIC is an NF-κB target gene, although a direct interaction between any NF-
κB dimer and the BIC promoter/enhancer has not been convincingly shown. Therefore, 
the research in Chapter 3 sought to answer two main questions. First, does NF-κB bind to 
the BIC promoter/enhancer region, directing increased miR-155 expression, and if so, 
what cis regulatory element is responsible for this effect? And second, does NF-κB-
induced expression of miR-155 lead to decreased PU.1 and ultimately to reduced PU.1-
mediated CD10 expression? This work shows for the first time that the NF-κB p50/p65 
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heterodimer binds to a site in the BIC promoter, activating transcription, and also outlines 
how increased NF-κB activity can negatively regulate expression of CD10 in DLBCL. 
 The genetic differences found between the GCB and ABC DLBCL subtypes can 
often be used to explain the response of patients to chemotherapy. GCB patients have a 
more favorable outcome as compared to the ABC subtype in response to standard 
antibody/chemotherapeutic approaches. Although these subtypes have been informative 
and standard therapeutics have been successful in treating some DLBCL patients, a large 
number of patients do not survive past five years. New therapeutics are currently being 
studied including HDACi compounds, which have been shown to induce BCL-2-
mediated apoptosis in tumor cells with little toxicity to patients (Bolden et al., 2006; Zain 
and O’Connor, 2010). Two such compounds, vorinostat and romidepsin, have been FDA 
approved for the treatment of certain T-cell lymphomas. Therefore, the research outlined 
in Chapter 4 seeks to understand the molecular mechanisms governing HDACi-
sensitivity in DLBCL cell lines. Results show that DLBCL cell lines have a range of 
sensitivity to HDACi treatment and that this sensitivity can be modulated by varying the 
dynamics of the BCL-2 family of proteins. These results suggest that HDACi-resistant 
patients would benefit from combination therapies that include HDACi’s like vorinostat 
and the BCL-2 antagonist ABT-737. 
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Table 1.1 DLBCL gene expression profile subtype classifications 
 
Method Subtype Description Reference 
Cell of origin GCB Similar to germinal  Alizadeh et al., 2000; 
   center B cells Bea et al., 2005; 
  Low NF-κB activity Davis et al., 2001; 
  Low miR-155 Eis et al., 2005; 
  High BCL6 Hans et al., 2003; 
  High CD10 Lenz et al., 2008b, c; 
  Clinically favorable  Obermann et al., 2009;  
 Survival Wright et al., 2003 
 ABC Similar to activated B cells    
  High NF-κB activity  
  High miR-155  
  Low BCL6 
  Low CD10 
 PMBCL No correlation with  
   NF-κB activity 
  No correlation with survival 
 
Consensus Cluster Ox/Phos Increased expression of   Monti et al., 2005 
   oxidative phosphorylation   
   and mitochondrial genes 
 BCR/ Increased expression of  
 proliferation  cell-cycle regulators and  
   DNA repair genes 
 Host   Increased expression of  
 Response  T cell-mediated immune 
   response, inflammatory, 
   and connective tissue genes 
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Table 1.2 Summary of HDACs and their function in hematopoietic cells 
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Table 1.3 HDACi compounds shown to induce apoptosis in lymphoma, leukemia, 
and myeloma. 
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Table 1.3 HDACi compounds shown to induce apoptosis in lymphoma, leukemia, 
and myeloma. 
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Table 1.3 HDACi compounds shown to induce apoptosis in lymphoma, leukemia, 
and myeloma. 
 
Cell Types: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APL, 
acute promyelocytic leukemia; BL, Burkitt’s lymphoma; CLL, chronic lymphocytic 
leukemia; CML, chronic myelogenous leukemia; CTCL, cutaneous T-cell lymphoma; 
DLBCL, diffuse large B-cell lymphoma; EBV+ BL, Epstein-Barr virus positive BL; HL, 
Hodgkin lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; NHL, non-
Hodgkin lymphoma; PTCL, peripheral T-cell lymphoma; SLL, small lymphocytic 
lymphoma 
 
Drug Types: 17-AAG (Hsp90 inhibitor); ABT-737 (BH3-mimetic); ATRA (all-trans 
retinoic acid); Azacitidine (DNA methyltransferase inhibitor); Bexarotene (antineoplastic 
agent); Bortezomib (proteasome inhibitor); Cambinol (Sirtuin inhibitor); Carboplatin 
(antineoplastic agent); Carfilzomib (proteasome inhibitor); Cisplatin (alkylating agent); 
Cladribine (adenosine deaminase inhibitor); Cyclophosphamide (alkylating agent); 
Cytarabine (DNA synthesis inhibitor); Decitabine (DNA methyltransferase inhibitor); 
Dexamethasone (glucocorticoid steroid); Docetaxel (anti-mitotic agent); Eltrombopag 
(thrombopoeitin receptor agonist); Enzastaurin (PKCbeta inhibitor); Etoposide 
(topoisomerase inhibitor); Everolimus (mTOR inhibitor); EX527 (Sirtuin inhibitor); 
Gemcitabine (nucleoside analog); GX15-070 (BH3-mimetic); Idarubicin (topoisomerase 
II inhibitor); Imatinib (tyrosine kinase inhibitor); Ifosfamide (alkylating agent); 
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Isotretinoin (retinoic acid analog); Lenalidomide (TNFalpha inhibitor); Melphalan 
(alkylating agent); NPI-0052 (proteasome inhibitor); Pazopanib (tyrosine kinase 
inhibitor); Pemetrexed (folate antimetabolites); Pioglitazone (thiazolidinedione); 
Prednisone (glucocorticoid prodrug); Rituximab (anti-CD20 antibody); Sargramostin 
(recominant GM-CSF); Sirtinol (Sirtuin inhibitor); Sorafenib (tyrosine kinase inhibitor); 
Temozolomide (alkylating agent); TRAIL (TNF-related apoptosis-inducing ligand ); 
Vincristine (mitotic inhibitor) 
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Table 1.4 Summary of published clinical trials of FDA approved HDACi in 
lymphoma, leukemia, and myeloma. 
 
Legend: CR, Complete Response; PR, Partial Response; SD, Stable Disease 
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Figure 1.1. B-cell receptor mediated NF-κB signaling. BCR-mediated control of NF-
κB activity is regulated by a signal transduction pathway that involves the activation of 
PKCβ, formation of the CARD11-BCL10-MALT1 complex, activation of TAK1 kinase, 
and IKK-mediated degradation of IκB, resulting in nuclear localization and DNA binding 
of NF-κB dimers.
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Recombinant DNA Techniques 
 DNA subcloning was performed as previously described (Garbati, 2010). Briefly, 
approximately 1 µg of plasmid DNA was digested in 1X reaction buffer for 1 h with 1 µl 
of the appropriate restriction endonucleases (New England Biolabs [NEB], Ipswich, MA) 
at the appropriate temperature to obtain plasmid and insert DNA fragments. Digested 
vector DNA was incubated with 0.1 µg/µl calf intestinal alkaline phosphatase (NEB) for 
45 min at 37°C to prevent re-ligation. 
 
2.1.1 Preparation of Competent Cells 
Preparation of the E. coli strain DH5α competent cells for the propagation of 
plasmid DNA was performed as described previously (Herscovitch, 2008). Briefly, a 
single colony of DH5α cells was inoculated overnight in 2 ml of TYM (2% Bacto-
tryptone, 0.5% yeast extract, 0.1 M NaCl, 10 mM MgSO4). A series of dilutions in TYM 
and growth periods were performed: 1:250 dilution for approximately 3 h, then 1:8 for 
approximately 2 h, and a final 1:6 dilution for approximately 2 h to an O.D.600 of ~0.6. 
Cells were then collected by centrifugation at 4°C in a GS-3 rotor in a Sorvall RC-5B 
superspeed centrifuge and resuspended in 15 ml of TFB1 (30 mM potassium acetate, 100 
mM KCl, 50 mM MgCl2, 10 mM CaCl2, 15% w/v glycerol). Cells were then centrifuged 
as above, gently resuspended in 6 ml TFB2 (10 mM Na-MOPS, pH 7.0, 10 mM KCl, 75 
  
62 
 
mM CaCl2, 15% w/v glycerol), quickly aliquoted, frozen in dry ice, and stored at -80°C. 
Generally, competent cells could be used for 6-8 months after preparation. 
 
2.1.2 Plasmid Constructions 
Subcloning was performed using the reagents listed in Table 2.1 (plasmids) and 
Table 2.2 (primers). 
 
2.1.3 DNA Ligation and Transformation 
Plasmid and insert DNA were isolated from 1% low-melt agarose (FMC 
Bioproducts, Rockland, ME) gels. Ligations were performed with in-gel fragments or 
with DNA fragments extracted from agarose gels using the UltraClean 15 DNA 
Purification kit (MO BIO Laboratories, Carlsbad, CA). Ligations were set up by 
preparing a DNA mix at a ratio of approximately 10:1 (insert:vector) in T4 ligase buffer 
(5 mM Tris-HCl [pH 8.0], 1 mM MgCl2, 1 mM dithiothreitol [DTT], 0.1 mM ATP), 
supplemented with an additional 0.25 mM ATP, and 400 units of T4 DNA ligase (NEB) 
in a total volume of 40 µl. Ligations were incubated overnight at 18°C.  
 Transformations were performed by first heating the ligation mixture for 10 min 
at 72°C. The heating step was omitted for transformations of in tact, uncut plasmid DNA. 
Ligations or plasmid DNAs were then mixed with 60 µl of competent DH5α cells and 
170 µl of TCM buffer (10 mM Tris [pH 7.5], 10 mM CaCl2, 10 mM MgCl2) for 1 h on 
ice. Cells were then heat shocked at 42°C for 2 min, placed on ice for 2 min, and allowed 
to recover in 1 ml of LB for 30-45 min at 37°C. Next, cells were centrifuged for 2 min in 
  
63 
 
a desktop centrifuge, resuspended in approximately 100 µl of LB, and plated on LB 
plates containing 100 µg/ml ampicillin (Amp). Colonies were grown overnight at 37°C in 
a dry incubator. Colonies were picked and inoculated in 2 ml of LB containing 100 µg/ml 
of Amp, for small-scale plasmid preparation. 
 
2.1.4 Small-scale Plasmid Preparation 
Small-scale preparations of DNA were performed using the TENS method (Zhou 
et al., 1990). Briefly, bacterial cultures were grown for 8 h to overnight in 2 ml of LB 
plus 100 ug/ml Amp. Cells were then transferred to a microcentrifuge tube, while a small 
aliquot of the overnight culture was kept at 4°C for future use. Cultures were then 
centrifuged for 3 min at top speed in a microcentrifuge (Microfuge 12, Beckman Coulter, 
Fullerton, CA), the supernatants were removed, and the cell pellets were resuspended in 
300 µl of TENS buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA [pH 8.0]; 0.1 N NaOH, 
0.5% SDS) by vortexing. The cells were incubated on ice for 10 min and 150 µl of 3.0 M 
sodium acetate (pH 5.2) was then added to the samples, briefly vortexed, and placed on 
ice for 5 min. Samples were pelleted, the supernatants were added to 0.9 ml of 100% 
ethanol in new tubes, and incubated at room temperature (RT) for 10 min. DNA was 
pelleted for 10 min at 16,000 x g in a microcentrifuge. The supernatant was aspirated off, 
500 µl of 70% ethanol was added to the pellet, and samples were centrifuged for 5 min at 
16,000 x g. The supernatants were discarded and the tubes were dried by air-drying or 
using the speed vac (Speedvac concentrator, SVC 100H, Savant Instruments, Holbrook, 
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NY). The dried DNAs were resuspended in 20 µl of distilled water or TE (10 mM Tris, 
pH 8.0, 1mM EDTA). 
 
2.1.5 Large-scale, Cesium Chloride Gradient Plasmid Preparation 
Overnight cultures were started by inoculating with 10-100 µl of the small-scale-
prep culture of from a frozen bacterial stock and were grown for 18 h in 500 ml of 
Terrific Broth (1.2% tryptone, 2.6% yeast extract, 0.4% v/v glycerol, 17 mM KH2PO4, 72 
mM K2HPO4) containing 50-100 µg/ml Amp. Cells were pelleted for 10 min at 5,000 
rpm in a GS-3 rotor in a Sorvall RC-5B superspeed centrifuge at 4°C. Cell pellets were 
resuspended in 15 ml of solution I (25 mM Tris-HCl [pH 8.0], 50 mM glucose, 10 mM 
EDTA) and mixed well by vortexing. Five ml of 16 mg/ml lysozyme (freshly prepared in 
solution I) was then added to the cell mixtures and the samples were incubated for 5-10 
min at RT. Forty ml of freshly prepared solution II (0.2 N NaOH, 1% SDS) was added 
and the samples were gentle swirled to mix. The samples were incubated at RT for 10 
min to allow for further lysis. Next, 20 ml of cold solution III (3 M potassium acetate, 2 
M acetic acid, pH 4.8) was added to the mixtures, and samples were mixed vigorously, 
and incubated on ice for 10 min. The cell lysates were then centrifuged at 4,000 rpm in a 
Sorvall GS-3 rotor for 15 min at 4°C. The supernatants were carefully filtered through 
kimwipes and transferred to 500 ml centrifuge bottles containing 50 ml of isopropanol. 
Samples were mixed well and incubated for 15 min at RT, followed by centrifugation at 
5,000 rpm in a Sorvall GS-3 rotor at RT for 30 min. The supernatants were discarded, 
and the pellets were rinsed with 70% ethanol by gentle swirling and then air dried for 1-
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1.5 h. The pellets were resuspended in 2 ml of TE (pH 8.0), transferred to a new 14-ml 
snap-cap polypropylene tube (BD Falcon, Bedford, MA), and the mixture was brought up 
to 3.7 ml with TE (pH 8.0). Then, 4.7 g cesium chloride was added. After the cesium 
chloride was dissolved by gentle mixing, 0.3 ml of 10 mg/ml ethidium bromide (EtBr) 
was added to the samples, mixed, and samples were transferred to a 4.9-ml polyallomer 
quick-seal centrifuge tube (Beckman, Palo Alto, CA). The samples were centrifuged at 
70,000 rpm in a Beckman L8-M ultracentrifuge using a VTi90 rotor at 18°C overnight. 
Following ultracentrifugation, the DNA bands were removed from the quick-seal tubes 
using a 5-ml syringe with an 18-gauge needle (Becton Dickinson, Franklin Lakes, NJ). 
EtBr was then removed by extracting 2-4 times with 5-10 ml of isopropanol saturated 
with water and cesium chloride until the solution containing DNA was no longer pink. 
The extracted DNA was placed in a 50-ml polypropylene tube and sterile water was 
added to a volume of 5 ml. 25 ml of 100% ethanol was then added. DNA samples were 
incubated at RT for 30 min and centrifuged at 4,700 rpm in a Sorvall SH-3000 rotor for 
30 min at 14°C. The pellets were air dried for ~1 h at RT, with the tubes slightly inverted 
on the benchtop. Plasmid DNAs were resuspended in 400 µl of TE and extracted twice 
with equal amounts of phenol and once with chloroform. Then, 40 µl of 3 M sodium 
acetate (pH 5.2) and 1 ml of 100% ethanol were added to the samples, and the samples 
were incubated at RT for 30 min to precipitate the DNA. The samples were centrifuged at 
14,000 rpm in a Hermle Z180S microcentrifuge for 15 min at 4°C. DNAs were then air 
dried for 30-60 min at RT with the tubes slightly inverted on the benchtop. Samples were 
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resuspended in 200-1000 µl of TE and the concentration was determined using the ND-
1000 spectrophotometer (Nanodrop Technologies Inc., Wilmington, DE).  
 
2.2 Polymerase Chain Reaction (PCR) Based Site-directed Mutagenesis 
For site-directed mutagenesis, an overlapping PCR-based strategy was used to 
create the mutated DNA sequences. Two overlapping oligonucleotides, one forward and 
one reverse, were designed to contain the desired mutations (Table 2.2). The overlapping 
oligonucleotides were used in separate PCRs to generate two DNA molecules with the 
same overlapping mutation. Basically, one reaction contained a forward mutant oligo 
(e.g., BIC-(-)178mut-FW) with a downstream reverse primer (e.g., pGL3Basic-RV) 
whereas the second reaction contained the reverse mutant oligo (e.g., BIC-(-)178mut-RV) 
with an upstream forward primer (e.g., BIC-1494-FW). A final mix of 25 µl contained 
the following: 0.5 µl of each primer (50 pmol/µl), 2.5 µl of 10X Thermopol buffer 
(NEB), 2 µl of 2.5 mM dNTPs, ~100 ng of template DNA, and 1 µl of Vent polymerase 
(NEB). PCR was performed in the Gene Amp PCR System 9700 thermal cycler (Applied 
Biosystems [ABI], Foster City, CA). The following PCR cycling conditions were used:  
94°C for 10 min, 35 cycles of 94°C denaturation (30-90 sec), 60°C annealing (30-90 sec) 
and 72°C extension (30-90 sec), followed by 5 min at 72°C. Cycle times depended on the 
fragment size using 60 sec for each kilobase of DNA. The PCR products were purified 
using the UltraClean 15 DNA Purificatioon Kit (MO BIO Laboratories, Carlsbad, CA), 
and combined in equal molar amounts in a second PCR with the forward primer (e.g., 
BIC-1494-FW) and the reverse primer (e.g., pGL3Basic-RV). PCR products were 
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purified by phenol/chloroform extraction and ethanol precipitation, and were subcloned 
into the appropriate plasmid.  
 
2.3 Cell Culture 
2.3.1 General Cell Culture Protocols and Reagents 
This study used the following cell lines: Bosc23 (human embryonic kidney, gift 
of Dr. Youssef Jounaidi, Boston University); A293 and A293T (human embryonic 
kidney); 3T3 and 3T3-BC5052-/- (mouse embryonic fibroblast cells, gift of Dr. Alexander 
Hoffmann, UCSD); COS-1 (monkey kidney); DF-1 (chicken B-lymphoma, gift of Dr. 
David Foster, University of Arkansas); human B-lymphoma cell lines (Table 2.3) BJAB, 
IB4, and BL41 (gift of Dr. Elliott Kieff, Harvard Medical School), KMH2 (gift of Dr. 
Anthony Faber, Mass General Hospital), SUDHL2 and SUDHL8 (gift of Dr. Riccardo 
Dalla-Favera, Columbia University), SUDHL4, Daudi, and RC-K8 (gift of Dr. Louis 
Staudt, National Cancer Institute), L428 and Ramos (gift of Dr. Ellen McFarland, 
Harvard Medical School), SUDHL6 (Yeo et al., 2012), Pfeiffer and Farage (gift of Dr. 
Gerald Denis, Boston University School of Medicine). Cell lines were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Grand Island, NY) or RPMI 
medium 1640 (RPMI; Gibco, Grand Island, NY) supplemented with 10-20% fetal bovine 
serum (FBS; Biologos, Montgomery, IL), 50 units/ml penicillin, 50 µg/ml streptomycin, 
and maintained in a cell culture incubator at 37°C and 5% CO2. 
 For passage of adherent cells, culture media was aspirated, cells were washed 
twice with PBS, and incubated with 2 ml trypsin-EDTA (Invitrogen) (0.05% trypsin, 0.53 
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mM EDTA) at 37°C and 5% CO2 or RT for ~2 min to allow cells to detach from the dish. 
Cells in trypsin were resuspended in 8 ml of DMEM with 10% FBS, transferred to a 15-
ml tube, and centrifuged for 5 min at 2,000 rpm in an IEC clinical centrifuge 
(International Equipment Co., Needham, MA). Cells were resuspended in 10 ml of 
DMEM with 10% FBS and plated at the appropriate dilution in new tissue culture dishes.  
For passage of suspension cells, cells were transferred to a 15-ml conical tube, 
centrifuged as above, resuspended, and replated in the appropriate sized petri dishes. 
  
2.3.2 Freezing and Thawing Cells 
For freezing of cells, one or two 100-mm petri or tissue culture dishes at ~90% 
confluence were collected (as above) and then resuspended in 900 µl of FBS. To the cell 
mixture, 100 µl of DMSO was slowly added and the mixtures were quickly transferred to 
2-ml cryogenic vials (Corning Inc., Corning, NY). The vials were quickly placed on ice 
and incubated at -20°C for 2 h. Cells were then placed at -80°C overnight and transferred 
to liquid nitrogen for long-term storage or kept at -80°C for short-term storage. 
For thawing cells, the cryogenic vials were removed from the liquid nitrogen and 
placed on ice. Cells were partially thawed with room temperature DMEM by pipetting 
the cells into 20 ml of DMEM. Cells were centrifuged for 5 min at 2,000 rpm in an IEC 
clinical centrifuge and then resuspended in 10 ml of DMEM containing the appropriate 
amount of FBS and plated onto a 100-mm tissue culture or petri dish.  
 
2.4 Transfection of Adherent Cells 
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2.4.1 Polyethylenimine Method of Transfection  
Polyethylenimine (PEI)-based transfections were performed as previously 
described (Garbati, 2010). Briefly, transfection of Bosc23, COS-1, A293, or A293T cells 
for virus isolation, luciferase assays, and over-expression studies were performed PEI 
(Polysciences Inc, Warrington, PA). Cells were seeded in 24-well, 6-well, or 60-mm 
dishes to be 40-60% confluent on the day of transfection. DNA was incubated with PEI at 
a DNA:PEI ratio of 1:3 in serum free media for 15 min at RT. Next, 0.5-5 ml of 
DMEM/10% FBS was added to the DNA:PEI mix, and this mix was added to the cells. 
After incubation for 24 h, the media was replaced with 0.5-5 ml of DMEM/10% FBS. 
Cells were harvested for the appropriate assay 48 h post-transfection.  
 
2.4.2 Effectene Method of Transfection 
For transfections of 3T3 and 3T3-BC5052-/-, the Effectene (Qiagen, Valencia, 
CA) method and reagent was used. Briefly, 0.75 x 105 cells were seeded in 0.5 ml of 
media in a 24-well dish and transfected at the same time. Plasmid DNA was first mixed 
with a DNA:Enhancer ratio of 1:5.5 for 5 min and then a DNA:Effectene ratio of 1:7.9 
and incubated for 30 min at RT. Specifically, 200 ng of the pGL3-BIC reporter plasmid, 
200 ng of pcDNA-based NF-κB expression plasmids, 200 ng of empty vector pcDNA (to 
increased transfection efficiency), and 30 ng of RSV-Renilla luciferase reporter were 
mixed with the Enhancer and then with Effectene. The transfection mixtures were then 
added to the appropriate cells in DMEM/10% FBS, and the final mixture was then plated 
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in 24-well dishes. The next day, the transfection media was replaced with fresh 
DMEM/10% FBS. Cells were harvested and lysed 24 h later for luciferase assays.  
 
2.5 Dual Luciferase Assay 
COS-1, 3T3, and 3T3-BC5052-/- cells were seeded in 24-well tissue culture plates 
as described above. For transfections, 15 ng pRSV-Renilla (normalization plasmid), 200 
ng of appropriate Firefly-based luciferase plasmid, 400 ng of pcDNA-bassed expression 
plasmid, and the appropriate amount of PEI or Effectene was used. The Promega Dual 
Luciferase Assay System was used to measure luciferase activity. Forty-eight h post-
transfection, cells were washed once with 1X PBS (137 mM NaCl, 10 mM phosphate, 2.7 
mM KCl, pH 7.4) and then lysed directly on the plate with 100 µl 1X Passive Lysis 
Buffer (provided by Promega) and incubated at 4°C for 20 min on a table top shaker. If 
cell lysates were to be kept for future experiments, cells were transferred to 1.5-ml 
microcentrifuge tubes, cell debris was cleared by spinning in a microcentrifuge, and the 
supernatant was collected and frozen at -80°C. Otherwise, the 24-well plate containing 
the supernatants was placed on ice and used for luciferase activity determination as 
follows. Five ul of extract was transferred into a 96-well, white, flat-bottom plate 
(Thermo Fisher, Waltham, MA) and mixed with 30 µl of luciferase reagent. Firefly-based 
luminescence was measured immediately for 10 sec in multilabel plate reader (Perkin 
Elmer, Waltham, MA). Next, 30 ul of the Stop and Glo reagent was added to each well 
and the Renilla-based luminescence as recorded. To determine luciferase activity, the 
Firefly-based luciferase values were divided by Renilla-based luciferase values. Values 
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(average of three samples) were then normalized to the same control value, so that the 
control was equal to 1.0 (the average of the three control values). Experiments were 
performed three times in triplicate and the results represent the mean values +/- SE. 
 
2.6 Retroviral Stock Preparation and Cell Infection 
Virus stocks were prepared and used for infection as described (Thompson et al., 
2010). For creation of virus stocks directing target gene expression using pMSCV-based 
plasmids, A293T retroviral packaging cells were transfected in 60-mm dishes with 15 µg 
of the retroviral expression plasmid and 5 µg of the retroviral packaging plasmid 
(pcL10A1) using the PEI method (see above). For creation of virus stocks directing 
expression of pSIREN-based shRNA plasmids for target gene knock-down, Bosc23 
retroviral packaging cells were transfected in 60-mm dishes with 5 µg of the retroviral 
expression plasmid and 5 µg of each retroviral packaging plasmids pVpack-VSV and 
pVpack-GP using the PEI method (see above). Two days following transfection of 
A293T and Bosc23 cells, the supernatants from each dish were harvested, spun in a 
desktop centrifuge for 5 min at 5,000 rpm to remove remaining cells, and the 
supernatants were transferred to a new tube.  
For infection of target cells, polybrene was then added to a final concentration of 
8 µg/ml to the viral supernatant (2 ml) and incubated with 1 x 106 cells of interest in a 14-
ml snap-cap tube (BD Falcon). Cells were incubated with the virus/polybrene mix for 15 
min at RT then spun in a desktop centrifuge for ~2 h at 2,500 rpm at RT. Post-spin, the 
virus/ploybrene mix was carefully aspirated off the cell pellet and the cells were 
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resuspended in 2 ml of fresh media containing the appropriate concentration of FBS and 
Pen/Strep, and cells were then placed in tissue culture incubator. Puromycin (Sigma-
Aldrich, St. Louis, MO) was added to the cells two days later to a final concentration of 
0.5-2.5 µg/ml, as determined by titration (Table 2.4). Cells were selected for 7-21 days in 
puromycin and the expression of the given protein was determined by Western blotting.  
 
2.7 Soft Agar Colony Formation Assay 
Soft agar colony formation assays were performed as described previously (Chin 
et al., 2009). Agar was prepared by mixing 1 g of BactoAgar (Difco Laboratories, 
Detroit, MI) in 30 ml of distilled water and then autoclaving for 30 min. For the plating 
media, 10 ml of the agar mix (equilibrated to 56°C) was added to 90 ml of 37°C DMEM 
containing 20% FBS. Cells that had been previously counted using a hemocytometer 
were initially diluted to 1 x 105 cells/ml, and further diluted to concentrations of 1 x 104 
cells/ml and then 1 x 103 cells/ml. Equal numbers of cells (250 or 500) were quickly 
added to 5 ml of the plating media, mixed, and placed in 60-mm petri dishes. Dishes were 
kept at RT for ~15 min until the media was almost solid and then incubated at 37°C in a 
humid incubator with 5% CO2. Macroscopic soft agar colonies were counted 14 days 
after plating and were performed for both empty plasmid control (MSCV) and gene of 
interest (GOI) cell lines. For normalizing soft agar colony formation, 1 x 106 cells were 
collected from the above cell counts, whole cell extracts were prepared, and protein 
concentration was calculated (section 2.10). For each independent experiment, soft agar 
colony counts were normalized to the protein concentration calculated above as follows: 
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for MSCV cells, ([MSCV]/[MSCV]) x n colonies; for GOI cells, ([MSCV]/[GOI]) x n 
colonies. Data are presented as relative soft agar colony formation of five independent 
experiments performed with 5 plates of cells. Results represent the mean values +/- SE. 
 
2.8 Preparation of Whole Cell Extracts Using Triton-X-100 (AT) Buffer Method 
Adherent cells were washed 2X with PBS, scraped in 1 ml of PBS, and collected 
into a 1.5-ml microcentrifuge tube. Suspension cells were collected into 15-ml centrifuge 
tubes and pelleted by centrifugation at 3,000 rpm for 5 min at RT. Cells were 
resuspended in 1 ml PBS and transferred to a 1.5-ml microcentrifuge tube. Cells were 
then pelleted by centrifugation at 5,000 rpm for 5 min at 4°C. The PBS was aspirated 
from the cells and the cell pellet was resuspended in 100-200 µl of AT buffer (20 mM 
HEPES [pH 7.9], 1 mM EDTA, 1 mM EGTA, 20 mM NaF, 1 mM Na4P2O7-H20, 1 mM 
DTT, 20% w/v glycerol, 1% v/v Triton-X-100, 1 mM Na3VO4, 1 mg/ml of leupeptin, 
aprotinin, pepstatin and 1 mM PMSF), depending on the size of the cell pellet, by 
repeated suspension using a 27.5 gauge needle (Becton Dickinson, Franklin Lakes, NJ). 
To the cell lysates, 3.1 µl (for 100 µl of AT buffer) or 6.2 µl (for 200 µl of AT buffer) of 
5 M NaCl was added to a final concentration of ~150 mM. The samples were centrifuged 
at 14,000 rpm for 30 min at 4°C, supernatants were collected, and stored at -80°C.  
 
2.9 Preparation of Cytosolic and Nuclear cell Extracts 
Adherent cells were washed twice with PBS, gently scraped using a rubber 
scraper in 1 ml of PBS and collected in 1.5 ml microcentrifuge tubes. All suspension cells 
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were transferred from their culture dish into 15 ml centrifuge tubes and pelleted by 
centrifugation at 3,000 rpm for 5 min at RT. Cells were resuspended in 1 ml PBS and 
transferred to a 1.5 ml microcentrifuge tube. For both cell types, cells were pelleted by 
centrifugation at 5,000 rpm for 5 min at 4°C. The supernatant was then aspirated off and 
the remaining cell pellet was resuspended in 400 µl of Buffer “E” (10 mM HEPES [pH 
7.9], 10 mM KCl, 0.1 mM EDTA [pH 8.0], 0.1 mM EGTA [pH 8.0], 1 mM DTT, 1 mM 
Na3VO4, 5 µg/ml leupeptin, 62.5 µg/ml aprotinin, 1 µg/ml pepstatin, and 1 mM PMSF), 
supplemented with 55 µl of 5% IGEPAL, and cells were vortexed vigorously for 10 sec. 
Samples were incubated on ice for 15 min, centrifuged at 4°C for 10 min at 14,000 rpm, 
and the supernatant (cytoplasmic fraction) was carefully removed. The nuclear pellet was 
then washed once in 100 µl of Buffer “E”, and re-centrifuged as above. The supernatant 
was once again removed and combined with the rest of the cytoplasmic fraction. The 
washed pellet was resuspended in 100 µl of Buffer “F” (20 mM HEPES [pH 7.9], 400 
mM NaCl, 1 mM EDTA, 1 mM EGTA [pH 8.0], 1 mM DTT, 1 mM Na3VO4, 5 µg/ml 
leupeptin, 62.5 µg/ml aprotinin, 1 µg/ml pepstatin, and 1 mM PMSF), vortexed 
vigorously for 15 sec, and incubated on ice for 15 min. The sample was then centrifuged 
for 15 min at 14,000 rpm at 4°C and the supernatant (nuclear fraction) was then carefully 
removed and stored at -80°C. For long-term storage (>1 week), the fractions were 
supplemented with glycerol to 20% (i.e., by adding 140 µl of 100% glycerol to 
cytoplasmic fractions and 25 µl to nuclear fractions).  
 
2.10 Protein Concentration Determination 
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The protein concentration of whole cell, nuclear, and cytoplasmic fractions was 
determined using the Bradford protein assay reagent (Bio-Rad, 500-0006). Briefly, the 
reagent was diluted at 1:5 in dH2O. Using a 96-well plate (BD Falcon, 353911), 200 µl of 
the diluted reagent was added to each well. A series of wells were used to create a 
standard curve using BSA as the known protein. BSA was added to the wells (0-5 µg). 
Next, 1 µl of each cell extract was added to the 96-well plate in duplicate to produce 
more reliable results. The absorbance was then measured at 595 nm. A standard curve 
was generated by using the concentration of BSA vs the absorbance of BSA and a best-fit 
line was generated in Excel (Microsoft, Redmond, WA). Protein concentrations for the 
unknown samples were extrapolated from this line and ranged from 0.2–5 µg/µl.  
 
2.11 SDS-polyacrylamide Gel Electrophoresis and Western Blotting 
2.11.1 SDS-polyacrylamide Gels 
SDS-polyacrylamide gels were poured using the Mini-PROTEAN® III system 
(Bio-Rad, Hercules, CA). The resolving gel (bottom) was prepared at concentrations of 
acrylamide (National Diagnostics, Atlanta, GA) ranging from 7.5 – 12.5%, based on the 
protein being analyzed. The appropriate amount of polyacrylamide was mixed with 1X 
lower gel buffer (375 mM Tris-HCl [pH 8.8], 0.1% w/v SDS) and final concentrations of 
0.15% ammonium persulfate (APS) and 0.25% v/v TEMED (N, N, N, N’ 
tetramethylethylenediamine). The stacking gel (top) was always prepared using 4% 
polyacrylamide and 1X stacking buffer (125 mM Tris-HCl [pH 6.8], 0.1% w/v SDS) and 
the same equivalents of APS and TEMED for polymerization. SDS-polyacrylamide gels 
  
76 
 
were electrophoresed in 1X SDS running buffer (25 mM Tris-HCl, 192 mM glycine, 
0.1% w/v SDS [pH 8.3]) at 60 V while the proteins travelled through the stacking gel, 
and at 180 V when the proteins were resolved in the lower gel.  
 
2.11.2 Western Blotting 
Proteins were first separated on SDS-polyacrylamide gels and then transferred 
onto nitrocellulose membranes (Micron Separation Inc., Westborough, MA) prior to 
blotting. Transferring of proteins from gel to nitrocellulose membrane was performed in 
1X transfer buffer (20 mM Tris-HCl, 150 mM glycine) containing 20% methanol at 160 
mAmps for 1-2 h at 4°C using a Bio-Rad transfer apparatus. Following transfer, the 
membranes were blocked with 5% instant non-fat milk (Lab Science, Livingston, NJ) in 
TBS containing 0.5% Tween-20 (TBST) for 1 h at RT or overnight at 4°C. For PU.1 and 
PARP blots, blocking was performed overnight at 4°C. The filters were then incubated 
with primary antibody in TBST or in TBS supplemented with 1% BSA (for antibodies 
from Cell Signaling Technology [CST]) at the dilutions listed in Table 2.5 for 1 h at RT 
or overnight at 4 °C. All CST, PU.1, and CD10 antibodies were incubated with the 
membranes overnight. Next, membranes were washed 3 times in TBST (~5 min per 
wash) and then probed with the appropriate secondary antibody (Table 2.5) in 5% instant 
non-fat milk in TBST for 1 h at RT. Following secondary antibody (conjugated to 
Horseradish peroxidase [HRP]) probing, membranes were washed 3 times in TBST and 
two times in TBS for 5 min each. The membranes were then carefully placed on saran 
wrap, 1 ml of 1:1 Pierce SuperSignal West Dura Extended Duration Substrate (Thermo 
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Fisher) was added to the membrane, and incubated for 5 min. The HRP reaction products 
were then visualized by exposing the membranes to X-ray film for 1 sec – 10 min. 
 
2.12  Electrophoretic Mobility Shift Assays (EMSAs) 
2.12.1 Annealing of Double-Stranded Probes for EMSAs 
Oligonucleotides were resuspended at a concentration of 1 mM in TE and 10 µl of 
each were combined in a final volume of 50 µl containing 10 mM Tris-HCl pH 7.6, 10 
mM NaCl, 2 mM MgCl2 and 0.1 mM EDTA. The mixture was then heated at 95°C for 10 
min in a heat block, and then allowed to slowly cool by turning off the heat block and 
allowing the oligonucleotides (probe) to anneal while coming to RT overnight. The 
annealed probe was then diluted to a final concentration of 1 pmol/µl and labeled 
appropriately. 
  
2.12.2 Double-Stranded Probe End-labeling with Polynucleotide Kinase  
In a final volume of 15 µl, 2 µl of 1 pmol/µl probe was mixed with 1.5 µl of T4 
polynucleotide kinase (PNK) buffer (NEB), 1 µl of T4 PNK, and 2 µl (20 µCi) of [γ-32P]-
ATP (GE Healthcare) and incubated for 2 h at 37°C. Following incubation, the sample 
was diluted to 100 µl with TE buffer (pH 8.0). A spin column (Bio-Rad) was prepared by 
snapping off the lid and placing the column in a 2-ml microcentrifuge tube. Excess buffer 
was allowed to drain out of the column by gravity and was discarded. The spin column 
was then placed in a 14-ml snap-cap tube and centrifuged for 2 min at 1000×g for 2 min. 
The column was placed in a new 1.5-ml microcentrifuge tube, with the lid removed and 
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then the column and tube were placed in a 14-ml snap cap tube. The probe mixture was 
gently applied to the center of the column (within the 14-ml tube). The snap-cap tube was 
then centrifuged for 5 min at 1000×g. The column was removed using forceps and 
discarded appropriately. The 1.5 -ml microcentrifuge tube which contained and the 
labeled probe was removed and the sample was transferred to a new microcentrifuge 
tube. In a scintillation vial, 2 µl of the probe was added along with 5 ml of scintillation 
fluid. The counts per minute (cpm) were then determined using a scintillation counter.  
 
2.12.3 EMSA Assay 
 The appropriate whole cell or nuclear extracts were prepared and protein 
concentrations were determined (section 2.10). Reactions were prepared in a total volume 
of 50 µl containing 32P end-labeled double-stranded probes (Table 2.2) (~100,000 cpm), 
binding buffer (25 mM Tris [pH 7.4], 100 mM KCl, 6.25 mM MgCl2, 50 mM NaCl, 0.5 
mM EDTA, 1 mM DTT, 4% w/v glycerol], 2 µg poly dI/dC, and 10 µg of the appropriate 
cell extract. Reactions were incubated at RT or 30°C for 30 min, and complexes were 
then resolved on a 5% nondenaturing polyacrylamide gel. Supershifts were performed by 
adding 3 µl of the appropriate antibody (Table 2.5) for an additional 1 h on ice and 
protein-DNA complexes were detected using autoradiography or phosphorimaging.  
 
2.13 RNA Isolation 
Total RNA was extracted from cells using TRIzol (15596-026, Invitrogen, 
Carlsbad, CA). Briefly, cells were transferred to a 1.5-ml microcentrifuge tube and 
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washed once in PBS. TRIzol was added to cells at the appropriate volumes as follows: 1 
ml for a 100-mm culture dish, 500 µl for a 60-mm culture dish, or 350 µl for a 35-mm 
culture dish. Samples were incubated at RT for 5 min. Next, 200 µl of chloroform (per 1 
ml of TRIzol) was added to each sample, the tube was vortexed vigorously for 10 sec, 
and incubated for 3 min at RT. Next, the sample was centrifuged at 12,000 rpm for 15 
min at 4°C. The supernatant was removed and placed in a new RNase-free tube, 
containing 500 µl of isopropanol (per 1 ml TRIzol) and incubated at RT for 10 min. 
Samples were centrifuged at 12,000 rpm for 10 min at 4°C. The supernatant was 
discarded and the RNA pellet was washed with 0.5 ml of 70% ethanol and pelletted at 
12,000 rpm for 5 min at 4°C. The supernatant was discarded and the pellet was allowed 
to air dry at RT. The RNA pellet was resuspended in 20-40 µl of RNase-free dH2O and 
stored at -80°C. 
 
2.14 Reverse Transcriptase-PCR (RT-PCR) of Whole Cell RNA 
To prepare a whole cell cDNA library from the RNA samples, 2 µg of RNA was 
incubated with 6.7 µl of 15.4 mM random primers (Promega) at 65°C for 5 min and then 
placed on ice for 5 min. Next, 6 µl of 2.5 mM dNTPs, 1 µl of RNasin (Promega), 1 µl M-
MLV reverse transcriptase (Promega), and 6 µl of 5X M-MLV buffer was added to the 
samples. Samples were incubated in a dry heat block at 37°C for 1 h. For most PCRs, 2 
µl of the reverse transcribed cDNA was used. 
For quantification of RNA, RT-PCR was performed on cDNA using the primers 
listed in Table 2.2. Conditions for PCR were as follows: GAPDH PCR consisted of 22 
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cycles and BIC and CD10 PCR consisted of 26-28 cycles of 94°C denaturation (30 sec), 
58°C annealing (30 sec) and 72°C extension (30 sec). 
 
2.15 Quantitative-PCR (qPCR) 
On reverse-transcribed cDNA, quantitative PCR amplification was performed 
using the Power SYBR Green PCR Master Mix (4368577, ABI) and primers are listed in 
Table 2.2. A master mix of each of the following per sample was made: 15 µl SYBR-
green, 0.5 µl forward primer (10 pmoles), 0.5 µl reverse primer (10 pmoles), and 12 µl 
dH2O to a total of 28 µl. Next, 28 µl of the master mix was added to 2 µl of cDNA and 
8.5 µl of this mix was added to each of three wells in a 384 microwell plate (4309849, 
ABI), which was then placed in the real-time PCR cycler (7900HT, ABI). The following 
parameters were used for PCR: 2 min at 50°C, 2 min at 95°C, and then 40 cycles of 15 
sec at 95°C and 60 sec at 60°C. Once the reactions were complete, the data were 
analyzed using the sequence detection software (SDS 2.2, ABI). Reactions were 
performed with three biological samples, in three technical replicates for each sample. To 
normalize the data, the CT for the target gene was subtracted from the CT of the control 
(GAPDH or 5S), an this value is known as the deltaCT. Then the deltaCT from the control 
gene sample (i.e., untreated or 0 h) was subtracted from the deltaCT of the experimental 
sample (i.e., treated for x h), to give a deltadeltaCT value. Finally, the relative expression 
was determined by calculating 1/2X, where x is the deltadeltaCT.  
 
2.16 Reverse Transcription and qPCR of microRNAs and Small RNAs 
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Total RNA was extracted from cells using TRIzol, as described above. Reverse 
transcription was then performed using a stem-loop specific primer listed in Table 2.2 
(Chen et al., 2005; Thompson et al., 2010) and the Taqman miRNA Reverse 
Transcription Kit (4366596, ABI). A mix of 0.15 µl of dNTPs (to a final concentration 
100 µM), 1.5 µl of 10X reverse transcription buffer (ABI), 0.19 µl of RNase inhibitor (4 
U, ABI), 0.75 µl of each stem-loop specific primer (to a final concentration of 50 nM), 
500 ng of RNA, and 1 µl (50 U) of MultiScribe Reverse Transcriptase (ABI) were 
combined in a 0.2 ml polypropylene tube and samples were brought up to 15 µl with 
nuclease-free H2O. The reaction was placed on ice for 5 min and then loaded into a 
thermal cycler (Gene Amp PCR System 9700, ABI) and the following parameters were 
used for the reverse transcription reaction: 30 min at 16°C, 30 min at 42°C, and 5 min at 
85°C. Once the reverse transcription was completed, the cDNAs were kept at 4°C.  
Quantitative PCR amplification was then performed using the Power SYBR 
Green PCR Master Mix (4368577, ABI). The universal reverse and specific forward 
primers (0.5 µl/10 pmoles of each) listed in Table 2.2 were combined in SYBR Green, 
water, and cDNA and samples were analyzed as above.  
 
2.17 5-aza-2′ Deoxycytidine, Tricostatin A, Vorinostat, ABT-737, and 
Lipopolysaccharide Treatment of DLBCL Cell Lines 
For all treatment experiments, except for acridine orange and ethidium bromide 
staining (see below), 1 x 106 cells were plated in 2 ml of media and allowed to grow for 6 
h. 5-aza-2′ deoxycytidine (AZA) (MP Bio, Santa Ana, CA), Trichostatin A (TSA) (Sigma 
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Aldrich, St. Louis, MO), vorinostat (Cayman Chemical, Ann Arbor, MI), ABT-737 
(Active Biochemicals Co., Ltd., Hong Kong), and/or lipopolysaccharide (LPS) (Sigma 
Aldrich, St. Louis, MO) were then added directly to the cultures at the indicated 
concentrations, and cells were incubated for the indicated times. 
 
2.18 Caspase-3 Activity Assay 
Total caspase-3 activity was measured as previously described (Yeo et al., 2012). 
Cells were treated with either TSA or vorinostat for the indicated time (see section 2.17). 
Cells were washed with PBS and resuspended in 250 µl of lysis buffer (reaction buffer 
[10 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS] with 5 mM DTT, 350 µg/ml 
PMSF, 10 µg/ml pepstatin, 10 µg/ml aprotinin, 20 µg/ml leupeptin), and lysed by three 
freeze-thaw cycles. Equal amounts of cell extract (25-50 µl) were then incubated in 
reaction buffer containing 50 µM of the fluorogenic substrate Ac-DEVD-AMC (Biomol 
Research Labs, Plymouth Meeting, PA) in a total volume of 200 µl for 1 h at 37°C. 
Caspase-3 activity was then measured using a Victor3 1420 fluorimeter (Perkin Elmer, 
Waltham, MA) using an excitation of 380 nm and measuring an emission of 460 nm. The 
assay was performed three times in triplicate. Values indicate the relative fluorescence of 
samples prepared from treated cells compared to control, mock-treated cells. 
 
2.19 Percent Growth Inhibition of HDACi Treated Cells 
The percent growth inhibition by vorinostat was assessed by plating 1 x 105 cells 
in 0.5 ml of the appropriate media in a 24-well dish and then treated with increasing 
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amounts of vorinostat for 72 h. Cells were then counted using a hemocytometer and the 
number of cells were reported as a percentage compared to untreated cells for the same 
time point. The results are the averages of three separate treatments and error bars 
indicate standard deviation. 
 
2.20 Acridine Orange and Ethidium Bromide Stain for Apoptosis and Necrosis 
 Acridine orange and ethidium bromide staining for apoptosis was performed as 
previously described (Ribble et al., 2005). Briefly, 2.5 x 105 cells in 2 ml of the 
appropriate media were treated with 3 µM vorinostat for 14 h. Cells were then transferred 
into a 15-ml tube, spun in desk-top centrifuge, and resuspended in 1 ml of PBS. Next, 
100 µl of cells were transferred into a well in a 96-well dish and spun at 1,000 rpm for 5 
min in a swing arm centrifuge (Beckman Coulter, Allegra 6R centrifuge). Next, cells 
were treated with 8 µl of a mixture containing 100 µg/ml of acridine orange and 100 
µg/ml of ethidium bromide mixture. The 96-well plate was then immediately visualized 
with an Olympus 1X70 microscope and images were taken with 400X magnification and 
excitation at both 480 and 430 nm. More than 130 cells per field were counted. Values 
are the average of three independent experiments and error bars indicate standard error. 
 
2.21 Selection of HDACi-resistant Variant of the SUDHL4 Cell Line 
Selection of SUDHL4 vorinostat-resistant (SUDHL4-VR) cells was performed by 
treating parental SUDHL4 cells with 1 µM vorinostat for 24 h and then allowing the cells 
to recover in the absence of drug. When the cells repopulated the dish, they were treated 
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with 1 µM vorinostat for 48 h and allowed to recover. These cells were then treated with 
1 µM vorinostat for 72 h and allowed to recover. Once the cells repopulated the dish, the 
same treatment cycle was performed with 2 µM and then 3 µM vorinostat for 24 h, 48 h, 
and then 72 h. For each treatment, a fraction of the recovered cells were grown in the 
absence of vorinostat, representing the most recent vorinostat-resistant population, in case 
the current treatment was toxic to the cells. SUDHL4-VR cells were able to survive in 3 
µM vorinostat for 48 h, and these populations were used for studies in this paper. 
 
2.22 Prediction of Transcription Factor Binding Sites in the BIC Promoter 
 Prediction of NF-κB transcription factor binding sites in the human BIC promoter 
was performed by the using online prediction models PROMO 
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) and 
Transcriptional Regulatory Element Database (TRED, http://rulai.cshl.edu/cgi-
bin/TRED/tred.cgi?process=home). The three highest scoring sites, including the -1150 
site described previously (Yin et al., 2008) in both programs were selected for future 
experiments. 
 
2.23 Statistical Analysis 
The standard error (SE) was calculated for all bar graphs, unless otherwise noted.  
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Table 2.1 Plasmids used in this study 
Mammalian expression plasmids 
pcDNA3.1(+/-)   CMV promoter expression plasmid (Promega) 
pcDNA-FLAG Plasmid for expression of the epitope tag FLAG 
(DYKDDDDK). Gift of Dr. Bakary Sylla (World 
Health Organization, Lyon, France) 
pcDNA-FLAG-p65 Expression plasmid for FLAG-p65 (human) driven 
by the CMV promoter (Morin et al., 1993). 
pcDNA-FLAG-p50 Expression plasmid for FLAG-p50 (human) driven 
by the CMV promoter. Gift of Dr. Alain Israel 
(Institut Pasteur, Paris, France). 
pcDNA-FLAG-REL Expression plasmid for FLAG-REL (human) driven 
by the CMV promoter (Garbati, 2010). 
 
Retroviral plasmids 
pMSCV Retroviral plasmid containing the puromycin 
resistance cassette (Morgenstern and Land, 1990). 
pMSCV-PU.1 Retroviral plasmid containing the human PU.1 
cDNA and the puromycin resistance cassette. Gift 
of Dr. Barbara Nikolajcyzk (Boston University 
Medical School, Boston, MA). 
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pMSCV-CARD11 Retroviral plasmid containing the human CARD11 
cDNA with an HA tag and puromycin resistance 
cassette. Gift of Dr. Georg Lenz (NCI, Bethesda, 
MD). A 3 kb SfiI-NotI HA-CARD11 fragment was 
digested out of pRetoCMV/TO and subcloned into 
SfiI-NotI-digest pMSCV-CARD11mut10 backbone 
(the remaining pMSCV-puro plasmid was separated 
from CARD11mut10 and used for subcloning). 
pMSCV-CARD11mut10 Retroviral plasmid containing the human CARD11 
mutant 10 cDNA with an HA tag and puromycin 
resistance cassette. Gift of Dr. Georg Lenz (NCI). A 
3.5 kb BamHI-NotI HA-CARD11mut10 fragment 
was digested out of pRetoCMV/TO and subcloned 
into BamHI-NotI-digested pcDNA3.1(+). Then a 
3.5 kb AflI-XbaI HA-CARD11mut10 fragment was 
digested out of pcDNA3.1(+) and subcloned into 
AflI-XbaI-digested pSL1180. Lastly, a 3.5 kb 
BamHI HA-CARD11mut10 fragment was digested 
out of pSL1180 and subcloned into BglII-digested 
pMSCV-puro. 
pMSCV-CD10 Retroviral plasmid containing the human CD10 
cDNA and the puromycin resistance cassette. 
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Created by PCR amplifying the CD10 cDNA and 
subcloning it into BamHI-digested pMSCV. 
pMSCV-BIC Retroviral plasmid containing the human BIC 
cDNA and the puromycin resistance cassette. Gift 
of Dr. Ricardo Aguiar (The University of Texas 
Health Science Center at San Antonio, TX). 
pMSCV-BCL-2 Retroviral plasmid containing the mouse BCL-2 
cDNA and the puromycin resistance cassette (Yeo 
et al., 2012). 
pMSCV-BCL-XL Retroviral plasmid containing the human BCL-XL 
cDNA and the puromycin resistance cassette (Yeo 
et al., 2012). 
pMSCV-BIM Retroviral plasmid containing the human BIM 
cDNA and the puromycin resistance cassette. 
Created by PCR amplifying the BIM cDNA and 
subcloning it into BglII/EcoRI-digested pMSCV. 
pSIREN-MCS Retroviral plasmid containing the puromycin 
resistance cassette and used for over-expression of 
shRNAs. pSIREN-MCS was created by excising a 
BamHI-EcoRI fragment from pSIREN-RetroQ 
containing a shRNA against HMGN1 (gift of Dr. 
Ulla Hansen, Boston University, Boston, MA) and 
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then ligating it together with a BamHI-EcoRI 
fragment from the multiple cloning site (MCS) of 
the pSL1180. 
pSIREN-control-shRNA Retroviral plasmid containing an shRNA against an 
irrelevant sequence (Scherr et al., 2003) and the 
puromycin resistance cassette. The shRNA was 
subcloned into pSIREN-MCS as a BamHI-EcoRI 
fragment. 
pSIREN-PU.1-shRNA Retroviral plasmid containing an shRNA against 
human PU.1 cDNA (Nagel et al., 2007) and the 
puromycin resistance cassette. The shRNA was 
subcloned into pSIREN-MCS as a BamHI-EcoRI 
fragment. 
pcL10A1 Retroviral packaging plasmid. Gift of Dr. David 
Waxman (Boston University). 
pVpack-VSV  Retroviral packaging plasmid. Gift of Dr. Ulla 
Hansen (Boston University). 
pVpack-GP Retroviral packaging plasmid. Gift of Dr. Ulla 
Hansen (Boston University). 
   
Reporter plasmids 
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pGL2-3X-kB-luciferase 3X-κB-Luciferase-pGL2 reporter plasmid has a 
minimal c-fos promoter element and three copies of 
the major histocompatibility (MHC) class I κB 
element (TGGGGATTCCCCA) upstream of the 
luciferase gene. Gift of Dr. George Mosialos 
(Fleming Institute, Vari, Greece). 
pGL3-promoter Plasmid for expression of the luciferase gene, which 
contains an SV40 promoter sequence (Promega). 
pGL3-promoterCD10 A 720 bp fragment of the CD10 promoter was PCR 
amplified from BJAB genomic DNA, digested with 
KpnI/XmaI and subcloned into KpnI/XmaI-digested 
pGL3-promoter plasmid (called pCD10-luc). 
pGL3-promoterCD10-1-470 A fragment of the CD10 promoter from nucleotide 
1-470 was PCR amplified from the pGL3-
promoterCD10 plasmid, digested with KpnI/XmaI, 
and subcloned into KpnI/XmaI-digested pGL3-
promoter plasmid (called pCD10-1-470). 
pGL3-promoterCD10-449-717 A fragment of the CD10 promoter from nucleotide 
449-717 was PCR amplified from the pGL3-
promoterCD10 plasmid, digested with KpnI/XmaI, 
and subcloned into KpnI/XmaI-digested pGL3-
promoter plasmid (called pCD10-449-717). 
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 pGL3-BIC A 1494 bp fragment of the BIC promoter subcloned 
into the pGL3-promoter plasmid (Yin et al., 2008). 
Gift of Dr. Eric Flemmington (Louisiana Cancer 
Research Consortium). 
pGL3-BIC-(-)1150mut A 1494 bp fragment of the BIC promoter subcloned 
into the pGL3-promoter plasmid containing a XhoI 
site in the proposed NF-κB site found 1150 bp 
upstream of the transcription start site (Yin et al., 
2008). Gift of Dr. Eric Flemmington (Louisiana 
Cancer Research Consortium). 
pGL3-BIC-AP-1mut A 1494 bp fragment of the BIC promoter subcloned 
into the pGL3-promoter plasmid containing a XhoI 
site in the proposed AP-1 site found 40 bp upstream 
of the transcription start site (Yin et al., 2008). Gift 
of Dr. Eric Flemmington (Louisiana Cancer 
Research Consortium, New Orleans, LA). 
pGL3-BIC-(-)441mut Site-directed mutagenesis was performed using two 
synthetic complementary oligonucleotide primers, 
which inserted an XhoI site in the middle of the NF-
κB site found 441 bp upstream of the transcription 
start site, and two flanking primers (Table 2.2). The 
final PCR product was digested with NheI and 
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HindIII and used to replace the corresponding 
NheI/HindIII fragment in pGL3-BIC.  
pGL3-BIC-(-)178mut Site-directed mutagenesis was performed using two 
synthetic complementary oligonucleotide primers, 
which inserted an XhoI site in the middle of the NF-
κB site found 178 bp upstream of the transcription 
start site, and two flanking primers (Table 2.2). The 
final PCR product was digested with NheI and 
HindIII and used to replace the corresponding 
NheI/HindIII fragment in pGL3-BIC.  
pGL3-BIC-(-)530truncation Truncation of the pGL3-BIC plasmid to 530 bp 
upstream of the transcription start site was 
performed using two synthetic complementary 
oligonucleotide primers (Table 2.2). The final PCR 
product was digested with NheI and HindIII and 
used to replace the corresponding NheI/HindIII 
fragment in pGL3-BIC.  
pGL3-BIC-(-)91truncation Truncation of the pGL3-BIC plasmid to 530 bp 
upstream of the transcription start site was 
performed using two synthetic complementary 
oligonucleotide primers (Table 2.2). The final PCR 
product was digested with NheI and HindIII and 
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used to replace the corresponding NheI/HindIII 
fragment in pGL3-BIC.  
RSV-renilla RSV-driven renilla luciferase. Gift of Dr. Anthony 
Faber (Mass General Hospital, Boston, MA). 
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Table 2.2 Oligonucleotides Used in This Study 
Primers used for PCR-based subcloning of the CD10 cDNA 
CD10-FW 5’-CTTTGGATCCATGGGCAAGTCAGAAAGTCAGATG-3’ 
CD10-RV 5’-CTAAGGATCCTCACCAAACCCGGCACTTCT-3’ 
The BamHI restriction enzyme site in each primer is italicized. 
 
Primers used for PCR-based generation of BIC mutants and truncations 
BIC-1494-FW 5’-GCAGCTAGCCCAGGGTTGGAACTGAGTTTGA-3’ 
BIC-(-)530-FW 5’-GCAGCTAGCCTCTTGAAGGGTGATGAGGTAGG-3’ 
BIC-(-)91-FW 5’-GCAGCTAGCCCAAGAACAGGCAGGAGGG-3’ 
pGL3Basic-RV 5’-GCGTAAGTGATGTCCACCTCG-3’ 
BIC-(-)441mut-FW 5’-CAGGAGGAActcgagC CCACTTGCT-3’ 
BIC-(-)441mut-RV 5’-AGCAAGTGGGctcgagTTCCTCCTG-3’ 
BIC-(-)178mut-FW 5’-GGAAAGGGGctcgagCCAACTACCC-3’ 
BIC-(-)178mut-RV 5’- GGGTAGTTGGctcgagCCCCTTTCC-3’ 
The NheI restriction enzyme site in the PCR products is italicized. 
The NF-κB mutations where an XhoI site was created are lowercase and underlined. 
 
Primers used for PCR cloning of sections of the CD10 promoter 
pCD10-1-470-FW 5’-GAATGGTACCCAGTATGAATTCCGCAGTGGAGTGTG-3’ 
pCD10-1-470-RV 5’-GAATCCCGGGCTGAACTGAAACTCTCCGCTCC-3’ 
pCD10-449-717-FW 5’-GAATGGTACCGGAGCGGAGAGTTTCAGTTCAG-3’ 
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pCD10-449-717-RV 5’-GAATCCCGGGACCGGAGACTATAATGCTTGCCTC-3’ 
The restriction enzyme sites in the PCR products are italicized. Forward primers contain 
a KpnI site and reverse primers contain a XmaI site. 
 
Primers used for RT-PCR of human genes (unless otherwise noted) 
BIC-FW    5’AAGAACAACCTACCAGAGACCTTAC-3’   
BIC-RV    5’-AATGATAAAAACAAACATGGGCTTGAC-3’ 
CD10-FW   5’-CAATGCTACGGCTAAACCTGAAG-3’ 
CD10-RV    5’-CCATCCAAGTGAGGTCATCTAAAGTCTG-3’ 
REL-FW    5’GCTATCACAGAACCCGTAACAG3’ 
REL-RV    5’ACCCCTGTAGGCATTTCTCTCACA3’ 
GAPDH-FW    5’-TGGTATCGTGGAAGGACTCATGAC-3’  
GAPDH-RV    5’-ATGCCAGTGAGCTTCCCGTTCAGC-3’ 
Chicken-PU.1-FW  5’-GTGAAACAGGCAGCAAGAAAAAG -3’ 
Chicken-PU.1-RV  5’-CCCTGTCTTGCCGTAGTTTCTC-3’ 
Chicken-GAPDH-FW 5’-CCTCTCTGGCAAAGTCCAAG-3’ 
Chicken-GAPDH-RV  5’-CATCTGCCCATTTGATGTTG-3’ 
 
Primers used for qPCR 
BCL-2-FW 5’-GCATCTTCTCCTCCCAGCC-3’ 
BCL-2-RV 5’-CACCTACCCAGCCTCCGTTATC-3’ 
BCL-XL-FW 5’-CTGGTGGTTGACTTTCTCTCCTAC-3’ 
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BCL-XL-RV 5’-CATTGATGGCACTGGGGGTC-3’ 
BIM-FW  5’-CCTTCTGATGTAAGTTCTGAGTGTGAC-3’ 
BIM-RV 5’-CTTGTGGCTCTGTCTGTAGGGAG-3’ 
BAX-FW 5’-CTTTTGCTTCAGGGTTTCATCC-3’ 
BAX-RV 5’-GCCACTCGGAAAAAGACCTCTC-3’ 
BIC-Exon2-FW 5’-CATTTCAAGAACAACCTACCAGAGAC-3’ 
BIC-Exon/Intron2-FW  5’-CAATGGAGATGGCTCTAATGGTAAGG-3’ 
BIC-Intron2-RV 5’-CTGTGAAACTTTGGACTTGTCATAATC-3’ 
GAPDH-FW 5’-TGGTATCGTGGAAGGACTCATGAC-3’ 
GAPDH-RV 5’-ATGCCAGTGAGCTTCCCGTTCAGC-3’ 
 
Primers used for reverse transcription and qPCR of microRNAs and small RNAs 
Universal Reverse  5’-GTGCAGGGTCCGAGGT-3’ 
miR-155-RT-Stemloop 
5’GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACACCCCT3’ 
miR-155-FW  5’-GCCGCCTTAATGCTAATCGTGAT-3’ 
5S-RT-Stemloop   
5’GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACAAAGCC3’ 
5S-FW 5’-CGCCTGGGAATACCGGGTG-3’ 
 
Oligonucleaotides used as DNA-binding probes for EMSA assays 
IFN-β (NF-κB)    5’-TCGAGAGGTCGGGAAATTCCCCCCCG-3’ 
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    5’-TCGACGGGGGGGAATTTCCCGACCTC-3’ 
CD10promoter (PU-1) 5’-TCGAGATTCAAAAGAGGAAAGGGATCAG-3’ 
    5’-TCGACTGATCCCTTTCCTCTTTTGAATC-3’ 
CD10promoter (PU-2) 5’-TCGACCCTTTGAGGAGGAATCGCTGTGT-3’ 
    5’-TCGAACACAGCGATTCCTCCTCAAAGGG-3’ 
CD10promoter (PU-3) 5’-TCGAGGATTCAGGGAGGAAAGGGAGCGG-3’ 
    5’-TCGACCGCTCCCTTTCCTCCCTGAATCC-3’ 
BIC-(-)178 (NF-κB)  5’-TCGAGGAAAGGGGAAAACACCAACTA-3’ 
  5’-TCGATAGTTGGTGTTTTCCCCTTTCC-3’ 
NF-κB and PU.1 binding sites are underlined. 
All oligonucleotides were synthesized at Invitrogen (Carlsbad, CA). 
 
Oligos used for shRNA-mediated knock down 
control shRNA Top Strand    5'-gatccGCAAGCTGCCCGTGCCCTGTTCAAGAGA 
        CAGGGCACGGGCAGCTTGCTTTTTTACGCGTg-3' 
control shRNA Bottom Strand  5'-aattcACGCGTAAAAAAGCAAGCTGCCCGTGCC 
          CTGTCTCTTGAACAGGGCACGGGCAGCTTGCg-3' 
PU.1 shRNA Top Strand   5’-gatccGAAGCTCACCTACCAGTTCTTCAAGAGA 
           GAACTGGTAGGTGAGCTTCTTTTTTACGCGTg-3' 
PU.1 shRNA Bottom Strand  5’-aattcACGCGTAAAAAAGAAGCTCACCTACCAG 
            TTCTCTCTTGAAGAACTGGTAGGTGAGCTTCg-3' 
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Table 2.3 B-lymphoma Cell Lines Used in This Study 
Cell Line Lymphoma Media NF-κB Reference 
 Type  Mutation  
BJAB GCB-DLBCL DMEM-20 - Ngo et al., 2006 
SUDHL4 GCB-DLBCL DMEM-10 - Davis et al., 2001 
Pfeiffer GCB-DLBCL RPMI-10 - Singh et al., 2010 
SUDHL6 GCB-DLBCL RPMI-10 - Ngo et al., 2006 
Farage GCB-DLBCL RPMI-10 - Dia et al., 2011 
SUDHL8 GCB-DLBCL RPMI-20 - Pasqualucci et al., 2006 
SUDHL2 ABC-DLBCL RPMI-10 A20 Compagno et al., 2009 
   EP300 Pasqualucci et al., 2011 
   CREBBP Pasqualucci et al., 2011 
RC-K8 ABC-DLBCL DMEM-10 REL-NRG Kalaitzidis et al., 2002 
 A20 Compagno et al., 2009  
 EP300 Garbati et al., 2010 and 2011 
 IκB Kalaitzidis et al., 2002 
BL41 FL DMEM-10 - Carter et al., 2002 
Daudi BL DMEM-10 - Contreras-Salazar et al., 1990 
Ramos BL DMEM-10 - Zhang et al., 2001 
KMH2 HL RPMI-10 IκB Emmerich et al., 1999 
L428 HL RPMI-10 IκB Emmerich et al., 1999 
IB4 B-lymphoblastoid  DMEM-10 LMP1+ Carter et al., 2002 
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Abbreviations: ABC-DLBCL, activated B-cell-like diffuse large B-cell lymphoma; BL, 
Burkitt’s lymphoma; DMEM-10, DMEM supplemented with 10% FBS; DMEM-20, 
DMEM supplemented with 20% FBS; FL, follicular lymphoma; GCB-DLBCL, germinal 
center B-cell-like diffuse large B-cell lymphoma; HL, Hodgkin’s lymphoma; RPMI-10, 
RPMI supplemented with 10% FBS; RPMI-20, RPMI supplemented with 20% FBS 
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Table 2.4 Concentration of Puromycin Used For Selections 
Cell Type  Concentration [µg/ml] 
BJAB 2.5 
SUDHL2 0.5 
SUDHL4  2  
Farage  1 
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Table 2.5 Antibodies Used in This Study 
Primary Antibodies 
Name Protocol Diltution Host Source 
BCL-2 WB 1:500 mouse BDT #610538 
BCL6 WB 1:1000 rabbit CST #4242s 
BAX WB 1:5000 rabbit CST #2772 
BCL-XL WB 1:1000 rabbit CST #2762 
BID WB 1:1000 rabbit SCBT #11423 
BIM WB 1:1000 rabbit CST #2819 
β-tubulin WB 1:500 rabbit SCBT #9104 
CARD11 WB 1:500 goat SCBT #20458 
Caspase-3 WB 1:500 rabbit SCBT #7148  
Caspase-8 WB 1:500 rabbit SCBT #7890 
CD10 WB 1:500 mouse SCBT #58939 
CD40 WB 1:500 rabbit SCBT #975 
FLAG epitope WB 1:500 rabbit CST #2368 
HA epitope WB 1:500 rabbit SCBT #805 
HRK WB 1:1000 rabbit ProSci #3771 
MCL-1 WB 1:500 rabbit SCBT #819 
p50 WB 1:500 rabbit SCBT #7178 
p65 WB/SS 1:2000 mouse Gift of Nancy Rice #1226 
p65 SS - rabbit SCBT #372X  
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Poly (ADP-ribose) WB 1:500 rabbit SCBT #7150 
Polymerase (PARP) WB 1:500 rabbit SCBT #1750    
PU.1 WB/SS 1:300 rabbit SCBT #352 or #352X 
REL, C-terminal WB 1:1000 rabbit Gift of Nancy Rice #265 
v-Rel WB 1:1000 rabbit Gilmore and Temin, 1986 
  
Secondary Antibodies 
Name Protocol Diltution Source 
Anti-rabbit-HRP  WB  1:2000  CST #7071 
Anti-mouse-HRP  WB  1:2000  CST #7072 
Rabbit-α-Goat-HRP  WB  1:10000 Pierce #31402  
Abbreviations: SCBT, Santa Cruz Biotechnology; CST, Cell Signaling Technology; 
BDT, BD Transduction Laboratories; SS, supershift; WB, western blotting  
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CHAPTER 3 
NF-κB DOWN-REGULATES EXPRESSION OF THE B-LYMPHOMA MARKER 
CD10 THROUGH A MIR-155/PU.1 PATHWAY 
 
3.1 Introduction 
CD10, also known as the common acute lymphocytic leukemia antigen (CALLA) 
or neutral endopeptidase (NEP), is a cell-surface zinc metallo-endopeptidase (Shipp et 
al., 1989; Salles et al., 1992). CD10’s ability to cleave signal peptides at the cell surface 
can affect cell proliferation, differentiation, and migration (Salles et al., 1992; Sumitomo 
et al., 2005; Sunday et al., 1992) and expression of CD10 is used as a diagnostic marker 
for a variety of cancers (Alizadeh et al., 2000; Deschamps et al., 2006; Ishimaru et al., 
1996; Langer et al., 2004; Wright et al., 2003). Relevant to this study, CD10 is highly 
expressed in the germinal center B-cell (GCB) molecular subtype of diffuse large B-cell 
lymphoma (DLBCL), whereas CD10 expression is low in the activated B-cell (ABC) 
subtype of DLBCL (Alizadeh et al., 2000; Wright et al., 2003). ABC DLBCLs also have 
a high NF-κB gene expression profile and a poorer clinical prognosis as compared to 
GCB DLBCLs (Staudt and Dave, 2005). As such, reduced expression of CD10 and high 
NF-κB activity are both correlated with a less favorable DLBCL patient outcome (Hans 
et al., 2004; Iqbal et al., 2007; Staudt and Dave, 2005). 
 The correlation between high NF-κB activity and reduced CD10 expression has 
been observed in several other settings as well. Our lab previously showed that over-
expression of an activated mutant of the NF-κB family transcription factor REL in the 
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GCB-like B-lymphoma cell line BJAB leads to reduced expression of CD10 (Chin et al., 
2009). Also, infection of cells with Epstein-Barr virus (EBV) or human cytomegalovirus, 
both inducers of NF-κB, causes reduced expression of CD10 (Carter et al., 2002; Phillips 
et al., 1998). Taken together, such results suggested that NF-κB or a target gene of NF-
κB is involved in repressing CD10 gene/protein expression in certain B-cell lymphomas. 
 Little is known about the control of CD10 transcription. Sequence analysis of the 
CD10 promoter/enhancer region revealed the presence of three consensus binding sites 
for the transcription factor PU.1 (Ishimaru and Shipp, 1995). PU.1 is a member of the Ets 
family of transcription factors and is required for proper B-cell development and 
differentiation (Medina et al., 2004). Additionally, increased PU.1 expression has been 
correlated with GCB DLBCL (Alizadeh et al., 2000). Therefore, we were interested in 
investigating whether PU.1 contributes to the regulation of CD10 expression in B-cell 
lymphoma. Moreover, PU.1 expression can be regulated by the product of BIC (B-cell 
integration cluster), microRNA miR-155 (Faraoni et al., 2009; Martinez-Nunez et al., 
2009; Vigorito et al., 2007), suggesting an NF-κB-driven regulatory network.  
 BIC has been proposed to be an NF-κB target gene because increased expression 
of miR-155 is correlated with high NF-κB activity in a number of settings, including B-
lymphoma cells, which have acquired mutations in the NF-κB signal transduction 
pathways or are infected with the LMP1-expressing Epstein Barr Virus (EBV) (Davis et 
al., 2001; Eis et al., 2005; Faraoni et al., 2009; Gatto et al., 2008; Kluiver et al., 2005; 
Lawrie et al., 2007; Luftig et al., 2003; Rahadiani et al., 2008; Rai et al., 2008; Song et 
al., 2006 and 2008). Some studies have claimed to identify the cis regulatory element in 
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the BIC promoter that is responsible for directing miR-155 expression: as a proximal AP-
1 site (Yin et al., 2008), an NF-κB site more than 1100 nt upstream of the TSS (Gatto et 
al., 2008), or via an indirect mechanism in which NF-κB up-regulates AP-1 components, 
which then bind to the proximal AP-1 site (Cremer et al., 2012). Nevertheless, none of 
these studies has been convincing and questions remain about the transcriptional control 
of BIC. Therefore, it is not precisely known how activation of NF-κB leads to increased 
levels of miR-155. 
 This chapter will provide evidence for a functional link between NF-κB activity 
and reduced expression of CD10. Prior to the work presented here, Dr. Melanie 
Herscovitch showed the there was a correlation between increased NF-κB activity and 
miR-155 expression with decreased PU.1 and CD10 expression (Herscovitch, 2009). 
What her work failed to do was mechanistically link NF-κB proteins and DNA-binding 
activity to the regulation of CD10 expression. Thus, this chapter presents the work that I 
performed that provides evidence supporting an indirect link between activation of NF-
κB in the GCB-like DLBCL cell line BJAB and the down-regulation CD10 expression. 
Specifically, I aimed to identify the NF-κB-responsive site in the BIC promoter and to 
provide convincing evidence that NF-κB can regulate PU.1-mediated CD10 expression 
through miR-155 activity. Moreover, it is shown that there is a correlation between high 
miR-155 expression and low PU.1/CD10 levels in a variety of B-lymphoma cell lines. 
Furthermore, it is shown that the NF-κB dimer p50/p65 directly binds to a site in the 
promoter/enhancer of BIC, directing transcriptional expression. These results reveal an 
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NF-κB-dependent molecular mechanism for down-regulation of CD10, a key marker for 
predicting the clinical response of patients with DLBCL.  
 
3.2 PU.1 and CD10 Protein Levels Are Inversely Correlated with miR-155 
Levels in Several B-Lymphoma Cell Lines 
CD10 mRNA and protein levels are low in the less favorable ABC subtype of 
DLBCL (Alizadeh et al., 2000; Hans et al., 2004; Iqbal et al., 2007; Wright et al., 2003). 
In contrast, GCB-like DLBCL primary tumors and cell lines express readily detectable 
levels of CD10 mRNA and protein (Chin et al., 2009; Rahadiani et al., 2008; Rai et al., 
2008). If PU.1 does bind and activate transcription from the CD10 promoter, then it is 
expected that the levels of these two proteins would show a positive correlation in 
DLBCL cell lines. Based on this hypothesis, a panel of six B-lymphoma-like cell lines, 
which have varying levels of NF-κB activity, were analyzed for the expression levels of 
PU.1 and CD10 by Western blotting. Two cell lines, IB4 and RC-K8 (Table 2.3), have 
gene expression profiles consistent with high levels of NF-κB activity; four cell lines—
BJAB, SUDHL4, BL41, and Daudi (Table 2.3)—are not known to have high NF-κB-
driven gene expression. PU.1 and CD10 protein were expressed at readily detectable 
levels in the four cell lines with low NF-κB activity, whereas PU.1 and CD10 protein 
levels were much lower in the high NF-κB activity IB4 and RC-K8 cell lines (Fig. 3.1). 
(Note, a band [n.s.] that runs just below PU.1 is seen in many westerns with the antibody 
used here.) 
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 Based on the above findings and previously published work showing that miR-
155 can control PU.1 expression and that there are three consensus PU.1 binding sites in 
the CD10 promoter (Faraoni et al., 2009; Ishimaru and Shipp, 1995), it was hypothesized 
that CD10 and PU.1 levels would negatively correlate with miR-155 levels. Therefore, 
the same panel of six B-lymphoma-like cell lines with varying levels of NF-κB-
dependent gene expression were also assessed for miR-155 expression by qPCR. The 
four lymphoma cell lines with low NF-κB activity (BJAB, SUDHL4, BL41, Daudi) 
contained low levels of miR-155, whereas miR-155 was present at increased levels in the 
high NF-κB activity IB4 and RC-K8 cell lines (in which miR-155 levels were 
approximately 30-50 times higher than BJAB cells) (Fig. 3.1; performed by Dr. Melanie 
Herscovitch [Herscovitch, 2009]). These results indicate that PU.1 and CD10 levels are 
low in transformed B-lymphoid cell lines where miR-155 levels and NF-κB activity are 
high (e.g., IB4, RC-K8).  
  
3.3 Lipopolysaccharide Treatment Causes NF-κB-mediated Expression of miR-
155 and Loss of PU.1-induced Expression of CD10 in BJAB Cells  
NF-κB activity and miR-155 expression have been found to be induced by 
lipopolysaccharide (LPS) in macrophages (Eis et al., 2005; O’Connell et al., 2007). 
Therefore, to determine whether there is a normal association between high NF-κB/miR-
155 and reduced expression of CD10, BJAB cells were treated with LPS, and then 
assessed for p65 nuclear localization, expression of miR-155 and CD10, and DNA-
binding activity of p65 at the BIC promoter and of PU.1 at the CD10 promoter. As shown 
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by Dr. Melanie Herscovitch (Herscovitch, 2009), treatment of BJAB cells with 5 µg/ml 
LPS for 6 h resulted in an increase in BIC mRNA levels that remained elevated at 24 h-
post treatment, as assessed by RT-PCR. Additionally, reverse transcription and qPCR of 
microRNAs and small RNAs (Section 2.16) for miR-155 showed that miR-155 levels 
increased by approximately 2-fold after 6 h of LPS treatment and by approximately 3-
fold at 24 h, as compared to untreated cells. Moreover, treatment of BJAB cells with 5 
µg/ml LPS led to a decrease in CD10 transcript levels within 6 h and CD10 transcript 
levels remained decreased at 24 h, as assessed by RT-PCR. LPS treatment also resulted in 
a time-dependent decrease in CD10 protein levels over a 72-h period, as assessed by 
Western blotting. 
 
3.3.1  LPS Treatment Decreases PU.1 Binding to the PU-1 Site in the CD10 
Promoter 
Given that LPS treament of BJAB cells leads to increase miR-155 and decreased 
CD10 levels, it was hypothesized that LPS would reduce the amount of PU.1 binding to a 
site in the CD10 promoter (presumably through increased NF-κB and miR-155 activity). 
To that end, EMSA analysis was performed using the 32P-labeled PU-1 probe 
(Herscovitch, 2009) using nuclear extracts from BJAB cells treated with 5 µg/ml LPS for 
72 h. Results showed that LPS-treated BJAB cells had decreased nuclear PU.1 DNA-
binding activity as compared to untreated BJAB cells (Fig. 3.2), suggesting that NF-κB 
activation decreases PU.1 DNA-binding activity. 
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3.3.2 p65 Nuclear Translocation, Increased miR-155 Expression, and Increased 
DNA Binding to the BIC Promoter are Early Responses to LPS Treatment 
To determine whether BIC is an early response gene in LPS-induced NF-κB 
signaling, it was first determined how quickly p65 translocated to the nucleus following 
LPS treatment. BJAB cells were treated with 5 µg/ml LPS for increasing times up to 60 
min and nuclear extracts were made. Anti-p65 Western blotting showed that p65 started 
to increase in the nucleus within 15 min of LPS treatment and, by 60 min, there was a 
substantial increase in nuclear p65 (Fig. 3.3.A). PARP was used as the nuclear extract 
control, β-tubulin as the cytosolic extract control, and the extracts were compared to 
BJAB whole cell extracts (WCE) as a size marker for each protein. 
To determine whether nuclear translocation of p65 coincided with increased 
expression of miR-155, BJAB cells were treated with LPS for up to 60 min, cDNA was 
prepared, and qPCR was performed for the unspliced BIC transcript and mature miR-155. 
To measure the unspliced BIC transcript, one primer located in exon 2 and one in intron 2 
of the BIC gene were used (Table 2.2). Following LPS treatment, there was a time-
dependent increase in unspliced BIC transcript levels, and after 60 min of LPS treatment, 
the BIC transcript was increased 5-fold as compared to untreated cells (Fig. 3.3.B). 
Additionally, in BJAB and IB4 cells, treatment with 5 µg/ml LPS for 24 h resulted in 5.5-
fold and 3.2-fold increases, respectively, in mature miR-155 levels (Fig. 3.3.C). Of note, 
IB4 cells have ~100 times more miR-155 in unstimulated cells as compared to 
unstimulated BJAB cells, suggesting that induction of miR-155 expression is not 
dependent on the resting levels of miR-155. 
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To assess the DNA-binding ability of the LPS-induced nuclear p65, EMSA 
analysis using a probe from the BIC promoter (described in Figure 3.5) was performed. 
BJAB cells were treated with 5 µg/ml LPS for 60 min and 32P-labeled probes were 
incubated with nuclear extracts. After 60 min of LPS treatment, a band corresponding to 
the p50/p65 dimer appeared and this band was super-shifted with the p65 antibody (Fig. 
3.3.D). The increase in p50/p65 binding to the NF-κB site in the BIC promoter is 
concurrent with increased nuclear localization of p65 (Fig. 3.3.D, bottom panel). 
 
3.4 Expression of a Constitutively Active Form of CARD11 in BJAB Cells 
Causes Down-regulation of CD10 and PU.1 Protein Expression and Up-regulation 
of miR-155 Expression 
3.4.1 Stable Expression of CARD11-mutant10 Down-regulates PU.1 and CD10 
and Up-regulates BCL-2 and miR-155 
Mutations in the scaffolding protein CARD11, which cause it to be a constitutive 
activator of NF-κB, have been identified in a subset of patients with DLBCL, primarily of 
the ABC subtype (Lenz et al., 2008a). To determine whether expression of one such 
CARD11 mutant (mut10; Lenz et al., 2008a) could affect CD10 expression, retroviral 
transduction was used to create a stable BJAB cell line expressing an HA-tagged version 
of CARD11mut10. Western blotting confirmed that HA-CARD11mut10 was expressed 
in retrovirally transduced BJAB cells, but no such protein was detected in the parallel 
control cells (Fig. 3.4.A). CD10 and PU.1 protein levels were both decreased in BJAB 
cells expressing HA-CARD11mut10 as compared to non-transduced BJAB or MSCV 
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vector-transduced cells (Fig. 3.4.A). Consistent with CARD11mut10’s ability to activate 
NF-κB (Lenz et al., 2008a), BCL-2, an NF-κB target gene and an ABC DLBCL marker, 
showed increased protein expression in BJAB-CARD11mut10 cells (Fig. 3.4.A). Finally, 
miR-155 levels were increased by approximately 6-fold in BJAB-CARD11mut10 cells as 
compared to BJAB or BJAB-MSCV control cells (Fig. 3.4.A; performed by Dr. Melanie 
Herscovitch). These results demonstrate that mutations in the NF-κB signal transduction 
pathway can lead to increased NF-κB activity and correlate with increased miR-155 and 
decreased PU.1 and CD10 levels. 
 
3.4.2 Dox Inducible CARD11-mutant10 Down-regulates CD10 and Up-regulates 
miR-155 
To further demonstrate that CARD11mut10 protein expression could lead to 
reduced CD10 expression, an inducible expression system for CARD11mut10 protein 
(using a tet-ON retroviral transduction system [Gossen et al., 1995]) (created by Tyler J. 
Ford) was created in BJAB cells. Induction of CARD11mut10 expression for seven days 
led to reduced CD10 protein and increased miR-155 (Fig. 3.4.B), further demonstrating 
that control of CD10 expression in BJAB cells can be regulated in an NF-κB-dependent 
manner, as seen with LPS treatment (see Fig. 3.2). 
 
3.4.3 Stable Expression of CARD11-mutant10 Down-regulates PU.1 DNA Binding 
and Up-regulates NF-κB DNA Binding 
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Next, nuclear DNA-binding activity was assessed for PU.1 and NF-κB in BJAB-
MSCV versus BJAB-CARD11mut10 cells (Fig. 3.4.C). Control BJAB-MSCV cells had 
considerable nuclear PU-1 site (as described by Herscovitch, 2009) DNA-binding 
activity, which was clearly reduced in BJAB-CARD11mut10 cells. Conversely, nuclear 
NF-κB DNA-binding activity was increased in BJAB-CARD11mut10 cells as compared 
to control BJAB-MSCV cells, which is consistent with the reported ability of 
CARD11mut10 to activate NF-κB (Lenz et al., 2008a). As previously reported (Chin et 
al., 2009), BJAB cells expressing an activated REL mutant (RELΔTAD1) also have 
increased levels of nuclear NF-κB site DNA-binding activity (Fig. 3.4.C).  
In conclusion, over-expression of CARD11mut10 in BJAB cells results in 
increased NF-κB activity and increased expression of miR-155. Additionally, 
CARD11mut10 decreases DNA binding to the PU-1 site in the CD10 promoter/enhancer 
and decreases PU.1 and CD10 levels. These results suggest a mechanism by which 
activating mutations in the NF-κB signaling pathway lead to increased expression of 
CD10, namely, that increased NF-κB activity leads to increased miR-155 which reduces 
PU.1 DNA binding and consequently CD10 transcription. 
 
3.5 NF-κB Family Member p65 Binds to the BIC Promoter and Directs Gene 
Transcription 
3.5.1 There are at Least Three Predicted NF-κB Binding Sites in the BIC 
Promoter 
The BIC gene has long been thought to be an NF-κB target gene, but an NF-κB 
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binding site has not be convincingly indentified. This research aimed to identify an NF-
κB-responsive site using a 1494 bp region of the BIC promoter that contains at least three 
predicted NF-κB binding sites: one previously reported site at -1150 (Yin et al., 2008) 
and two site predicted using online prediction models at -441 and -178 (PROMO and 
TRED programs) (section 2.23; Fig. 3.5.A). This proximal upstream region of the BIC 
promoter was used to assess the regulation of miR-155 expression by NF-κB for two 
reasons. First, that region has been shown to be responsive to NF-κB and other immune-
related transcription factor activity in reporter gene assays and EMSA analyses (Cremer 
et al., 2012; Gatto et al., 2008; Yin et al., 2008). Second, although only approximately 
20-30% of induced p65 binding sites are located within ~2 kbp of TSS (Lim et al., 2007; 
Martone et al., 2003), approximately 50-60% of the coactivator p300/CBP binding is 
located within proximal promoters of actively transcribed genes (Ramos et al., 2010; 
Wang et al., 2009), suggesting that much of the biologically relevant transcription 
inducing p65 binding occurs through proximal sequences of genes. 
 
3.5.2 p65 Up-regulates Luciferase Activity Driven by a 1494 bp Portion of the BIC 
Promoter 
A luciferase reporter plasmid containing a 1494 bp region of the BIC promoter 
(pGL3-BIC; Yin et al., 2008) was used to assess the ability of pcDNA-based plasmids 
containing the NF-κB proteins FLAG-p65, REL, or FLAG-p50 to enhance BIC 
transcription. As shown in Fig. 3.5.B, in COS-1 cells p65 activated the BIC promoter 
reporter plasmid ~17-fold as compared to the empty vector pcDNA, whereas REL 
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induced only a two-fold increase and p50 did not activate gene transcription (Fig. 3.5.B, 
top panel). These results suggest that BIC is a p65-responsive gene. The same pcDNA-
based plasmids were then again expressed in COS-1 cells and whole cell extract were 
prepared and probed via Western blotting for p65, REL, and p50 to confirm expression of 
all three proteins (Fig. 3.5.B, bottom panel).  
 
3.5.3 Deletion Mutants of the BIC Promoter Reveals an NF-κB-responsive Region  
To identify the p65-responsive region in the BIC promoter, truncations of the BIC 
promoter in the pGL3-BIC plasmid were created to obtain the pGL3-BIC-(-)530 and 
pGL3-BIC-(-)91 plasmids (Table 2.1). To further delineate the p65-responsive region, 
reporter assays were performed comparing the two truncated plasmids to the 1494 bp 
pGL3-BIC plasmid. The pGL3-BIC-(-)530 plasmid, which retained the predicted -441 
and -178 NF-κB binding sites, was activated to approximately the same level by p65 as 
the full-length, 1494 bp plasmid whereas the -91 truncation mutant reporter was not 
activated by p65 (Fig. 3.5.C). These results map the p65-responsive site to a region 
between nucleotides 530-91 upstream of the TSS in the BIC promoter. 
 
3.5.4 Mutation of the Predicted NF-κB Binding Sites Revealed the p65-responsive 
Site in the BIC Promoter 
Given the above results, it was hypothesized that the p65-responsive site would be 
either the -441 or the -178 site and not the previously identified -1150 site. To determine 
whether one of the three putative sites is the p65-responsive NF-κB site, mutations of 
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these sites in the 1494 bp pGL3-BIC plasmid were created. The pGL3-BIC-(-)1150 
mutant was obtained and had previously been created previously by inserting an XhoI 
site in the middle of the NF-κB site (Yin et al., 2008). The pGL3-BIC-(-)441 and pGL3-
BIC-(-)178 NF-κB site mutants were created in the same manner (Table 2.1). Reporter 
assays were performed, comparing the ability of p65 to enhance transcription of the three 
mutant plasmids to the wild-type pGL3-BIC plasmid. The pGL3-BIC-(-)178 showed a 
nearly complete loss of p65-induced activation while the other two mutant plasmids did 
not show a substantial loss in activation (Fig. 3.5.D), demonstrating that the p65-
responsive site in the BIC promoter was located 178 nt upstream of the TSS. 
 
3.5.5 The p50/p65 Heterodimer Binds to the -178 Site in the BIC Promoter 
To assess the ability of p65 to bind the -178 site in the BIC promoter, EMSA 
assays were performed using 32P-labeled probes containing the -178 site and a consensus 
NF-κB site (as a DNA-binding site control). First, FLAG-tagged versions of p65 and p50 
were over-expressed alone or together in A293 cells. Western blotting confirmed their 
expression (Fig. 3.6.A). An EMSA was then performed by incubating 10 ng of each 
extract with a consensus NF-κB site (from the IFN-β promoter, Table 2.2). As seen in 
Fig. 3.6.B, p65 (lane 3) and p50 (lane 4) can individually bind the NF-κB-site probe. 
When the p65 and p50 plasmids are co-transfected, a strong band slightly smaller than 
p65 alone and slightly larger that p50 alone appears (Fig. 3.6.B, lane 5), which is 
presumably the p50/p65 heterodimer commonly found to drive gene expression in the 
canonical NF-κB pathway (Hayden and Ghosh, 2008).  
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 To assess the ability of these proteins to bind the -178 site in the BIC promoter, 10 
ng of extracts from A293 cells expressing p65, p50, and p50/p65 were incubated with the 
-178-site probe (Table 2.2) in an EMSA. Interestingly, p65 alone did not bind to the -178 
site (Fig. 3.6.C, lane 3) whereas p50 showed strong binding to this site (Fig. 3.6.C, lane 
4). In extracts from cells contransfected with p50 and p65, a band larger than p50 alone 
appears, indicating that the p50/p65 heterodimer can bind to this site (Fig. 3.6.C, lane 5). 
This band can be competed with 50X cold probe (Fig. 3.6.C, lane 6). Additionally, 
supershifts (SS) using two antibodies against p65 (SC-372x and NR #1226, Fig. 3.5.G, 
lanes 8 and 9, respectively) revealed that this presumed p50/p65 heterodimer does indeed 
contain p65. This band is not supershifted with pre-immune serum (Fig. 3.6.C, lane 7). In 
conclusion, these results demonstrate that the proposed -178 NF-κB site is a p50/p65 
DNA-binding site. 
 
3.5.6 p65-mediated Transcription From the BIC Promoter Requires Other NF-κB 
Family Members 
Because p65 alone cannot bind to the -178 site (Fig. 3.6.C) but transfection of p65 
in COS-1 cells is sufficient to induce reporter activity from this site (Fig. 3.5.D), it was 
hypothesized that cells lacking expression of other NF-κB members would show reduced 
p65-enhanced reporter gene activity. To test this hypothesis, 3T3 cells that lacked all NF-
κB family members except p65 (3T3-5052BC-/-) were obtained (kind gift of Dr. 
Alexander Hoffmann). Luciferase assays were performed in 3T3 and 3T3-5052BC-/- cells 
by co-transfection with the pGL3-BIC reporter and the FLAG-tagged expression 
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plasmids for p65, p50, or an empty vector control. Relative luciferase activity was 
measured and normalized to RSV-renilla values. In 3T3 cells, p65 activated the BIC 
promoter approximately 4.2-fold as compared to the empty vector control whereas in 
3T3-5052BC-/- cells, p65 activated luciferase activity only 1.5-fold (Fig. 3.6.D). 
Transfection of p50 did not enhance luciferase activity in either cell type. In fact, p50 
decreased luciferase activity by approximately two-fold in both cell types, suggesting that 
p50 homodimers either form more readily and outnumber p50/p65 heterodimers or have a 
stronger binding activity for the -178 site, as seen in Fig 3.6.C. These results are 
consistent with the hypothesis that the BIC promoter can be activated by p65 but requires 
other NF-κB family members, especially p50, to achieve high expression of miR-155. 
 
3.5.7 Increased NF-κB Activity Correlates with Mature miR-155 Expression in a 
Panel of B-lymphoma Cell Lines 
 Given that increased NF-κB activity correlates with increased miR-155 
expression (see section 1.3) and that the -178 NF-κB site is bound by the p50/p65 
heterodimer (Fig. 3.6.C), it was hypothesized that B-lymphoma cells with high miR-155 
would also have high nuclear p65 levels in their resting state whereas cells expressing a 
low level of miR-155 would have low nuclear p65. Nine B-lymphoma cell lines with 
known NF-κB activity levels were chosen (low NF-κB; Ramos, Daudi, SUDHL4, 
Pfeiffer, BL41, and BJAB; high NF-κB; IB4, KMH2, and L428) (Table 2.3). miR-155 
was measured from cDNA prepared from resting cells by RT-PCR and qPCR of 
microRNAs and small RNAs. The three cell lines with high NF-κB activity due to LMP1 
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expression (IB4 [Carter et al., 2002]) or loss of IκB (KMH2 and L428 [Emmerich et al., 
1999]) had significantly more mature miR-155 than the six cell lines with low NF-κB 
activity (Fig. 3.7, top panel).  
Nuclear extracts were then made from these nine cell lines and probed for p65, 
REL, and PARP (as a normalizing control) by Western blotting. Mature miR-155 
expression did not fully correlated with nuclear p65 levels (Fig 3.7, bottom panel). Of the 
three cell lines with high NF-κB activity and high miR-155 expression, IB4 and KMH2 
had high levels of nuclear p65, whereas L428 cells did not. Western blotting for nuclear 
REL demonstrated that IB4, KMH2, and L428 cells also had high levels of REL, as did 
SUDHL4 cells, which have low NF-κB and express IκB (Davis et al., 2001; Liang et al., 
2006). These data suggest that increased nuclear NF-κB activity is necessary for miR-155 
expression and not merely increased nuclear protein levels of individual NF-κB proteins, 
as seen with SUDHL4 cells which have low NF-κB activity due to the inhibitory effects 
of IκB but high nuclear REL expression. 
 
3.6 CD10 Protein Levels Are Affected by Alterations in the Expression of miR-
155 or PU.1 
PU.1 has been proposed to control CD10 expression due to the presence of 
predicted PU.1 DNA binding sites in the CD10 promoter (Ishimaru and Shipp, 1995) and 
miR-155 has been shown to down-regulate PU.1 expression (Faraoni et al., 2009; 
Martinez-Nunez et al., 2009; Vigorito et al., 2007). If CD10 is a target for PU.1-driven 
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expression, then over-expression of miR-155 or shRNA-mediated knock-down of PU.1 
(to mimic the effects of miR-155 activity) should reduce expression of PU.1 and CD10. 
 
3.6.1 Over-expression of miR-155 in BJAB Cells Down-regulates CD10 and PU.1 
 To determine whether miR-155 expression would result in decreased PU.1 and 
CD10 levels, stable over-expression of miR-155 was achieved by retroviral transduction 
of the BIC gene (with vector MSCV-BIC) into BJAB cells (performed by Ian Zhao). 
Over-expression of BIC resulted in an approximately 110-fold increase in mature miR-
155 levels (Fig. 3.8.A). This high expression of miR-155 also led to reduced levels of 
PU.1 protein and CD10 protein and mRNA (Figs. 3.8.B and C). These results are 
consistent with previous findings that miR-155 down-regulates PU.1 expression (Faraoni 
et al., 2009; Marinez-Nunez et al., 2009; Vigorito et al., 2007) and suggest that loss of 
PU.1 expression causes decreased levels of CD10. 
 
3.6.2 Knockdown of PU.1 Results in Down-regulation of CD10 
To determine whether CD10 levels are dependent on PU.1, shRNA-mediated 
knockdown of PU.1 was performed in BJAB cells, and PU.1 and CD10 levels were 
measured by Western blotting (Fig. 3.8.D). Knockdown of PU.1 led to a loss of CD10 
protein, consistent with PU.1 controlling CD10 expression in BJAB cells.  
 
3.6.3 Stable Expression of v-Rel in Chicken DT40 Fibroblasts Resulted in Down-
regulation of PU.1 mRNA 
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The oncogenic NF-κB transcription factor v-Rel has been shown to up-regulate 
miR-155 expression (Bolisetty et al., 2009). Therefore, we predicted that v-Rel 
expression should also cause expression of PU.1 to decrease. To test this hypothesis, the 
levels of PU.1 mRNA were compared in control avian DT40 B-lymphoma cells and 
DT40 cells stably expressing v-Rel (Gupta et al., 2008). As seen in Fig 3.8.E, expression 
of v-Rel results in a reduction of PU.1 mRNA levels. These results further suggest that 
NF-κB-directed expression of miR-155 can lead to reduced expression of PU.1. 
 
3.7 Alternative Ways to Regulate CD10 Expression 
3.7.1 Identification of Non-consensus PU.1 Binding Sites in the CD10 Promoter 
Herscovitch (2009) showed that PU.1 could activate transcription from a 717 bp 
upstream fragment of the CD10 promoter, and that activation is partially depended on a 
consensus (GAGGAA) site. Variations of PU.1 consensus GAGGAA sequences or 
differences in bases around the core sequence can alter PU.1 DNA binding though (Li et 
al., 1999; Smith et al., 1998). In fact, PU.1 has been shown to bind to AAGGAA 
sequences in some gene promoters (Eisenbeis et al., 1993; Kwon et al., 2006). After 
careful examination of the 717 bp region of CD10 promoter region described by Dr. 
Melanie Herscovitch [Herscovitch, 2009], it was discovered that six AAGGAA 
sequences were present. Five of these AAGGAA sites are in a repeat region termed the 
AAGGAA repeat and one, termed PU-4, is located between PU-1 and PU-2 (Fig. 3.9.A).  
Therefore, it was hypothesized that regulation of CD10 transcription by PU.1 
could depend on cooperative transcriptional control due to multiple PU.1 binding sites in 
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the CD10 promoter. To test this, the CD10 promoter region in pCD10-luc (as described 
in Herscovitch, 2009) was divided into two parts in order to separate the three predicted 
5’ PU.1 binding sites from the AAGGAA repeat and PU-3 sites. These two sections of 
the CD10 promoter were subcloned into the pGL3-promoter plasmid to give pCD10-1-
470-luc and pCD10-449-717-luc (Table 2.1; Fig. 3.9.A). Reporter assays were performed 
by co-transfecting each plasmid with a PU.1 expression vector, and the results were 
compared to the intact promoter in pCD10-luc. Results showed that the full-length CD10 
promoter was activated approximately 4.6-fold by PU.1 while both sections of the CD10 
promoter contribute approximately equally to activation of the promoter by PU.1 (Fig. 
3.9.B), suggesting that consensus and non-consensus PU.1 binding sites in the CD10 
promoter are important in driving CD10 expression. 
 
3.7.2 Changes in Epigenetic Function can Control CD10 Expression 
A common method for exploring gene regulation is to assess the epigenetic status, 
typically DNA methylation and histone tail acetylation, of the promoter region of a given 
gene. These modifications determine chromatin structure, degree of DNA condensation, 
and gene regulation. Most commonly, acetylation of lysines (K) in the histone tails 
coupled with demethylated DNA decondenses the DNA so that it can be remodeled for 
transcription and DNA repair. Conversely, histone deacetylation in a specific region 
allows the DNA to be methylated, condensing the DNA into heterochromatin and 
subsequent gene silencing (Thiagalingam et al., 2003). Methyltransferase inhibitors such 
as 5-aza-2-deoxycytidine (AZA) and histone deacetylase inhibitors (HDACs) such as 
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trichostatin A (TSA) are frequently used to study epigenetic gene regulation (Choi et al., 
2005; Liu et al., 2011; Piotrowska and Jagodzinski, 2007). In this study, both compounds 
were used in an attempt to determine whether CD10 expression in B-cell lymphomas 
could be regulated via epigenetic modification.  
 RC-K8 cells have low levels of CD10 mRNA and protein, making them a good 
candidate cell line to test whether treatment with AZA and TSA would result in increased 
transcription of CD10. RC-K8 cells were treated with either 5 µM AZA for 48 h, 600 nM 
TSA for 24 h, or both drugs in combination for the same time points. RT-PCR was then 
performed on CD10 and GAPDH (as a normalizing control). All three conditions 
increased CD10 expression in RC-K8 cells, with an approximately 7-fold increase with 
the combined treatments (Fig. 3.9.C). 
Considering the success of the AZA/TSA treatment in inducing CD10 
transcription in RC-K8 cells, additional cell lines were added to the analysis. RC-K8, 
KMH2, and L428 cells were treated with 5 µM AZA for 24 h and then 600 nM TSA was 
added for an additional 24 h. CD10 mRNA expression was increased in all three cell lines 
(Fig. 3.9.D): 3.5-fold in RC-K8 cells, 1.7-fold in KMH2 cells, and 1.3-fold in L428 cells. 
These results indicate that CD10 expression can be controlled by epigenetic 
modifications in some B-lymphoma cell lines. 
 
3.8 Over-expression of CD10 in BJAB Cells Results in ~2.2 Fold Increase in Soft 
Agar Colony Formation 
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 The ability of cells to form colonies in soft agar is a useful way to measure the 
transformed state of a cell. In many such experiments, a cell type is stably transduced 
with a gene of interest, plated in soft agar, grown for 14 days, and the number of visible 
colonies is counted and compared to non-transduced control cells. If the transduced cell 
line has more colonies than the control cell line, then the gene of interest is considered 
transforming in that cell type, as our lab has previously shown with the mutant form of 
the REL (RELΔTAD1) in BJAB cells (Chin et al., 2009). To determine whether CD10 
has transforming capabilities, BJAB cells were transduced with a retroviral vector 
containing the CD10 cDNA and pools of cells were selected for puromycin resistance. 
Western blotting confirmed over-expression of CD10 in these cells (Fig. 3.10.A). Soft 
agar colony formation assays showed an ~2.2 fold increase in soft agar colony formation 
in the BJAB-CD10 cells as compared to empty vector control cells (BJAB-Puro) (Fig. 
3.10.B). These results suggest that CD10 expression can enable B-lymphoma cells to 
grow more readily in soft agar. 
 
3.9  Chapter 3 Summary 
This chapter describes for the first time a molecular mechanism whereby 
increased NF-κB activity can lead to reduced expression of CD10. Both high NF-κB 
activity and low CD10 expression are poor prognostic markers for B-cell lymphoma. 
These results have established a direct link between increased NF-κB activity in B-
lymphoma cells and increased expression of microRNA miR-155, which then causes 
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decreased PU.1 protein levels and consequently reduced transcription from the CD10 
promoter (leading to reduced CD10 protein levels). Or, more simply,  
↑NF-κB → ↑miR-155 → ↓PU.1 → ↓CD10 
  This gene regulatory network is of particular interest because less clinically 
favorable DLBCLs (e.g., the ABC subtype) can have several types of gene mutations that 
endow them with constitutive activation of NF-κB and reduced expression of CD10 
(Compagno et al., 2009; Hans et al., 2004; Kato et al., 2009; Lenz et al., 2008a, c). The 
effects of CD10 expression in B-lymphoma pathogenesis are not well understood, but 
understanding the molecular control of CD10 expression could lead to improved 
therapeutics approaches. This is further substantiated by the demonstration that CD10 
over-expression in BJAB cells resulted in increased soft agar colony formation, 
indicating that CD10 expression is advantageous for cell growth under some 
circumstances. Therapeutic targeting of CD10 in B-lymphoma could be a potent way to 
decrease cell growth and lead to improved patient prognosis. 
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Figure 3.1. Elevated miR-155 expression correlates with reduced PU.1 and CD10 
expression levels in several B-lymphoma cell lines. Whole cell extracts were prepared 
from six transformed B-lymphoid cell lines (BJAB, SUDHL4, BL41, Daudi, IB4, RC-
K8). Details of the lymphoma cell lines are indicated as follows: GCB DLBCL, germinal 
center B-cell diffuse large B-cell lymphoma; EBV– FL, Epstein-Barr Virus-negative 
follicular lymphoma; EBV+ LMP1– FL, Epstein-Barr Virus-positive, latent membrane 
protein 1-negative follicular lymphoma; EBV+ B-cell, Epstein-Barr Virus-transformed B-
lymphoblastoid cell line; and ABC DLBCL, activated B-cell diffuse large B-cell 
lymphoma. Western blotting was performed for PU.1, CD10, and β-tubulin (performed 
by Ryan Thompson). cDNA preps were also prepared from the same six cells lines and 
the mature miR-155 levels were quantified using qPCR. The levels of miR-155 in each 
cell line are relative to expression in BJAB cells (1.0). The qPCR experiments were 
performed by Dr. Melanie Herscovitch (Herscovitch, 2009). 
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Figure 3.1. Elevated miR-155 expression correlates with reduced PU.1 and CD10 
expression levels in several B-lymphoma cell lines. 
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Figure 3.2. LPS treatment of BJAB cells causes a loss in PU.1 binding to the CD10 
promoter. BJAB cells were treated with 5 µg/ml LPS for 72 h and nuclear extracts were 
analyzed by EMSA using the PU-1 site from the CD10 promoter (as described by Dr. 
Melanie Herscovitch [Herscovitch, 2009]).  
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Figure 3.3. LPS treatment of BJAB cells leads to p65 nuclear localization and 
increased DNA binding to the BIC promoter. BJAB cells were treated with 5 µg/ml of 
LPS for the indicated amounts of time (h). A, BJAB cells were treated with LPS for 0, 15, 
30, and 60 min and nuclear extracts were made. Western blots were performed on p65, 
PARP (nuclear control), and β-tubulin (cytosolic control). Whole cell extracts (WCE) of 
BJAB cells were prepared and used as a control. B, BJAB cells were treated with LPS as 
in panel B and cDNA preps were prepared. The expression levels of unspliced BIC were 
assessed via qPCR and normalized to GAPDH. Values were normalized to untreated cells 
(1.0), +/- SE and * indicates p<0.003. C, BJAB and IB4 cells were treated with LPS for 
24 h and cDNA preps for small RNAs were prepared. The mature miR-155 expression 
levels were then assessed and normalized to 5S rRNA. Bars were normalized to untreated 
samples for each cell type and the relative expression (Rel. Exp.) values are relative to 
untreated BJAB cells. The * indicates p<0.003. D, BJAB cells were treated with LPS for 
0 or 60 min and nuclear extracts were made. Extracts were bound to a 32P-labeled probe 
containing the putative -178 NF-κB site in the BIC promoter (to be discussed in Fig. 3.6) 
with and without the addition of an antibody specific for p65. A light exposure shows 
p50/p65 heterodimer binding just above the p50 homodimer band and the dark exposure 
shows the supershift with a p65 antibody (SC-372x). The last lane is a size control made 
from WCE of A293 cells transfected with p65 and p50 plasmids (to be discussed in Fig. 
3.4.E). Extracts were also probed for p65 nuclear translocation (bottom panel). 
 
 
  
128 
 
Figure 3.3. LPS treatment of BJAB cells leads to p65 nuclear localization and 
increased DNA binding to the BIC promoter. 
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Figure 3.3. LPS treatment of BJAB cells leads to p65 nuclear localization and 
increased DNA binding to the BIC promoter. 
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Figure 3.4. Expression of the B-lymphoma CARD11mut10 protein can decrease the 
expression of PU.1 and CD10 in BJAB cells. A, Western blotting for HA, CD10, PU.1, 
BCL-2, and β-tubulin was performed on whole cell extracts from non-transduced BJAB 
cells (-) or BJAB cells stably transduced with MSCV or MSCV-HA-CARD11mut10. 
Mature miR-155 was quantified in the indicated cell lines using qPCR as in Fig. 3.3.C 
(performed by Dr. Melanie Herscovitch). B, BJAB cells were transduced with a 
doxycycline-inducible retroviral vector for HA-CARD11mut10 (cell lines were 
established by Tyler J. Ford). In the absence (-) or presence (+) of doxycycline (Dox), the 
levels of HA-CARD11mut10 and CD10 were analyzed by Western blotting and the 
levels of mature miR-155 by qPCR. Non-transduced BJAB cells served as a negative 
control. C, Nuclear extracts from BJAB-MSCV control cells or BJAB cells expressing 
HA-CARD11mut10 were incubated with 32P-labeled DNA probes (PU-1, top panel; NF-
κB, bottom panel). The first lane in each case contains probe alone (no extract). As a size 
control for PU-1 binding, an extract from A293 cells over-expressing PU.1 was included 
(top panel, last lane). As an NF-κB DNA-binding control, a nuclear extract sample from 
BJAB cells expressing RELΔTAD1 (Chin et al, 2008) was included (bottom panel, last 
lane). 
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Figure 3.4. Expression of the B-lymphoma CARD11mut10 protein can decrease the 
expression of PU.1 and CD10 in BJAB cells. 
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Figure 3.5. NF-κB family member p65 directs reporter gene transcription from the 
BIC promoter. A, The BIC promoter has at least three predicted NF-κB binding sites in 
the 1494 bp region upstream of the transcription start site. One is at -1150 (Yin et al., 
2008), one is at -441, and one is at -178. B, COS-1 cells were transfected with the pGL3-
BIC-luc plasmid contain the wild-type BIC promoter (Yin et al., 2008) and either 
pcDNA-based versions of FLAG-p65, REL, FLAG-p50, or empty vector; a plasmid 
encoding RSV-renilla was also included for transfection normalization. Cells were lysed 
and luciferase activity was measured. Relative luciferase activity is indicated +/- SE and 
the * indicates p<0.2E-8. The extracts that were prepared for the luciferase assay were 
also probed via Western blotting for p65, REL, p50, and β-tubulin (as a normalizing 
control) to confirm expression of each pcDNA-based vector. C, Truncations of the pGL3-
BIC-luc plasmid were created to obtain pGL3-BIC-(-530) and pGL3-BIC-(-91). 
Luciferase assays were performed as in panel B with pcDNA-FLAG and pcDNA-FLAG-
p65. The * indicates p<0.002. D, NF-κB binding site mutants of the pGL3-BIC-luc 
plasmid were created using PCR to obtain pGL3-BIC-(-)441mut and pGL3-BIC-(-
)178mut. The pGL3-BIC-(-)1150mut was created previously (Yin et al., 2008). 
Luciferase assays were performed as in panel B with pcDNA-FLAG and pcDNA-FLAG-
p65. The * indicates p<0.002.  
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Figure 3.5. NF-κB family member p65 directs reporter gene transcription from the 
BIC promoter. 
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Figure 3.5. NF-κB family member p65 directs reporter gene transcription from the 
BIC promoter. 
 
 
 
 
 
 
 
 
 
!
"
#$%&'!
%()*%&'!
%+,%&'!
%,-+-
. %()*
. %+,
/,
012
.
#$%&'!
%,,(*314%&'!
%--,314%&'!
%,56314%&'!
%,-+-
. %()*
. %+,
/,
012
.
%,-+-
. %()*
. %+,
/,
012
.
%,-+-
. %()*
. %+,
/,
012
.
,6 7*,8,-,7,*68-7*
98(%:;<=;2>?@A>9BC4>C@D24EFE4G
%,-+-
. %()*
. %+,
/,
012
.
%()*
. %+,
/,
012
.
%+,
/,
012
,6 7*,8,-,7,*68-7*
98(%:;<=;2>?@A>9BC4>C@D24EFE4G
H
H
  
135 
 
Figure 3.6. p65-activated transcription from the BIC promoter requires other NF-
κB family members. A, Whole cell extracts were made from A293 cells expressing 
pcDNA-FLAG versions of p65, p50, both p65 and p50, or empty vector and probed via 
Western blotting for the FLAG, p65, p50, or β-tubulin (as a normalizing control). B, An 
EMSA was performed by incubating the extracts in panel A with 32P-labeled consensus 
NF-κB-site probe: Probe only (Lane 1), empty vector (Lane 2), p65 only (Lane 3), p50 
only (Lane 4), p50/p65 heterodimer (Lane5). C, An EMSA was performed using the 
extracts in E with 32P-labeled -178-site probe: Probe only (Lane 1), empty vector (Lane 
2), p65 only (Lane 3), p50 only (Lane 4), p50/p65 heterodimer (Lane 5), p50/p65 
heterodimer with 50X cold probe competition (Lane 6), p50/p65 heterodimer with pre-
immune serum (Lane 7), p50/p65 heterodimer with SC-372x p65 antibody (Lane 8), 
p50/p65 heterodimer with NR-1226 p65 antibody (Lane 9). The supershifted p50/p65 
complex is indicated by ss and an arrow. D, Reporter assays were performed in 3T3 and 
3T3-BC5052-/- cells transfected with the WT-BIC reported plasmid and FLAG-tagged 
versions of either pcDNA alone (-), pcDNA-p65, or pcDNA-p50. Values for each 
transfection were normalized to RSV-renilla and then compared to pcDNA alone (1.0), 
+/- SE. The * indicates p<0.03 and statistically not significant is indicated by n.s.   
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Figure 3.6. p65-activated transcription from the BIC promoter requires other NF-
κB family members.  
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Figure 3.6. p65-activated transcription from the BIC promoter requires other NF-
κB family members.  
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Figure 3.6. p65-activated transcription from the BIC promoter requires other NF-
κB family members.  
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Figure 3.7. Activation of the NF-κB signaling pathway correlates with expression of 
miR-155. The levels of mature miR-155 were assessed via qPCR (top panel) and nuclear 
p65, REL, and PARP (as a normalizing control) were assessed via Western blotting 
(bottom panel) in a panel of nine B-lymphoma cell lines, as previously performed. 
Including in this panel are cell lines known to have low NF-κB activity (Ramos, Daudi, 
SUDHL4, Pfeiffer, BL41, and BJAB) and cell lines known to have high NF-κB activity 
(IB4, KMH2, and L428) (Table 2.3). MiR-155 expression values are relative to Ramos 
cells (1.0) and error bars indicate +/- SE. 
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Figure 3.8. Alterations in the cellular levels of miR-155 or PU.1 affect the expression 
of CD10. A, qPCR was performed to assess the levels of mature miR-155 in BJAB cells 
transduced with a pMSCV-puro (-) or pMSCV-BIC (+) expression vector (cell lines 
established by Ian Zhao). Values were normalized to the 5S rRNA levels and represent 
the mean values of three experiments performed with three samples +/- SE. B, The 
protein levels of PU.1, CD10, and β-tubulin (as a normalizing control) were compared in 
the same cell types as in Fig. 3.8.A by Western blotting. C, The mRNA levels of CD10 
and β-tubulin (as a normalizing control) were compared in the same cell types as in Fig. 
3.8.A by RT-PCR, agarose gel electrophoresis, and staining with ethidium bromide. D, 
Western blots for PU.1, CD10, and β-tubulin (as a normalizing control) were compared 
in BJAB cells expressing an shRNA directed against PU.1 or an irrelevant shRNA (con) 
that does not recognize any human sequence (negative control) (Table 2.2). E, Whole cell 
extracts were made from DT40 and DT40-v-Rel cells (Gupta et al., 2008), and anti-v-Rel 
Western blotting was performed (left panel); a v-Rel-transformed chicken spleen cell line 
served as the positive control for v-Rel expression. In the right panel, PU.1 and GAPDH 
(as a normalizing control) transcript levels were analyzed by RT-PCR. 
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Figure 3.8. Alterations in the cellular levels of miR-155 or PU.1 affect the expression 
of CD10. 
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Figure 3.9. Alternate ways to control CD10 expression. A, The 717 base pair region of 
the CD10 promoter contains three putative PU.1 binding sites (PU-1, PU-2, PU-3) with 
the consensus sequence of GAGGAA and two regions (PU-4, AAGGAA repeat) with 
non-consensus sequences of AAGGAA. This region of the CD10 promoter was split into 
two sections by PCR amplification from the pCD10-luc vector to make pCD10-1-470-luc 
and pCD10-449-717-luc using primers listed in Table 2.2. The PCR products were 
purified using the UltraClean 15 DNA Purification Kit (MO BIO Laboratories), digested 
with KpnI and XmaI, and subcloned into the pGL3 promoter vector (Promega). B, 
Luciferase assays were performed on both halves of the CD10 promoter (pCD10-1-470-
luc and pCD10-449-717-luc [Table 2.1]) that were co-transfected with pcDNA alone or 
pcDNA-PU.1 expression plasmids (Table 2.1). Relative luciferase activity is indicated +/- 
SE, * indicates p<0.02, and ** indicates p<0.002. Averages are from three assays 
performed with triplicate samples. The relative expression values (Rel. Exp.) represent 
the relative luciferase expression of each plasmid as compared to the full-length CD10 
promoter with no PU.1 protein (1.0). C and D, Cells were plated at a density of 1 x 106 
cells in 2 ml of media for 6 h and then treated with either 5 µM AZA for 48 h later, 600 
nM TSA for 24 h, or both drugs in combination for the same time points as above. RNA 
was extracted and cDNA was prepared. RT-PCR was performed on CD10 and GAPDH 
(as a normalizing control). Fold change values were calculated using ImageJ.       
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Figure 3.9. Alternate ways to control CD10 expression.  
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Figure 3.9. Alternate ways to control CD10 expression.   
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Figure 3.10. Over-expression of CD10 in BJAB cells causes ~2.2 fold increase in soft 
agar colony formation. A, BJAB cells were transduced with a retroviral vector 
containing the CD10 cDNA or an empty vector control, and pools of cells were selected 
for puromycin resistance. Western blotting for CD10 and β-tubulin (as a normalizing 
control) confirmed CD10 over-expression. B, Soft agar colony formation was performed 
(section 2.7) on BJAB-Puro (empty vector control cells) and BJAB-CD10 cells. Relative 
colony formation is indicated +/- SE and * indicates p<0.002. Averages are from five 
assays performed with five samples. 
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CHAPTER 4 
THE SENSITIVITY OF DIFFUSE LARGE B-CELL LYMPHOMA CELL LINES 
TO HISTONE DEACETYLASE INHIBITOR-INDUCED APOPTOSIS IS 
MODULATED BY BCL-2 FAMILY PROTEIN ACTIVITY 
 
4.1 Introduction 
Diffuse large B-cell lymphoma (DLBCL) is the most common form of 
lymphoma, accounting for 40% of non-Hodgkin lymphomas and 30% of all lymphomas 
(Hunt et al., 2008). Gene expression arrays have revealed distinct DLBCL subtypes that 
differ in their response to the standard antibody/chemotherapy regimen, R-CHOP (Lenz 
et al., 2008b; Rosenwald et al., 2002). Nevertheless, there is a need for the identification 
of additional predictive gene signatures, in part because many patients do not respond to 
R-CHOP therapy and because there are a number of new chemotherapeutic approaches 
being evaluated (Leonard et al., 2008). 
One class of therapeutic agents currently in clinical trials includes epigenetic 
modifiers, such as histone deacetylase inhibitors (HDACi’s) and DNA methyltrasferase 
inhibitors. HDAC’s comprise a family of proteins that deacetylate a variety of protein 
substrates, generally ones involved in transcriptional control (Bolden et al., 2006; Cotto 
et al., 2010). HDACi’s have been shown to be effective at inducing cell death in cancers 
on their own and in combination with other drugs, both in cell lines and patients (Bolden 
et al., 2006; Cotto et al., 2010; Wiegmans et al., 2011). For instance, the HDACi’s 
vorinostat and valproic acid induce apoptosis in human lymphoid cancers, which is 
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associated with cell cycle arrest (Bodo et al., 2011; Sakajiri et al., 2005). Vorinostat was 
approved for the treatment of T-cell lymphoma (Crump et al., 2008), and is currently in 
clinical trials for the treatment of a variety of B-cell lymphomas, showing promising 
results for certain advanced hematologic malignancies (O’Connor et al., 2006), but not 
for patients with relapsed DLBCL (Crump et al., 2008). Additionally, vorinostat has been 
shown to synergize with the proteasome inhibitors bortezomib in multiple myeloma and 
carfilzomib in DLBCL (Bolden et al., 2006; Dasmahapatra et al., 2010), with the BH3 
mimetic ABT-737 in breast cancer and in certain transgenic murine lymphomas (Chen et 
al., 2011; Wiegmans et al., 2011), and with the PKCβ inhibitor enzastaurin in DLBCL 
and T-cell lymphoma (Bodo et al., 2011).  
 The BCL-2 protein family plays a pivotal role in regulating mitochondrial-derived 
apoptosis in normal and malignant cell types. The BCL-2 family can be divided into three 
classes: anti-apoptotic (BCL-2, BCL-XL, MCL-1, A1, BCL-W, BCL-B), BH3-only pro-
apoptotic modulators of apoptosis (BIM, BID, PUMA, BIK, BAD, NOXA, BMF), and 
pro-apoptotic activators (BAK, BAX, BOD) (Shamas-Din et al., 2011; Strasser et al., 
2011; Walensky and Gavathiotis, 2011). BCL-2 family proteins act as regulators of cell 
survival in a variety of cancers, including non-small cell lung cancer and breast cancer 
(Faber et al., 2009 and 2011), colon adenocarcinomas (Rampino et al., 1997), clear-cell 
renal cell carcinoma (Sturm et al., 2006), non-Hodgkin B-cell lymphoma (Mestre-
Escorihuela et al., 2007), and other hematopoietic malignancies (Brimmell et al., 1998). 
Two examples of BCL-2 misregulation are the occurrence of the BCL-2 gene as part of 
the t(14;18) translocation found in a number of non-Hodgkin B-cell lymphomas (Yarkoni 
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et al., 1996) and the increased expression of BCL-2 in different cancers, in which 
elevated BCL-2 levels correlate with chemoresistance (Youle et al., 2008). Neverthelss, 
high BCL-2 expression, regardless of microarray-based classification, has also recently 
been reported to define a subset of DLBCL patients with a better outcome in response to 
R-CHOP therapy (Jing et al., 2011). 
 It is well-established that anti-apoptotic proteins like BCL-2, BCL-XL, and MCL-
1 sequester many different pro-apoptotic proteins, including BIM and BAX, to inhibit 
apoptosis in several cancer types (Faber et al., 2011; Jing et al., 2011; Oltersdorf et al., 
2005; Walensky and Gavathiotis, 2011). While HDACi-induced apoptosis has been 
shown to occur via up-regulation of the pro-apoptotic BH3-only protein BIM (Bolden et 
al., 2006; Chen et al., 2009), many tumor cells are protected from apoptosis-inducing 
agents by having increased expression of anti-apoptotic proteins or decreased expression 
of pro-apoptotic proteins. The interaction between anti-apoptotic and pro-apoptotic 
proteins has been a target of therapeutic discovery, yielding the BAD-like BH3 mimetic 
ABT-737 (Oltersdorf et al., 2005), which specifically targets the BH3 binding pocket of 
BCL-2, BCL-XL, and BCL-W, thereby blocking their ability to bind to BH3 modulators 
and pro-apoptotic activators (Chen et al., 2009; Morales et al., 2011; Shamas-Din et al., 
2011; Strasser et al., 2011). ABT-737 can increase cell death in several cancer types as a 
monotherapy or in combination with other compounds (Allaman-Pillet et al, 2011; Chen 
et al., 2011; Debien et al., 2011; Del Gaizo Moore et al., 2007; Fang et al., 2011; 
Ishitsuka et al., 2012; Risberg et al., 2001). Relevant to this study, ABT-737 has been 
investigated as part of a combination therapy with vorinostat (Wiegmans et al., 2011) and 
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bortezomib (Paoluzzi et al., 2008) in multiple myeloma and in a variety of lymphomas 
and leukemias, respectively. However, the precise interplay between BCL-2 family 
proteins and the sensitivity of DLBCL to HDACi’s has not been fully characterized.  
 Based on those studies, as well as others from our lab (Yeo et al., 2012), it was 
hypothesized that BCL-2 family member expression would play a role in affecting the 
sensitivity of DLBCL to HDACi-induced apoptosis. The findings presented in this 
chapter show that many common DLBCL cell lines are susceptible to HDACi-induced 
apoptosis through a caspase-dependent mechanism and that exogenous expression of 
specific BCL-2 family members or treatment with ABT-737 can alter DLBCL cell line 
sensitivity to HDACi treatment. A vorinostat-resistant variant of the HDACi-sensitive 
cell line SUDHL4 revealed that HDACi resistance is correlated with increased BCL-XL 
expression. 
 
4.2 Inhibition of HDAC Activity Induces Apoptosis in the Majority of Cell Lines 
from a Select Panel of Diffuse Large B-cell Lymphoma Cell Lines 
As a first assessment of the ability of HDACi’s to induce apoptosis in human 
DLBCL, eight cell lines, from different DLBCL subtypes (GCB: BJAB, SUDHL4, 
SUDHL6, Pfeiffer, Farage, and SUDHL6; ABC: SUDHL2 and RC-K8) (Table 2.3), were 
treated with either 300 nM trichostatin A (TSA) (Hrzenjak et al., 2010) or 3 µM 
vorinostat (Pitts et al., 2009; Zhao et al., 2005) for 24 h. Whole-cell extracts were then 
prepared, and cleavage of the caspase-3 substrate PARP was measured by Western 
blotting. As shown in Fig. 4.1, there was a range of PARP cleavage in these cell lines 
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following treatment with either HDACi. SUDHL2, Pfeiffer, and SUDHL4 cells showed 
nearly complete cleavage of PARP and there was partial cleavage of PARP in BJAB, 
Farage, RC-K8, and SUDHL8 cell lines after treatment with TSA or vorinostat. In one 
cell line, SUDHL6, there was no detectable PARP cleavage following treatment with 
either HDACi. 
 
4.3 Trichostatin A and Vorinostat Induce Apoptosis in SUDHL4, but not in 
SUDHL6 Cells 
4.3.1 Trichostatin A and Vorinostat Induce Apoptosis in a Time- and Dose-
Dependent Manner in SUDHL4 Cells 
To further investigate the ability of TSA and vorinostat to induce apoptosis in 
sensitive vs. resistant DLBCL cell lines (SUDHL4 vs. SUDHL6, respectively), cells were 
treated with 300 nM TSA or 3 µM vorinostat for increasing times up to 24 h and PARP 
cleavage was assessed via Western blotting. Following treatment with either drug, 
SUDHL4 cells showed a time-dependent increase in PARP cleavage, whereas SUDHL6 
cells showed no significant change in PARP cleavage, even at 24 h (Fig. 4.2.A). 
Similarly, both TSA and vorinostat induced PARP cleavage and caspase-3 activity in a 
dose-dependent manner in SUDHL4 cells, but not in SUDHL6 cells (Figs. 4.2.B and C). 
SUDHL4 cells treated for 14 h with 3 µM vorinostat also showed an approximately 40% 
increase in apoptotic nuclei compared to untreated cells, as judged by acridine orange and 
ethidium bromide staining; SUDHL6 cell showed no increase in apoptotic nuclei (Fig. 
4.2.D). Of note, there was no change in necrotic nuclei in either cell line, confirming that 
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the cell death induced by vorinostat in SUDHL4 cells is apoptosis. These results show 
that TSA and vorinostat are able to induce apoptosis in DLBCL cell lines. 
 
4.3.2 Vorinostat Inhibits Cell Proliferation in SUDHL4 at a Lower IC50 Than 
SUDHL6 Cells 
The effect of vorinostat on cell proliferation was assessed by treating SUDHL4 
and SUDHL6 cells with increasing concentrations of vorinostat for 72 h and then 
comparing the number of cells to control untreated plates (Fig. 4.2.E). SUDHL4 cells 
were quite sensitive to inhibition of cell proliferation by vorinostat, showing an IC50 of 
less than 0.5 µM, whereas the IC50 for SUDHL6 cells was approximately 6-fold higher 
(~3 µM). These results indicate that SUDHL4 cells are also more sensitive to cell growth 
inhibition by vorinostat than SUDHL6 cells and that the doses of vorinostat required to 
inhibit cell proliferation are lower than those required to induce apoptosis. 
 
4.3.3 Vorinostat Induces BIM Expression in HDACi-resistant SUDHL6 cells 
HDACi treatment has been shown to up-regulate expression of the pro-apoptotic 
BH3-only protein BIM in human colon carcinoma, osteosarcoma, leukemia, and multiple 
myeloma cell lines (Chen et al., 2009; Henderson et al., 2003). Therefore, we wished to 
determine whether BIM was up-regulated by vorinostat in the resistant SUDHL6 cell 
line. SUDHL6 cells were treated with vorinostat for 4 h in Western blotting for BIM was 
performed. As shown in Figure 4.2.F, BIM increased in a dose-dependent fashion after 
treatment with increasing amounts of vorinostat. Therefore, the relative resistance of 
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SUDHL6 cells to vorinostat-induced apoptosis does not appear to be due to an inability 
of BIM to be induced by vorinostat in these cells, although the level of BIM induction 
may not be high enough to overcome the anti-apoptotic actions of BCL-2, BCL-XL, and 
MCL-1. 
 
4.3.4 SUDHL6 Cells Are Not Resistant to all Chemotherapeutic Agents  
To determine if the HDACi-resistant cell line SUDHL6 is generally resistant to 
apoptosis-inducing agents, SUDHL6 cells were treated with the protein kinase inhibitor 
staurosporine, which is a potent inducer of apoptosis in a variety of cell types (Manns et 
al., 2011; Rommelaere et al., 2011). As shown in Figure 4.2.G, PARP was cleaved in a 
dose-dependent fashion in SUDHL6 cells following treatment with staurosporine. These 
results indicate that SUDHL6 cells can be induced to undergo apoptosis by staurosporine, 
indicating that these cells do not have a general resistance to apoptosis-inducing agents. 
 
4.4 Over-expression of BCL-2, BCL-XL, and BIM Can Affect the Sensitivity of 
DLBCL Cell Lines to HDACi-induced Apoptosis  
TSA and vorinostat have been shown to induce apoptosis through a BCL-
2/caspase-3-dependent mechanism in a number of cell types including mammary 
carcinomas (Henderson et al., 2003), retinoblastoma (Dalgard et al., 2008), and leukemic 
T cells (Morales et al., 2010). Therefore, we hypothesized that shifting the overall 
balance of the BCL-2 family proteins to favor an anti- or pro-apoptotic expression profile 
would be sufficient to alter a DLBCL cell’s resistance or sensitivity, respectively, to 
  
153 
 
apoptosis-inducing agents. To test this hypothesis, we modulated the levels of BCL-2 
family members by over-expression of relevant anti- or pro-apoptotic proteins and 
assessed whether there was a change in DLBCL sensitivity to vorinostat and TSA.  
 
4.4.1 Over-expression of BCL-2 in SUDHL2 Cells Confers Decreased Sensitivity to 
HDACi-Induced Apoptosis 
To determine whether BCL-2 could protect HDACi-sensitive cells from HDACi-
induced apoptosis, SUDHL2 cells were infected with a retroviral vector that directed 
increased expression of mouse BCL-2 protein, which is slightly smaller than the 
endogenous human BCL-2 in these cells (Yeo et al., 2012). Pools of infected cells were 
selected for puromycin resistance and Western blotting confirmed over-expression of 
BCL-2 (Fig. 4.3.A). Control and SUDHL2-BCL-2 cells were treated with 300 nM TSA or 
3 µM vorinostat for 24 h, and extracts were probed for PARP cleavage (Fig. 4.3.A). TSA 
and vorinostat both induced less PARP cleavage in SUDHL2-BCL-2 cells as compared to 
control cells (Fig. 4.3.A, Table 4.1), indicating that ectopic expression of BCL-2 has an 
anti-apoptotic effect on these cells. 
 
4.4.2 Over-expression of BCL-XL in SUDHL4 and Farage Cells Confers 
Decreased Sensitivity to HDACi-Induced Apoptosis 
To determine whether over-expression of the anti-apoptotic protein BCL-XL 
could also render DLBCL cells less sensitive to HDACi treatment, SUDHL4 and Farage 
cells (which express moderately low levels of BCL-XL) were infected with a retroviral 
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vector encoding BCL-XL or with the empty vector. Pools of infected cells were selected 
with puromycin, and Western blotting confirmed over-expression of BCL-XL in these 
retrovirally transduced cell lines (Fig. 4.3.B and C). The relative sensitivity of the BCL-
XL-over-expressing cells to HDACi-induced apoptosis was compared to control cells by 
treating them with 300 nM TSA or 3 µM vorinostat for 24 h and probing extracts for 
PARP cleavage (Fig. 4.3.B and C). In both cell types, over-expression of BCL-XL 
reduced PARP cleavage in response to treatment with TSA or vorinostat (Fig. 4.3.B and 
C; Table 4.1), indicating that over-expression of BCL-XL has a protective effect.  
 
4.4.3 Over-expression of BIM in Farage Cells Confers Increased Sensitivity to 
HDACi-Induced Apoptosis 
To determine whether Farage cells, which express moderately low amounts of 
pro-apoptotic BIM, could be made more sensitive to HDACi treatment by over-
expression of BIM, Farage cells were infected with a retroviral vector encoding BIM or 
the empty vector control, pools of cells were treated with puromycin, and Western 
blotting confirmed over-expression of BIM (Fig. 4.3.D). As above, control and Farage-
BIM cells were then treated with 300 nM TSA or 3 µM vorinostat for 24 h and extracts 
were probed for PARP cleavage (Fig. 4.3.D). TSA and vorinostat both induced more 
PARP cleavage in Farage-BIM cells as compared to control Farage cells (Fig. 4.3.D, 
Table 4.1), indicating that over-expression of BIM sensitizes these cells to HDACi’s. 
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4.5 Pharmacological Modulation of BCL-2 Family Member Interactions Can 
Also Sensitize DLBCL Cell Lines to Vorinostat-induced Apoptosis  
ABT-737 is a BH3 mimetic that disrupts the interaction of BCL-2 and BCL-XL 
with BH3-containing pro-apoptotic proteins, such as BIM, NOXA, and BMF (Chen et 
al., 2009; Morales et al., 2011; Wiegmans et al., 2011). Based on the results above and 
similar studies (Wiegmans et al., 2011), it was hypothesized that ABT-737 would 
sensitize DLBCL cell lines to HDACi-induced apoptosis. As shown in Fig. 4.4, treatment 
with up to 1 µM ABT-737 alone for 24 h induced little or no PARP cleavage in 
SUDHL4, Farage, BJAB, or SUDHL6 cells (Fig. 4.4.A-D, respectively). However, as 
judged by PARP cleavage, treatment with ABT-737 sensitized all four of these cell lines 
to vorinostat-induced apoptosis. In SUDHL4 and Farage cells, ABT-737 increased their 
sensitivity to suboptimal doses of vorinostat (0.5 µM) (Figs. 4.4.A and 4.4.B), whereas in 
BJAB and SUDHL6 cells (Figs. 4.4.C and 4.4.D, respectively), ABT-737 increased 
PARP cleavage only with higher doses of vorinostat (3 µM). Of note, RC-K8 cells, 
showed a high level of PARP cleavage with ABT-737 alone (Fig. 4.4.E). Nevertheless, 
these data show that combined HDACi/ABT-737 treatment is more effective than either 
agent alone at inducing apoptosis in some DLBCL cell lines. In particular, the HDACi-
resistant cell line SUDHL6 was sensitive to apoptosis induced by combined treatment 
with HDACi/ABT-737 under conditions where neither agent alone induced apoptosis. 
The ability of ABT-737 to sensitize DLBCL cell lines to HDACi’s implicates BCL-2 
protein activity in sensitivity vs. resistance to HDACi treatment.  
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To determine whether there is BCL-2 family expression pattern that would be 
predictive of HDACi sensitivity, Western blotting of the eight-cell line panel was 
performed for the anti-apoptotic proteins BCL-2, BCL-XL, and MCL-1, the pro-
apoptotic proteins BIM, HRK, BID, and BAX, and two caspases (3 and 8). There was no 
individual BCL-2 family protein (or caspase) whose expression obviously correlated with 
HDACi sensitivity or resistance among the eight DLBCL cell lines analyzed here (Fig. 
4.5.A). Thus, it is likely that a balance of pro- and anti-apoptotic BCL-2 protein 
expression governs sensitivity to HDACi’s (Walensky and Gavathiotis, 2011).   
Similarly, Western blotting for common DLBCL markers (NF-κB members REL 
and p65, BCL6, CD10, and BCL-2) was performed on the eight-cell line panel. There 
was no individual protein or expression pattern that correlated with HDACi sensitivity 
(Fig. 4.5.B), suggesting that DBLCL subtype per se is not predictive of HDACi 
sensitivity. 
 
4.6 Creation of SUDHL4 Cell Line with Reduced Sensitivity to Vorinostat 
In an effort to select for cells with decreased sensitivity to vorinostat, the HDACi-
sensitive cell line SUDHL4 was treated repeatedly with increasing concentrations of 
vorinostat, from 1 µM to 3 µM, with time to recover between each treatment (section 
2.21). SUDHL4-vorinostat-resistant (SUDHL-VR) cells could tolerate up to 3 µM 
vorinostat for 48 h, but after that, the cultures did not survive. After selection of 
SUDHL4-VR cells, the cells were then cultured in media without vorinostat in order to 
assess the ability of vorinostat to induce apoptosis and proliferation arrest in these cells. 
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4.6.1 SUDHL4-VR Cells Display Resistance to HDACi Treatment 
 To compare the HDACi sensitivity of SUDHL4-VR and parental SUDHL4 cells, 
both cell types were treated with increasing amounts of vorinostat for 24 h and apoptosis 
was assessed by PARP cleavage and caspase-3 activity. At 3 and 6 µM vorinostat, 
SUDHL4-VR cells displayed reduced PARP cleavage (Fig. 4.6.A) and reduced caspase-3 
activity (Fig. 4.6.B) as compared to control SUDHL4 cells. Additionally, as compared to 
parental SUDHL4 cells, SUDHL4-VR cells were less sensitive to vorinostat-induced 
inhibition of cell proliferation (Fig. 4.6.C). When treated with increasing concentrations 
of ABT-737, SUDHL4-VR cells showed nearly complete resistance to increasing 
concentrations of ABT-737 alone and only moderate PARP cleavage at high doses of 
ABT-737 in combination with low levels of vorinostat (Fig. 4.6.D, compare to Fig. 
4.4.A).  
To determine whether this resistance to vorinostat is HDACi specific, SUDHL4-
VR cells were also treated with increasing concentrations of TSA for 14 h and relative 
caspase-3 activity was measured. As compared to parental SUDHL4 cells, SUDHL4-VR 
cells were also less sensitive to TSA treatment than parental SUDHL4 cells (Fig. 4.6.E).  
 
4.6.2 SUDHL4-VR Cells are Sensitive to Staurosporine Treatment 
Considering that the HDACi-resistant SUDHL6 cell line is sensitive to caspase-
dependent apoptosis induced by the protein kinase inhibitor staurosporine (Fig. 4.2.G), 
SUDHL4-VR cells were treated with staurosporine to determine whether these cells were 
resistant to other apoptosis inducers as well. SUDHL4-VR exhibited PARP cleavage 
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when treated for 24 h with increasing amounts of staurosporine (Fig. 4.6.F), indicating 
that caspase-dependent apoptosis is not fully impaired in SUDHL4-VR cells. 
 
4.6.3 Induced Vorinostat Resistance May Be Due to Increased BCL-XL and  
MCL-1 Expression 
Because the ability of vorinostat to induce apoptosis in DLBCL cells appears to 
be dependent on the BCL-2 family protein dynamics, it was hypothesized that SUDHL4-
VR cells might have changes in their expression of BCL-2 protein family members. To 
investigate the mechanism by which SUDHL4-VR cells develop resistance to vorinostat, 
two independent isolates of SUDHL4-VR cells were compared to SUDHL4 cells for 
expression of the BCL-2 family members BCL-2, BCL-XL, MCL-1, BIM, and BAX 
(Fig. 4.6.G). Among these proteins, expression of at least two of the anti-apoptotic 
proteins BCL-2, BCL-XL, and MCL-1 were increased in both SUDHL4-VR cell lines: 
that is, expression of anti-apoptotic BCL-2 family proteins was increased in SUDHL4-
VR cells as compared to the parental SUDHL4 cells, indicating that these cells might be 
more resistant to vorinostat-induced apoptosis due to elevated levels of BCL-2, BCL-XL, 
and/or MCL-1. 
 
4.7 Chapter 4 Summary 
The aim of this research was to provide cell-based, pre-clinical evidence that 
DLBCL tumors may be candidates for treatment with FDA approved HDACi compounds 
like vorinostat, and to also elucidate the molecular mechanism that governs HDACi-
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sensitivity and -resistance. It is shown that vorinostat induces apoptosis in seven of eight 
DLBCL cell lines. Furthermore, vorinostat and the BH3 mimetic ABT-737 can cooperate 
to enhance cell death in many DLBCL cell lines. This is not surprising given that similar 
results have been observed when a combination of these compounds is used in other 
cancer types. One cell line, SUDHL6, is specifically resistant to vorinostat-induced 
apoptosis. Additionally, this research shows that a DLBCL cell line can be made resistant 
to vorinostat and that this resistance to vorinostat is associated with increased levels of 
BCL-XL. This finding may be useful in understanding the molecular mechanism by 
which patients develop HDACi-resistance in the clinic. Overall, these results suggest that 
HDACi-resistant patients may benefit from a combination therapy that uses both HDACi 
and ABT-737-like compounds. 
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Figure 4.1. Trichostatin A and vorinostat induce PARP cleavage in a subset of 
DLBCL cell lines. The indicated DLBCL cell lines were treated with either 300 nM TSA 
(top panel) or 3 µM vorinostat (bottom panel) for 24 h and Western blotting was 
performed for PARP and β-tubulin (as a normalizing control). Note: in cases where cells 
undergo extensive PARP cleavage (e.g., SUDHL4, Pfeiffer, SUDHL2), β-tubulin can 
appear under-loaded (likely because tubulin is also degraded in these dying cells). Cell 
lines used were GCB-like (BJAB, SUDHL4, SUDHL6, Pfeiffer, Farage, and SUDHL8) 
and ABC-like (RC-K8 and SUDHL2) (Table 2.3). Grey font indicates HDACi-sensitive 
cell lines; black font indicates the HDACi-resistant cell line (SUDHL6). The arrowhead 
indicates cleaved PARP. 
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Figure 4.2. Trichostatin A and vorinostat induce apoptosis and inhibit growth in a 
time- and dose-dependent manner. A, SUDHL4 and SUDHL6 cells were treated with 
either 300 nM TSA or 3 µM vorinostat for the indicated times. Whole-cell extracts were 
made and Western blotting for PARP and β-tubulin (as a normalizing control) was 
performed. B, SUDHL4 and SUDHL6 cells were treated for 14 h with the indicated 
concentrations of either TSA or vorinostat. PARP cleavage and β-tubulin were assessed 
as in panel A. C, Caspase-3 activity was measured in cells treated for 14 h with either 
TSA or vorinostat as indicated. The values represent the average relative fluorescence of 
three independent assays as compared to untreated samples (1.0). Error bars indicate SE. 
D, SUDHL4 and SUDHL6 cells were treated with 3 µM vorinostat for 14 h, cells were 
stained with acridine orange and ethidium bromide, and counted for live (black bars), 
necrotic (grey bars), and apoptotic (white bars) cells. Each value is the average of three 
independent experiments and error bars indicate SE. E, The relative growth inhibition 
induced by vorinostat was assessed by treating SUDHL4 and SUDHL6 cells with 
increasing concentrations of vorinostat for 72 h, and then counting cells using a 
hemocytometer. The relative number of cells is reported as a percentage as compared to 
untreated cells at the same time point (100). Results are the averages of three separate 
treatments and error bars indicate standard deviation. For the untreated samples at 72 h, 
6.7 x 105 SUDHL4 cells and 4.1 x 105 SUDHL6 cells were counted. F, SUDHL6 cells 
were treated with the indicated concentrations of vorinostat for 4 h. Expression of BIM 
and β-tubulin (as a normalizing control) was assessed by Western blotting of whole-cell 
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extracts. G, SUDHL6 cells were treated for 24 h with the indicated concentrations of 
staurosporine. PARP cleavage and β-tubulin were assessed as in panel A. 
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Figure 4.2. Trichostatin A and vorinostat induce apoptosis and inhibit growth in a 
time- and dose-dependent manner.  
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Figure 4.2. Trichostatin A and vorinostat induce apoptosis and inhibit growth in a 
time- and dose-dependent manner.  
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Figure 4.2. Trichostatin A and vorinostat induce apoptosis and inhibit growth in a 
time- and dose-dependent manner.  
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Figure 4.2. Trichostatin A and vorinostat induce apoptosis and inhibit growth in a 
time- and dose-dependent manner.  
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Figure 4.3.  HDACi sensitivity is decreased by over-expression of BCL-2 or BCL-XL 
and increased by over-expression of BIM. Four independent cell lines were created by 
retroviral infection (SUDHL2 cells over-expressing BCL-2, SUDHL4 cells over-
expressing BCL-XL, Farage cells over-expressing BCL-XL, and Farage cells over-
expressing BIM). Over-expression was confirmed by Western blotting for each relevant 
protein (BCL-2, BCL-XL, and BIM) and compared to empty-vector (-) transduced cells 
(A-D). β-tubulin was used as a normalizing control. A, SUDHL2-BCL-2, B, SUDHL4-
BCL-XL, C, Farage-BCL-XL, and D, Farage-BIM cell lines were treated with either 300 
nM TSA or 3 µM vorinostat for 24 h. Whole-cell extracts were made and Western 
blotting for PARP cleavage and β-tubulin (as a normalizing control) was performed. All 
cells over-expressing the protein of interest were compared to empty vector (-) 
transduced control cells.  
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Figure 4.3.  HDACi sensitivity is decreased by over-expression of BCL-2 or BCL-XL 
and increased by over-expression of BIM.  
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Figure 4.4. Vorinostat cooperates with the BH3 mimetic ABT-737 to increase 
apoptosis in DLBCL cell lines. A, SUDHL4, B, Farage, C, BJAB, D, SUDHL6, and E, 
RC-K8 cells were treated with ABT-737 in a dose-dependent manner with and without a 
sub-optimal level (0.5 µM) or a higher concentration (3 µM) of vorinostat. PARP 
cleavage and β-tubulin (as a normalizing control) were assessed by Western blotting of 
whole-cell extracts. 
 
!"#!
!"#$%$&'(
)*+'(*,#-#./012
$%&'()
345"676./012
" " " " *+, *+, *+, *+,
* *+- *+, -+* * *+- *+, -+*
!"#!
!"#$%$&'(
89":;
)*+'(*,#-#./012 " " " " *+, *+, *+, *+,
345"676./012 * *+- *+, -+* * *+- *+, -+*
!"#!
!"#$%$&'(
$%&'(.
)*+'(*,#-#./012 " " " " 7<= 7<= 7<= 7<=
345"676./012 * *+- *+, -+* * *+- *+, -+*
!"#!
!"#$%$&'(
)*+'(*,#-#./012
>-+-?@
345"676./012
" " " " *+, *+, *+, *+,
* *+- *+, -+* * *+- *+, -+*
!"#!
!"#$%$&'(
/0"/
)*+'(*,#-#./012 " " " " 7<= 7<= 7<= 7<=
345"676./012 * *+- *+, -+* * *+- *+, -+*
"
/
1
&
2
  
171 
 
Figure 4.5. The expression pattern of individual BCL-2 family members and 
common DLBCL markers does not correlate with HDACi sensitivity in DLBCL cell 
lines. A, The eight DLBCL cell line panel from Fig. 4.1 was probed for expression of the 
anti-apoptotic proteins BCL-2, BCL-XL, and MCL-1, the apoptosis sensitizers BIM, 
HRK, and BID, and the pro-apoptotic activator BAX. Also included in this screen were 
effector caspase-3 and -8 and β-tubulin (as a loading control). B, Western Blotting was 
performed for the indicated proteins in eight DLBCL cell lines. β-tubulin was used as a 
loading control. 
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Figure 4.5. Expression of individual BCL-2 family members and common DLBCL 
markers does not correlate with HDACi sensitivity in DLBCL cell lines.  
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Figure 4.5. Expression of individual BCL-2 family members and common DLBCL 
markers do not correlate with HDACi sensitivity in DLBCL cell lines.  
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Figure 4.6. SUDHL4 cells induced to be vorinostat-resistant show decreased 
sensitivity to vorinostat-induced apoptosis. A, SUDHL4 and SUDHL4-VR cells were 
treated for 24 h with the indicated concentrations of vorinostat. PARP cleavage and β-
tubulin (as a normalizing control) were assessed by Western blotting of whole-cell 
extracts. B, Relative caspase-3 activity was measured in cells treated for 14 h with 
vorinostat as indicated. The values represent the average relative fluorescence of three 
independent assays as compared to untreated samples. Error bars indicate SE. C, The 
relative growth inhibition by vorinostat was assessed by treating SUDHL4-VR cells with 
increasing amounts of vorinostat for 72 h, and cells were counted using a hemocytometer. 
The number of cells was then reported as a percentage as compared to untreated cells 
incubated for the same amount of time. The results are the averages of three separate 
treatment samples. Error bars indicate standard deviation. For the untreated samples at 72 
h, 3 x 105 SUDHL4 cells and 1.8 x 105 SUDHL6 cells were counted.  D, SUDHL4-VR 
cells were treated with ABT-737 in a dose-dependent manner with and without a sub-
optimal level (0.5 µM) of vorinostat. Whole-cell extracts were subjected to Western 
blotting for PARP cleavage and β-tubulin (as a normalizing control). E, Relative caspase-
3 activity was measured in cells treated for 14 h with TSA as indicated. The values 
represent the average relative fluorescence of three independent assays as compared to 
untreated samples. Error bars indicate SE. E, Cells were treated for 24 h with the 
indicated concentrations of staurosporine. PARP cleavage and β-tubulin (normalizing 
control) were assessed by Western blotting of whole-cell extracts. G, Western blotting for 
the indicated BCL-2 family members in parental SUDHL4 cells and in two independent 
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populations of SUDHL4-VR cells (1 and 2). β-tubulin was used as a protein loading 
control. The SUDHL4-VR (1) cell line was used for experiments in panels A-F. 
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Figure 4.6. SUDHL4 cells induced to be vorinostat-resistant show decreased 
sensitivity to vorinostat-induced apoptosis.  
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Figure 4.6. SUDHL4 cells induced to be vorinostat-resistant show decreased 
sensitivity to vorinostat-induced apoptosis.  
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Figure 4.6. SUDHL4 cells induced to be vorinostat-resistant show decreased 
sensitivity to vorinostat-induced apoptosis.  
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Figure 4.6. SUDHL4 cells induced to be vorinostat-resistant show decreased 
sensitivity to vorinostat-induced apoptosis.  
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CHAPTER 5 
DISCUSSION 
 
5.1  NF-κB Down-regulates Expression of the B-lymphoma Marker CD10 
Through a miR-155/PU.1 Pathway 
Chapter 3 describes for the first time a molecular link between increased NF-κB 
activity and reduced expression of CD10, both of which are poor prognostic markers for 
many cancer types, including DLBCL. These results suggest that increased NF-κB 
activity in B-lymphoma cells can directly increase expression of microRNA miR-155, 
which causes decreased PU.1 protein levels and consequently reduced transcription of 
CD10. Or, more simply,  
 
The evidence for this model is discussed below. 
 
5.1.1 The Importance of CD10 Regulation and Expression in DLBCL 
 NF-κB activity and expression of CD10 can be used to classify the two main 
molecular subtypes of DLBCL: GCB DLBCL patients and cell lines display low NF-κB 
activity and high levels of CD10 whereas ABC DLBCLs, which exhibit a worse clinical 
outcome as compared to GCB DLBCLs, have high nuclear NF-κB activity and low levels 
of CD10 (Alizadeh et al., 2000; Davis et al., 2006; Hans et al., 2004; Iqbal et al., 2007). 
This research demonstrates that increased NF-κB activity—as induced by expression of a 
!"#$%&& '()% *+%,-.$!/0
1
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lymphoma-derived mutant CARD11 protein or by exposure to LPS—leads to increased 
miR-155 and decreased CD10 levels in the GCB-like DLBCL cell line BJAB. Moreover, 
two B-lymphoma cell lines with high NF-κB activity (IB4, due to expression of the 
LMP1 protein of EBV, and RC-K8, due to inactivating mutations in IκBα, A20, and 
p300 [Table 2.3]), express little to no CD10 protein (Fig. 3.1), whereas four B-lymphoma 
cell lines not known to have high NF-κB activity (BJAB, SUDHL4, BL-41, and Daudi 
[Table 2.3]) have high CD10 levels. This correlation between high NF-κB activity and 
reduced CD10 expression has also been observed in prostate cancer (Voutsadakis et al., 
2012), in BJAB cells over-expressing an activated mutant of the REL (Chin et al., 2009), 
and following infection of B cells with Epstein-Barr virus (EBV) or human 
cytomegalovirus (Carter et al., 2002; Phillips et al., 1998).  
Although the factors that regulate transcription of CD10 are poorly characterized, 
the transcription factor PU.1 has been proposed to bind to the CD10 promoter and 
activate its expression. In fact, PU.1 and CD10 levels have been shown to have a positive 
correlation in several B-cell lymphomas by immunocytochemistry (Torlakovic et al., 
2005) and by microarray analysis in DLBCL tumors and primary B-cell populations 
(Alizadeh et al., 2000). Western blotting revealed a direct correlation between CD10 and 
PU.1 protein levels in six B-lymphoma cell lines (Fig. 3.1). Furthermore, CD10 protein 
expression and nuclear PU.1 DNA-binding activity in BJAB cells are considerably 
reduced by the expression of a mutant form of CARD11, CARD11mut10, which is a 
constitutive activator of NF-κB activity (Lenz et al., 2008a (Fig. 3.4.A and C). 
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Additionally, shRNA-mediated reduction in PU.1 expression led to a reduction of CD10 
protein levels in BJAB cells (Fig. 3.8.D). 
 This work also showed that PU.1 can activate a reporter plasmid containing 
sequences from the CD10 promoter (Fig. 3.9.A and B) (Herscovitch, 2009); however, the 
sites required for this activation have not been fully characterized. There are three 
consensus PU.1 binding sites in the CD10 promoter, all of which contain the same core 
sequence GAGGAA (Fig. 3.9.A); however, PU.1 was only able to bind one of these 
predicted sites (PU-1) in vitro (Herscovitch, 2009). While the core GAGGAA sequence is 
known to be required for efficient PU.1 binding, bases outside of this core motif can also 
affect PU.1 binding (Li et al., 1999; Smith et al., 1998). Mutation of the PU-1 binding 
site only partially reduced PU.1-induced activation of the CD10 promoter (Herscovitch, 
2009), and mutation of all three predicted PU.1 consensus sites did not further reduce 
PU.1-induced transactivation (data not shown). The residual PU.1-induced activation of 
the CD10 promoter in the presence of a mutated PU-1 site may be mediated through non-
consensus PU.1 binding sites in the CD10 promoter. Indeed, there are six AAGGAA sites 
within the CD10 promoter fragment used in this study, and PU.1 has been shown to bind 
to some AAGGAA sequences (Eisenbeis et al., 1993; Kwon et al., 2006). One of these 
AAGGAA sites (PU-4) is found within the first region of the CD10 promoter 
(nucleotides 1-470) and five of these sites are clustered in the second region of the 
promoter (nucleotides 449-717) (Fig. 3.9.A). Reporter plasmids containing each region 
can be weakly induced by PU.1 (Fig. 3.9.B), and the sum of the PU.1-induced activation 
of each region of the CD10 promoter is approximately equal to the induction of the full 
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717 bp CD10 promoter region (Fig. 3.9.B). These results suggest that non-consensus 
(probably AAGGAA) PU.1 sites play a role in PU.1-induced activation of CD10 
transcription.  
 
5.1.2 BIC/miR-155 Regulation and Activity in B-lymphoma Cell Lines 
One way to regulate PU.1 expression is through translational repression by 
microRNA miR-155 (product of the BIC gene) (Faraoni et al., 2009; Martinez-Nunez et 
al., 2009; Vigorito et al., 2007). Given that increased BIC expression has been correlated 
with increased NF-κB activity, this would link increased NF-κB activity to the control of 
PU.1 and CD10 expression. To test this hypothesis, BJAB cell lines retrovirally 
transduced to over-express miR-155 (by approximately 105-fold; Fig. 3.8.A) were 
created. Over-expression of miR-155 in BJAB cells resulted in reduced levels of PU.1 
protein and CD10 protein and mRNA (Figs. 3.8.B and C). Additionally, CARD11mut10 
over-expression in BJAB cells resulted in decreased CD10 and PU.1 expression, along 
with increased NF-κB activity and miR-155 levels (Fig. 3.4). Moreover, expression of the 
oncogenic NF-κB transcription factor v-Rel, which has been shown to up-regulate miR-
155 (O’Connell et al., 2007), in the avian DT40 B-lymphoma cell line was also 
correlated with a reduction of PU.1 mRNA levels (Fig. 3.8.E). These results are 
consistent with previous reports showing that the PU.1 mRNA is a direct target of miR-
155 in B cells (Martinez-Nunez et al., 2009; Vigorito et al., 2007).  
The transcriptional regulation of BIC has widely been accepted to be an NF-κB- 
dependent process, although little evidence showing a direct interaction between a 
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member of the NF-κB family and the promoter/enhancer of BIC has been produced. A 
number of studies have set out to identify the NF-κB-regulated cis elements in the BIC 
promoter, producing mixed and controversial results. One study claimed that a conserved 
AP-1 site 40 nt upstream of the BIC TSS is required for miR-155 expression in the EBV+, 
type III latency B-lymphoblast cell line JY (Yin et al., 2008). Moreover, they showed that 
expression of the EBV proteins LMP1 and LMP2A led to up-regulation of miR-155 
expression through increased AP-1 signaling. The problem with this study is that there 
appears to be no normalization in the reporter assays identifying the AP-1 site. More 
importantly, LMP1 and LMP2A mimic TNF signaling which results in increases in both 
AP-1 and NF-κB activity (Eliopoulos and Young, 2001; Thorley-Lawson, 2001). Another 
report showed that miR-155 expression is controlled by NF-κB through two distal NF-κB 
binding sites more than 1100 nt upstream of the TSS within 36 h of PMA treatment in the 
EBV- B-cell line DeFew (Gatto et al., 2008). There is a disconnect between experiments 
in this study however; different cell lines were used for different experiments without a 
solid rationale. EMSA and ChIP analyses were performed on the EBV+ cell line MC3, 
luciferase assays were performed on PMA-treated DeFew cells, and yet another set of 
luciferase assays were performed on LMP1-transfected MEFs. The data obtained from 
the LMP1-MEF luciferase assays were presented differently than the DeFew luciferase 
assays, meaning that they cannot be compared. Additionally, the time course used in 
other experiments was 24-72 h, indicating that results could be due to the activation of 
NF-κB target genes and not direct binding of NF-κB of the BIC promoter. A third study 
claimed that NF-κB activity up-regulates Fos/Jun expression, which then binds to the AP-
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1 site and directs miR-155 expression (Cremer et al., 2012). The issue with this study is it 
used an inhibitor approach instead of a direct DNA-binding approach to identify the 
control of miR-155 expression, which could result in deregulation of multiple genes that 
regulate miR-155 and other signaling mechanisms and therefore skew results.   
 In aggressive B-cell lymphomas such as DLBCL, there is a positive correlation 
between high NF-κB activity and miR-155 expression (Chin et al., 2009; Kluiver et al., 
2005; Lawrie et al., 2007; Rai et al., 2008; Thompson et al., 2010). In fact, in two 
DLBCL cell lines with both high NF-κB activity and miR-155 expression, OCI-Ly3 and 
OCI-Ly10, and one with low NF-κB activity and miR-155 expression, SUDHL4 (Kluiver 
et al., 2005; Lawrie et al., 2007; Rai et al., 2008), miR-155 expression correlated with 
nuclear p50/p65 heterodimers but not p50/REL heterodimers (Davis et al., 2001). 
Moreover, in BJAB cells, LPS-induced nuclear translocation of p65 and miR-155 
expression correlated with increased binding of the p50/p65 heterodimer to the -178 NF-
κB binding site (Fig. 3.3). Similar to the -178 site in the BIC promoter, the promoters of 
the pro-IL1β and ICAM-1 genes have both been shown to contain sites that selectivity 
bind p50/p65 heterodimers but not p50/REL heterodimers (Goto et al., 1999; Paxton et 
al., 1997). 
 Given the above results indicating that the NF-κB p50/p65 heterodimer directs 
transcription of the BIC promoter through the -178 site, it was important to know if there 
was a correlation between high miR-155 and high nuclear p65 in transformed B-
lymphoid cell lines. In this study, four B-lymphoma cell lines with increased NF-κB 
activity (RC-K8, IB4, KMH2, L428) due to inactivating mutations in IκB or expression 
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of the EBV LMP1 protein (Carter et al., 2002; Emmerich et al., 1999; Kalaitzidis et al., 
2002) also exhibited high expression of miR-155 (Fig. 3.1 and Fig. 3.7). Interestingly, 
IB4 and KMH2 cells have high nuclear p65 and REL whereas L428 cells have high 
nuclear REL and low p65. Another cell line with high nuclear REL and low nuclear p65, 
SUDHL4, has low miR-155. SUDHL4 cells express a full-length IκB protein (Liang et 
al., 2006) and have a low NF-κB gene expression profile consistent with the GCB 
DLBCL subtype (Davis et al., 2001). Therefore, in can be concluded that increased 
expression of miR-155 is concurrent with increased nuclear NF-κB activity and that 
increased miR-155 is usually attributed to increased nuclear p65. But in the absence of 
nuclear p65 and the presence of NF-κB-activating mutations, nuclear REL may to be 
sufficient to activate miR-155 expression in some DLBCL cell lines. 
Using reporter gene assays in COS-1 cells, we have identified an NF-κB p65-
responsive site (at -178 bp) within an ~1.5 kbp fragment of the human BIC TSS. These 
results suggest that the -178 site is important for activation of the BIC gene transcription 
by NF-κB in vivo. Nevertheless, ChIP assays will be need to be performed to confirm that 
p65 binding to this site occurs in cells. Several lines of evidence suggest that there are 
additional sites located outside of the ~1.5 kbp upstream region which contribute to 
activation of BIC transcription by NF-κB. First, overall only about 20-30% of induced 
p65 binding sites are present in promoter proximal sequences; indeed, approximately 
40% of induced p65 binding sites are located in introns (Lim et al., 2007; Martone et al., 
2003). Second, the upstream region of the mouse BIC gene does not appear to have a site 
analogous to the -178 NF-κB site that we have identified in the human BIC gene. Third, 
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the ~1.5 kbp fragment upstream of BIC does not appear to be activated by REL in COS-1 
cells, and yet two B-lymphoid cell lines (RC-K8 and L428) with high levels of miR-155 
have high levels of nuclear REL but negligible levels of nuclear p65, suggesting that 
there are additional NF-κB/REL-responsive sites for transcriptional activation of BIC 
located outside of the ~1.5 kbp fragment. However, it cannot be ruled out that the -178 
site is specifically activated by REL in B-lymphoid cells (e.g., due to interactions with 
other factors), but not in COS-1 cells. Further investigation into the role of REL in the 
transcription of BIC should be performed to understand the full capability of NF-κB to 
regulate miR-155 expression. 
Given that increased levels of miR-155 are associated with a number of cancers 
and that miR-155 transgenic mice have pre-leukemic pre-B-cell proliferation defects that 
eventually lead to B-cell malignancies (Costinean et al., 2006), it is likely that miR-155 
has oncogenic capabilities. Therefore, understanding how miR-155 expression is 
controlled could have therapeutic implications. 
 
5.1.3 The Clinical Implications of the ↑NF-κB → ↑miR-155 → ↓PU.1 → ↓CD10 
Pathway  
 This study has shed light on a B-lymphoma gene network controlled directly by 
NF-κB. This pathway is of particular interest because one subtype of clinically 
unfavorable DLBCLs (i.e., the ABC-subtype) can have several types of gene mutations 
that endow them with constitutive activation of NF-κB and reduced expression of CD10 
(Compagno et al., 2009; Hans et al., 2004; Kato et al., 2009; Lenz et al., 2008c). By 
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several criteria, this work shows that high miR-155 levels correlate with activation of NF-
κB and reduced levels of PU.1 and CD10 in B-lymphoma cell lines. First, transformed B-
lymphoid cell lines with high NF-κB activity have high miR-155 levels and low PU.1 and 
CD10 levels, whereas B-lymphoma cell lines with low NF-κB/miR-155 levels have 
increased levels of PU.1 and CD10 (Fig. 3.1). It is also shown that miR-155 expression 
can be directly controlled by the NF-κB heterodimer p50/p65 through the -178 site in the 
BIC promoter (Fig. 3.3.D, Fig. 3.5, and Fig. 3.6.C). Second, over-expression of miR-155 
leads to reduced levels of PU.1 and CD10 in BJAB cells (Fig. 3.8.A-C). Third, miR-155 
levels are up-regulated in BJAB cells by two inducers of NF-κB, namely, expression of a 
lymphoma-derived, constitutively active CARD11 mutant (Fig. 3.4.A and B) or by 
treatment with LPS (Fig. 3.3.B and C) (Herscovitch, 2009). Fourth, over-expression of v-
Rel in the chicken B-lymphoma cell line DT40 leads to decreased PU.1 mRNA levels 
(Fig 3.8.E), and v-Rel has been shown to increase miR-155 expression (Bolisetty et al., 
2009). Fifth, shRNA-mediated knockdown of PU.1 leads to reduced CD10 protein levels 
in BJAB cells (Fig. 3.8.D). Additionally, the CD10 promoter contains consensus and 
non-consensus PU.1 binding sites that all contribute to CD10 expression (Fig 3.9 A and 
B) (Herscovitch, 2009). Lastly, increased NF-κB activity and nuclear p65 levels generally 
correlate with miR-155 expression in a panel of B-lymphoma cell lines (Fig. 3.7). These 
results are consistent with previous reports showing that miR-155 is up-regulated in an 
NF-κB-dependent manner in response to various cytokines or inducers of Toll-like 
receptors, including LPS and TNFα, or expression of the EBV LMP1 protein (Baltimore 
et al., 2008; Gatto et al., 2008).  
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Of course, it is possible that CD10 can be regulated by factors in addition to PU.1, 
including other miR-155-mediated pathways. For example, the difference in CD10 down-
regulation when comparing BIC over-expression (Fig. 3.8.B) to shRNA-mediated knock-
down of PU.1 (Fig. 3.8.D) is noteworthy. Knock-down of PU.1 resulted in an 
approximately 50% reduction in CD10 expression whereas over-expression of BIC 
resulted in complete loss of CD10 protein, suggesting that miR-155 affects factors in 
addition to PU.1 to regulate CD10 expression or is able to down-regulate CD10 directly, 
although there is no evidence supporting a miR-155 binding sequence in the CD10 
3`UTR.  
 Studies like these dissect cancer cell biology in order to understand potential 
pathogenic pathways and novel therapeutics targets. This work establishes a regulatory 
pathway linking NF-κB activity and increased miR-155 expression to the modulation of 
CD10 protein levels, all of which have been used as diagnostic markers in a number of 
malignancies, including B-cell lymphomas. Low NF-κB activity and high CD10 
expression correlate with a superior clinical outcome in GCB DLBCL patients while 
ABC DLBCL cells (with a poorer outcome) are dependent on NF-κB activity. Targeting 
NF-κB activity is effective in inducing apoptosis in a number of cancer cell types, 
including DLBCL (Davis et al., 2010; Lam et al., 2005; Tian and Liou, 2009). However, 
it is not known if pharmacologically increased CD10 expression would cause cells 
lacking CD10 to be more susceptible to standard therapy.  
Over-expression of CD10 in BJAB cells leads to an approximately 2.2-fold 
increase in soft agar colony formation (Fig. 3.10), suggesting that increased CD10 
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expression is beneficial to the growth of some DLBCL cells. This is contrary to the 
findings from patient biopsies, in which patients with CD10-expressing DLBCL tumors 
(i.e., GCB patients) have a better clinical response to R-CHOP therapy than patients with 
little to no CD10 (i.e., ABC patients), suggesting that CD10 expression is an adverse 
marker for tumor survival in response to standard therapy. CD10 has been shown to 
cleave and inactivate peptides that normally stimulate early B-cell proliferation and 
differentiation, whereas loss of CD10 has been linked to tumor progression (Salles et al., 
1992 and 1993; Sumitomo et al., 2005; Sunday et al., 1992). Thus, although CD10 
expression has anti-proliferative activity in some contexts, many tumor types, which are 
undifferentiated cells that continually proliferate, express CD10. Therefore, it is 
reasonable to hypothesize that increased CD10 expression in certain DLBCL tumors, 
such as the CD10+ GCB-like DLBCL, might have a favorable effect on cell growth and 
oncogenesis by increasing CD10-mediated intracellular signaling by decreasing the 
available signaling peptides that typically signal for cell growth or proliferation. 
Therefore, future studies should aim at understanding the benefit of increased CD10 
expression by uncovering why some DLBCL tumors selectivity increase CD10 
expression, assessing the therapeutic benefit of modulating CD10 expression, and 
designing clinically safe modulators of CD10 expression and activity. 
 Understanding precisely how miR-155 expression is controlled and what 
transcripts it targets for down-regulation could be important for understanding its full 
biological effect in cancer and how modulation of miR-155 expression could be used for 
therapy. MicroRNA mimetics and antagomirs (down-regulators of specific microRNAs) 
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represent exciting small-molecule therapeutic approaches to modulate microRNA 
activity. 
 
5.2  The Sensitivity of Diffuse Large B-cell Lymphoma Cell Lines to Histone 
Deacetylase Inhibitor-induced Apoptosis is Modulated by BCL-2 Family Protein 
Activity 
The research described in Chapter 4 shows for the first time that the HDACi 
compound vorinostat and the BH3 mimetic ABT-737 can cooperate to induce cell death 
in DLBCL in a BCL-2 family protein-dependent manner, a finding that is similar to the 
effects of the combination of these compounds in other types of cancer (Chen et al., 
2011; Debien et al., 2011; Del Gaizo Moore et al., 2007; Fang et al., 2011; Fitzgerald et 
al., 2011; Ishitsuka et al., 2012; Risberg et al., 2011; Whitecross et al., 2009; Wiegmans 
et al., 2011). Additionally, DLBCL cell lines can be made resistant to vorinostat, which 
may be useful in understanding the molecular mechanism by which patients might 
develop HDACi-resistance in the clinic. 
HDACi’s are currently being used to treat a variety of lymphomas and leukemias. 
Vorinostat and other HDACi’s are thought to have anti-tumor call activity by regulating 
histone and non-histone proteins that ultimately regulate genes associated with inhibition 
of angiogenesis, effects on endoplasmic stress response, tumor suppressor genes or 
oncongenes, cellular differentiation, cell cycle arrest at both G1/S and G2/M phase 
transitions, and BCL-2 family-mediated apoptosis (Bolden et al., 2006; Cotto et al., 
2010; Piekarz and Bates, 2009; Wiegmans et al., 2011; Zain and O’Connor, 2010). Some 
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of these studies, as well as the results in this thesis, indicate that levels of BCL-2 family 
proteins may be important in determining sensitivity to HDACi treatment. The emerging 
model for BCL-2-dependent regulation of apoptosis proposes that anti-apoptotic proteins 
(such as BCL-2 and BCL-XL) neutralize BH3-containing apoptotic modulators and pro-
apoptotic activator proteins, while BH3-only modulators of apoptosis can also neutralize 
anti-apoptotic proteins, which decreases the level of activation needed to induce 
apoptosis (Walensky and Gavathiotis, 2011). To overcome the complex BCL-2 protein 
regulatory network, HDACi’s have been combined with the BH3 mimetic ABT-737 to 
release BH3-containing BCL-2 family members from sequestration by anti-apoptotic 
BCL-2 proteins (Shamas-Din et al., 2011; Strasser et al., 2011).  
 
5.2.1 HDACi-resistance in DLBCL Cell Lines Can be Overcome by Co-treatment 
with BH3 Antagonist ABT-737 
Although we found that BIM expression is increased rapidly by HDACi treatment 
in the HDACi-resistant SUDHL6 cell line (Fig. 4.2.F), it is important to note that these 
cells have approximately 10-fold lower levels of BIM in resting cells when compared to 
the HDACi-sensitive SUDHL4 cells (Fig. 4.5.A). This suggests that one way that DLBCL 
tumors may resist BIM-dependent apoptosis is by reducing the level of available BIM (or 
other pro-apoptotic proteins), which ultimately reduces the cell’s ability to be induced to 
undergo apoptosis. Additionally, SUDHL6 cells can be induced to undergo apoptosis 
when treated with a combination of vorinostat and ABT-737 (Fig. 4.4.D). These results 
suggest that although BIM is up-regulated by HDACi treatment in SUDHL6 cells, it is 
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not to a high enough level to prevent protective sequestration of BIM by BCL-2 and 
BCL-XL. This state can be overcome by treatment with ABT-737, thus releasing BIM or 
other apoptosis-sensitizing proteins from their binding pockets. Interestingly, retroviral 
over-expression of BIM could be tolerated in Farage cells, but not other cell lines, 
including the ABT-737-sensitive RC-K8 cell line. This suggests that some DLBCL cell 
lines can tolerate fluctuations in BCL-2 family protein expression while others are more 
sensitive to disruptions in the balance between anti- and pro-apoptotic BCL-2 proteins. 
One study reported that SUDHL6 cells show a significant accumulation of 
apoptotic cells after treatment with 5 µM vorinostat for 96 h (Sakajiri et al., 2005), a time 
and concentration much greater than used in this study. We showed that treatment of 
SUDHL6 cells with 6 µM vorinostat for 14 h (Fig. 4.2.B) did not induce appreciable 
amounts of PARP cleavage when compared to SUDHL4 cells. Additionally, SUDHL6 
cells exhibit an IC50 approximately 6-fold higher (~3 µM) than SUDHL4 cells (0.5 µM) 
(Fig. 4.2.E), suggesting that prolonged treatment of HDACi-resistant DLCBL cell lines 
with high doses of vorinostat is sufficient to induce cell cycle arrest and possibly 
apoptosis. But prolonged, high doses of vorinostat as a monotherapy used in laboratory 
studies do not necessarily translate into effective patient treatment strategies. Short term, 
low dose combination strategies, like the work described in this thesis involving 
vorinostat and ABT-737, represent a more realistic clinical approach to treating DLBCL 
patients. 
Two DLBCL cell lines (SUDHL4-VR) with reduced sensitivity to vorinostat 
have also been created and characterized (Fig. 4.6). In both SUDHL4-VR cell lines, 
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MCL-1 expression was increased as compared to parental cells, and in one of the VR cell 
lines, BCL-XL expression was also increased. Additionally, there is a slight increase in 
BCL-2 expression in both SUDHL4-VR cell lines. Expression of these anti-apoptotic 
proteins would be expected to shift the balance of the BCL-2 family towards an anti-
apoptotic profile. It is reasonable to hypothesize that the increased levels of these anti-
apoptotic proteins would sequester more BIM and BAX, making SUDHL-VR cells less 
susceptible to vorinostat-induced apoptosis. Of note, BCL-XL can be transcriptionally 
regulated by the NF-κB, JAK/STAT, AP-1, and Ets families of transcription factors 
(Chen et al., 2001; Sevilla et al., 2001), MCL-1 is a transcriptional target of STAT3 and 
both are often up-regulated in aggressive lymphomas (Bhattacharya et al., 2005; Ding et 
al., 2008; Gupta et al., 2011; Tsutsui et al., 2010; Wenzel et al., 2012), and BCL-2 is 
routinely associated with the ABC DLBCL subtype and increased NF-κB activity, and 
has been shown to be a transcriptional target of STAT3 (Alizadeh et al., 2000; 
Bhattacharya et al., 2005; Chin et al., 2009; Davis et al., 2001; Wright et al., 2003). 
Considering that HDACi treatment results in increased STAT and NF-κB signaling 
(Chen et al., 2001, 2002; Nusinzon et al., 2003; Yuan et al., 2005) and that some 
lymphoma cells that are less sensitive to HDACi have elevated levels of JAK/STAT 
activity (Fantin et al., 2008), it is not surprising that a HDACi-sensitive cell line 
(SUDHL4) might up-regulate expression of any number of the anti-apoptotic proteins 
BCL-XL, BCL-2, and/or MCL-1 in response to prolonged and repetitive exposure to 
HDACi treatment. Our in vitro finding with SUDHL4-VR cells suggests that similar 
tumor cell resistance could occur in DLBCL patients treated with repeated doses of 
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vorinostat. Acquired resistance to ABT-737 has also been observed in DLBCL cell lines, 
including SUDHL4 cells, which was attributed to an up-regulation in MCL-1 (Whitecross 
et al., 2009; Yecies et al., 2010). ABT-737, which displaces BH3-containing BCL-2 
family proteins from the BH3-binding pocket in BCL-2 and BCL-XL but not MCL-1 
(Oltersdorf et al., 2005; Strasser et al., 2011), and has been shown to induce apoptosis in 
MCL-1-expressing cells only when MCL-1 is down-regulated (Chen et al., 2007; van 
Delft et al., 2006) indicating that BCL-2 inhibitors that also target MCL-1 might have 
clinical importance (Mohammad et al., 2007).  
 
5.2.2 Clinical Implications of HDACi/ABT-737 Treatment of DLBCL 
The goal of this research was to identify the molecular mechanisms that determine 
HDACi-sensitivity in DLBCL. Our results show that DLBCL cells exhibit a range of 
HDACi-sensitivity that can be affected by proteins in the BCL-2 family. Ectopic 
expression of BCL-2 family members modulates HDACi-sensitive and vorinostat-
induced HDACi-resistance in an HDACi-sensitivity cell line leads to increased 
expression of the anti-apoptotic protein BCL-XL. Moreover, the combination of 
vorinostat and ABT-737 induced apoptosis in most DLBCL cell lines, including HDACi-
resistant cell lines. Overall, these results suggest that HDACi-resistant patients, like those 
with relapsed and refractory DLBCL following standard R-CHOP treatment (Crump et 
al., 2008), may benefit from a combination therapy of HDACi and ABT-737-like 
compounds. 
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Future experiments would aim to elucidate the exact mechanism by which 
HDACi induces apoptosis in lymphoma tumors. This would include microarrays or ChIP-
on-chip experiment to identify genes regulated by HDACi treatment at early time points. 
Such genes may include initiators of cell death. Moreover, defining the BCL-2 family 
interactions in response to HDACi treatment would be important in understanding which 
members are necessary for HDACi-induced apoptosis. Discovery of appropriate markers 
for the identification of patients who would benefit from HDACi or HDACi/ABT-737 
combination therapy is also imperative.  
5.3   Conclusions and Perspectives 
5.3.1 Linking HDAC Activity to the Opposing Actions of BCL6 and NF-κB 
Transcription Factor Activity in DLBCL 
At the onset of the work presented in Chapters 3 and 4, there was no clear link 
between the two projects. It was quickly determined that HDACi sensitivity did not 
correlate with the GCB or ABC DLBCL subtypes, and therefore an NF-κB-mediated 
regulation of HDACi sensitivity was also ruled out. But upon further literature research, 
it became clear that there are multiple lines of evidence that could tie the two projects 
together (refer to Fig. 5.1 for an illustration of the following model). First, the activity of 
NF-κB member p65 can be increased by HDAC activity. That is, increased p65-
acetylation leads to increased DNA binding, transcriptional activity, and association with 
its inhibitor IκB (Buerki et al., 2008; Chen et al., 2000; Chen et al., 2001 and 2002; Choi 
et al., 2005; Huang et al., 2010; Stehlik et al., 1998; Yang et al., 2009 and 2010; Yeung 
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et al., 2004). This suggests that HDACi treatment could regulate p65 function in cancers 
that depend on high NF-κB activity, including aggressive forms of leukemia and 
lymphoma. One of the NF-κB target genes affected by p65 regulation is miR-155 
(Kluiver et al., 2005; Lawrie et al., 2007; Rai et al., 2008). Moreover, the use of 
vorinostat has been shown to result in increased miR-155 levels in lymphoma (Kretzner 
et al., 2011), but the mechanism for this is not known. 
The transcription factor BCL6, which is the central regulator of germinal center 
formation and function, has also been tied to NF-κB, miR-155, and HDAC function. It is 
well appreciated that BCL6 and NF-κB have opposing effects on gene regulation and 
function in normal immune cells and hematopoietic malignancies. However, in recent 
years, BCL6 and NF-κB have been functionally and molecularly linked. In macrophages, 
genomic cis-regulatory elements that are bound by BCL6 repress expression of the target 
genes to keep macrophages in quiescence, whereas LPS-induced NF-κB activity relieves 
BCL6 repression and regulates a new set of pro-inflammatory genes (Barish et al., 2010). 
In GCB DLBCL, BCL6 can bind to p65 and inhibit its DNA-binding activity, and 
silencing of BCL6 results in increased basal NF-κB activity (Perez-Rosado et al., 2008). 
Moreover, GCB DLBCL, which resembles the BCL6-dependent germinal center (GC), is 
associated with low NF-κB and high BCL6, whereas ABC DLBCL, which resembles the 
post-GC B cell that is activated to secrete antibodies, is associated with high NF-κB and 
low BCL6 (Davis et al., 2001; Hans et al., 2004; Wright et al., 2003). In fact, BCL6 has 
been shown to bind to the BIC promoter and repress miR-155 expression in the GC, 
helping to sustain the GC state and allowing for expression of AID, an important factor in 
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immunoglobulin class switching and somatic hypermutation (Basso et al., 2012b). 
Additionally, increased expression of miR-155 in B cells from transgenic mice indirectly 
impairs BCL6 expression by down-regulating HDAC4, the corepressor partner of BCL6 
(Sandhu et al., 2012) while miR-155 has been shown to target BCL6 for down-regulation 
in pro-inflammatory macrophages (Nazari-Jahantigh et al., 2012).  
Therefore, a plausible model can be formed to describe the complex relationship 
between these molecules (Fig. 5.1). In GC B cells, there is high BCL6 that would 
transcriptionally inhibit BIC and bind to p65 to sequester it from activating target genes. 
During an immune response elicited by LPS or TNFα, LPM1 infection, or by mutations 
in the NF-κB signaling pathway, there is an increase in nuclear p65 and expression of p65 
target genes, including miR-155. Increased miR-155 down-regulates BCL6 (relieving 
BCL6 from sequestrating p65 and miR-155) and HDAC4 (resulting in increased p65 
acetylation), and both of these events would allow for even more NF-κB activity. 
Pharmacologic inhibition of HDAC activity with HDACi compounds like vorinostat 
could mimic the effects of LPS or TNFα by inhibiting the deacetylation of p65 and 
allowing for increased p65-target gene transcription. Although not tested in this work, it 
would be expected that HDACi-mediated induction of NF-κB activity would result in 
increased miR-155 expression, down-regulation of PU.1 DNA-binding activity, and loss 
of CD10 expression. Thus, HDACi-mediated down-regulation of CD10 in GCB DLBCL 
cells would likely further favor an apoptotic state, along with increasing BIM-mediated 
apoptosis and deregulation of the cell cycle by p21, causing toxicity to the tumor cell. 
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5.3.2 Combination Therapies Involving HDACi’s Represent a New Treatment 
Strategy for DLBCL Patients 
 To date, HDACi’s have been shown to exert their apoptotic effects by changing 
the balance of the BCL-2 proteins to favor a pro-apoptotic expression profile. How this is 
accomplished and whether other factors play a role in inducing apoptosis is not well 
understood. BCL6-expressing DLBCL cells are sensitive to the BCL6-peptide inhibitor 
(BPI) (Cerchietti et al., 2009; Polo et al., 2007) and the use of HDACi to down-regulate 
BCL6 through expression of miR-155 could mimic this response. Moreover, BPI and 
HDACi could be used in combination to treat DLBCL, in a similar way as the 
combination of ABT-737 and HDACi. Although NF-κB-dependent DLBCL cells already 
have a high level of NF-κB activity, treatment with HDACi could up-regulate a number 
of NF-κB-dependent pro-apoptotic genes, including Fas, Fas ligand, TRAIL, CD95, p53, 
BAX, and DR5 (Chan et al., 1999; Jennewein et al., 2012; Radhakrishnan and 
Kamalakaran, 2006) or indirectly down-regulate anti-apoptotic genes like BCL-XL, 
XIAP, or A20 (Farhana et al., 2005; Radhakrishnan and Kamalakaran, 2006), all of 
which would overwhelm the anti-apoptotic effect typically attributed to NF-κB activity. 
 It is clear that HDACi treatment is clinically beneficial. Low patient toxicity and 
broad subtype-independent success is being observed across many different cancer types, 
including B- and T-cell lymphomas. Although the exact mechanism by which NF-κB 
might play a role in HDACi-mediated cell death is not known, the above model 
(illustrated in Fig. 5.1) suggests an integral role for HDACi-induced NF-κB activity in 
apoptosis. Future studies aimed at testing this hypothesis would include treatment of 
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lymphoma cells with HDACi’s like vorinostat and quantification of acetylated and 
nuclear p65, NF-κB binding to pro- and anti-apoptotic genes, the effects of NF-κB-
modulation on HDACi-mediated apoptosis, and changes in microRNA regulation and 
their target genes. These types of studies could reveal new markers for patient prognosis 
and more appropriate treatment regimens. 
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Figure 5.1. Model of proposed NF-κB/HDACi regulatory network. 
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